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1   Summary 
   The metacestode larval stage of the fox tapeworm Echinococcus multilocularis is the 
causative agent of alveolar echinococcosis (AE), one of the most lethal zoonosis of the northern 
hemisphere. The development of metacestode vesicles by asexual multiplication and the almost 
unrestricted infiltrative growth within the host organs is ensured from a population of undifferentiated, 
proliferative cells, so-called germinative cells. AE treatment options include surgery, if possible, as well 
as Benzimidazole-based chemotherapy (BZ). Given that the cellular targets of BZs, the -tubulins, are 
highly conserved between cestodes and humans, the chemotherapy is associated with considerable 
side-effects. Therefore, BZ can only be applied in parasitostatic doses and has to be given lifelong. 
Furthermore, the current anti-AE chemotherapy is ineffective in eliminating the germinative cell 
population of the parasite, which leads to remission of parasite growth as soon as therapy is 
discontinued.  
This work focuses on protein kinases involved in the proliferation and development of the parasite with 
the intention of developing novel anti-AE therapies. Polo-like kinases (Plks) are important regulators of 
the eukaryotic cell cycle and are involved in the regulation and formation of the mitotic spindles during 
the M-phase of the cell cycle. Plks have already been shown to be associated with deregulated 
cellular growth in human cancers and have been investigated as novel drug targets in the flatworm 
parasite Schistosoma mansoni. In the first part of this work, the characterisation of a novel and 
druggable parasite enzyme, EmPlk1, which is homologous to the polo-like kinase 1 (Plk1) of humans 
and S. mansoni (SmPlk1), is presented. Through in situ hybridisation, it could be demonstrated that 
emplk1 is specifically expressed in the Echinococcus germinative cells. Upon heterologous expression 
in the Xenopus oocyte system, EmPlk1 induced germinal vesicle breakdown, thus indicating that it is 
an active kinase. Furthermore, BI 2536, a compound originally designed to inhibit the human ortholog 
of EmPlk1, inhibited the EmPlk1 activity at a concentration of 25 nM. In vitro treatment of parasite 
vesicles with similar concentrations of BI 2536 led to the elimination of the germinative cells from 
Echinococcus larvae, thus preventing the growth and further development of the parasite. In in vitro 
cultivation systems for parasite primary cells, BI 2536 effectively inhibited the formation of new 
metacestode vesicles from germinative cells. Thus, BI 2536 has profound anti-parasitic activities in 
vitro at concentrations well within the range of plasma levels measured after the administration of safe 
dosages to patients (50 nM after 24 h). This implies that EmPlk1 is a promising new drug target for the 
development of novel anti-AE drugs that would specifically affect the parasite’s stem cell population, 
namely the only parasite cells capable of proliferation. In addition to the chemotherapeutic aspects of 
this work, the inhibitor BI 2536 could be further used to study the function of stem cells in this model 
organism, utilising a method of injection of parasite stem cells into metacestode vesicles, for instance, 
as has been developed in this work. 
In the second part of this work, a novel receptor tyrosine kinase, the Venus flytrap kinase receptor 
(EmVKR) of E. multilocularis has been characterised. Members of this class of single-pass 
transmembrane receptors have recently been discovered in the related trematode S. mansoni and are 
associated with the growth and differentiation of sporocyst germinal cells and ovocytes. The ortholog 
receptor in EmVKR is characterised by an unusual domain composition of an extracellular Venus 
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flytrap module (VFT), which shows significant similarity to GABA receptors, such as the GABAB 
receptor (γ-amino butyric acid type B) and is linked through a single transmembrane domain to an 
intracellular tyrosine kinase domain with similarities to the kinase domains of human insulin receptors. 
Based upon the size (5112bp) of emvkr and nucleotide sequence specificities, efforts have been made 
to isolate the gene from cell culture samples to study the ligand for the activation of this receptor type 
in Xenopus oocytes. To date, this type of receptor has only been described in invertebrates, thus 
making it an attractive target for drug screening. In a first trial, the ATP competitive inhibitor AG 1024 
was tested in our in vitro cell culture.  
In conclusion, the EmVKR represents a novel receptor tyrosine kinase in E. multilocularis. Further 
efforts have to be made to identify the activating ligand of the receptor and its cellular function, which 
might strengthen the case for EmVKR as a potential drug target. The successful depletion of stem 
cells in the metacestode vesicle by the Plk1 inhibitor BI 2536 gives rise to optimising the chemical 
component for EmPlk1 as a new potential drug target. Furthermore, this inhibitor opens a new cell 
culture technique with high potential to study the cellular behaviour and influencing factors of stem 
cells in vitro.     
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2   Zusammenfassung 
 Das Verbreitungsgebiet des kleinen Fuchsbandwurms erstreckt sich über die nördliche 
Hemisphäre und eine Infektion des Menschen verursacht eine meist tödliche verlaufende Parasitose, 
die alveolaren Echinococcose (AE). Durch infiltratives und asexuelles Wachstum des Larvenstadiums 
der AE im betroffenen Wirtsorgan kommt es zu einer tödlich verlaufenden Krankheit. Das Wachstum 
der Metacestoden wird dabei durch undifferenzierte proliferierende Stammzellen, den sog. 
„germinativen Zellen“ des Fuchsbandwurmes verursacht. 
Die derzeitigen Behandlungsmöglichkeiten von AE sehen neben einem chirurgischen Eingriff, der in 
den meisten Fällen nicht möglich ist, nur eine Chemotherapie mit Benzimidazolen (BZ) vor. Die 
Chemotherapie mit BZ richtet sich dabei gegen die β-Tubuline des Parasiten und ist überwiegend mit 
einer lebenslangen Behandlung verbunden. Obwohl sich die Behandlungsmöglichkeiten und die 
Prognose für Patienten seit der Verwendung von Benzimidazolen bedeutsam verbessert haben, 
kommt es dennoch zu starken Nebenwirkungen und die angewendete Chemotherapie wirkt nur 
parasitostatisch. Der Grund dafür liegt an der hohen Homologie zwischen den β-Tubulinen des 
Parasiten und des Menschen, welche die Zielproteine von Benzimidazolen sind. Um die 
Nebenwirkungen für den Patienten gering zu halten, werden die Benzimidazole nur in 
Konzentrationen verabreicht, die parasitostatisch wirken, was zu keiner Abtötung des 
Parasitengewebes führt. Darüber hinaus sind die gegenwärtigen AE-Medikamente nicht wirksam 
gegen die germinativen Zellen des Parasiten, was zu einem Wiederauftreten des Wachstums von 
Parasitengewebe führt, sobald die Chemotherapie unterbrochen wird.   
Die hier vorliegende Arbeit konzentriert sich auf die Entwicklung eines neuen chemotherapeutischen 
Ansatzes gegen AE und befasst sich mit Proteinkinasen, die einen wesentlichen Einfluss auf die 
Proliferation und die Differenzierung von Zellen des Parasiten haben. Proteinkinasen, die in direkten 
Zusammenhang mit den Zellzyklus stehen, sind beispielsweise die Polo-like kinasen (Plk), welche die 
Bildung von mitotischen Spindelfasern während der M-Phase regulieren. Wie bereits in 
vorhergehenden Studien gezeigt werden konnte, sind Plks auch an der Entstehung von Krebs beteiligt 
und daher interessante Ansatzpunkte für die Entwicklung von neuen Chemotherapeutika. Darüber 
hinaus zeigte sich auch, dass Sie zur Chemotherapie von parasitären Krankheiten Verwendung finden 
könnten, wie zur Behandlung von Schistosomiasis, welche durch Schistosoma mansoni ausgelöst 
wird.   
Der erste Teil dieser Arbeit befasst sich mit der Charakterisierung der Polo-like kinase 1 (Plk1) aus E. 
multilocularis, die Homologien zur humanen Plk1 und der aus S. mansoni (SmPlk1) aufweist und 
daher als Ansatzpunkt für eine neuartige chemotherapeutische Behandlung von AE angesehen 
werden kann. Es konnte gezeigt werden, dass EmPlk1 in germinativen Zellen (Stammzellen) des 
Parasiten stark exprimiert wird und das es möglich ist, dieses orthologe Protein mit nanomolekularer 
Konzentration (25 nM) des Plk1 Inhibitors BI 2536 in seiner zellulären Funktion zu hemmen. Darüber 
hinaus führt die Behandlung in vitro zu einem Verlust von Stammzellen im Larvenstadium von E. 
multilocularis, was zu einer drastischen Verminderung des Wachstums und der Entwicklung des 
Parasiten führt. Des Weiteren konnte sehr deutlich gezeigt werden, dass bei Verwendung des 
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Inhibitors BI 2536 in Zellkultursystemen mit „Primärzellen“ (80% Stammzellen) des Parasiten diese 
nicht mit mehr in der Lage sind in Metacestoden zu regenerieren. Dabei ist entscheidend, dass die 
verwendeten Konzentrationen des Inhibitors BI 2536 innerhalb der gemessenen 
Plasmakonzentrationen von Krebspatienten liegen (50 nM nach 48 Stunden). Die Inhibierung der Plk1 
wird daher als vielversprechender neuer Ansatzpunkt einer Chemotherapie zur Behandlung der AE 
angesehen. Die Inhibierung der EmPlk1 hat einen wesentlichen Einfluss auf die Differenzierung von 
Stammzellen des Parasiten, wodurch das Wachstum und die weitere Entwicklung des Parasiten 
gehemmt werden. Des Weiteren kann neben der chemotherapeutischen Behandlung der Inhibitor 
BI2536 auch für das weitere Studium von Stammzellen und deren zelluläre Funktion in E. 
multilocularis genutzt werden. Dafür wurden erste in vitro Experimente mittels Injektion in 
stammzellfreie Metacestoden Vesikel durchgeführt.  
Der zweite Teil dieser Arbeit befasst sich mit einem neuen Transmembranrezeptor in E. multilocularis, 
der hier als Venus-Fliegenfallen-Rezeptor charakterisiert wird. Dieser Rezeptortyp wurde erst kürzlich 
in S. mansoni beschrieben und steht im Zusammenhang mit der Entwicklung und dem Wachstum von 
Keimzellen des Parasiten. Der Rezeptor weist eine ungewöhnliche Zusammensetzung aus einer 
extrazellulären Venusfliegenfallendomäne (VFT) mit starker Ähnlichkeit zu GABA Rezeptoren auf (γ-
amino-Buttersäure Typ B) und ist über eine einzelne Transmembrandomäne mit einer intrazellulären 
Tyrosinkinasedomäne verbunden, die eine hohe Homologie zu humanen Insulinrezeptoren zeigt. Der 
lange Genabschnitt (5112bp) von emvkr mit sequenzspezifischen Eigenschaften war schwierig zu 
klonieren, um eine anschließende Expression in Xenopus Oozyten durchzuführen. Bisher wurde 
dieser Rezeptor nur in Invertebraten beschrieben und stellt somit einen interessanten Ansatzpunkt für 
die Entwicklung von neuen Chemotherapeutika dar. In einem ersten Versuch wurde die Wirkung des 
ATP-Kompetitive Inhibitors AG 1024 in unserer in vitro Zellkultur untersucht.  
Zusammenfassend wurde die Relevanz von EmVKR als neuartiger Tyrosinkinaserezeptor in E. 
multilocularis verdeutlicht. In anschließenden Studien sollte die Aktivierung durch Ligandenbindung an 
den Rezeptor, sowie seine weitere zelluläre Funktion untersucht werden. Diese Erkenntnisse könnten 
dann eine entscheidende Rolle für die Entwicklung von neuen Medikamenten mit EmVKR spielen. 
Des Weiteren wurde die erfolgreiche Entfernung von Stammzellen aus Metacestoden Vesikel mit dem 
Plk1 Inhibitor BI 2536 gezeigt. Dies bietet nun die Option diesen Inhibitor auf das Wirkstoffziel EmPlk1 
weiter zu optimieren. Darüber hinaus hat die Verwendung dieses Inhibitors den entscheidenden 
Zugang für eine neue Zellkulturtechnik ermöglicht, die das Studieren von Stammzellen und deren 
Einflussfaktoren in vitro bietet. 
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3.   Introduction  
3.1.  Echinococcus Phylogeny 
   The phylogenetic position of E. multilocularis and its sister species within the genus 
Echinococcus are outlined in detail in Fig. 3.1.1 [1]. All currently distinguished Echinococcus species 
are part of the class Cestoda (true tapeworms), which - together with the sister classes Monogenea, 
Trematoda, and Turbellaria - form the phylum Plathelminthes (flatworms). Together with several other 
phyla such as annelids and molluscs, the flatworms are part of the clade of Lophotrochozoa, which - 
together with the sister clade Ecdysozoa - are grouped together to the clade of protostomes [2, 3]. 
After the Cambrian Explosion about 500-600 million years ago, the protostomes evolved out of the last 
common bilaterian ancestor as a sister group to the deuterostomes with several prominent phyla such 
as Echinodermata, and Chordata (including vertebrates and eventually humans). As such, 
Echinococcus species share relatively close phylogenetic relationships with the parasitic flukes 
(trematodes) and the free-living Turbellaria (including planarians as a model system). Of all 
invertebrate phyla, a relatively close relationship is present between flatworms, molluscs and annelids, 
whereas less homologies - particularly phylogenetic and developmental homologies - are shared 
between flatworms and Ecdysozoa. Among the Nemathelminthes and arthropods are well-studied 
model organisms such as Caenorhabditis elegans and Drosophila melanogaster [4, 5].  
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Figure 3.1.1 Phylogenetic tree of bilateral organisms. DNA sequences of mitochondrial (A) and 
nuclear genes (B) were used for reconstructing the tree. Decay indices are given by 
values of each node and inserted scale bars represent the number of substitution per 
nucleotide site. The tree was modified from Nakao et al. (2013) [1]. 
 
Today, the genus Echinococcus spp. comprises nine valid species, shown in a phylogenetic tree in Fig 
3.1.1 [1]. Two alternative phylogenies based upon the analyses of mitochondrial and nuclear markers 
are depicted in Fig. 3.1.1.A and Fig. 3.1.1.B, respectively. Further studies have to clarify the ongoing 
taxonomic rearrangements of the fox tapeworm regarding its position in the phylogenetic tree. 
The fox tapeworm is widely distributed in the northern hemisphere, with high endemic regions in the 
Republic of China, Turkey, Switzerland, Austria and the southern part of Germany (Fig. 3.1.2) [6, 7]. 
Unlike the fox tapeworm E. multilocularis, its close relative E. granulosus (dog tapeworm) is distributed 
worldwide [8]. These two species, which respectively cause alveolar (AE) and cystic echinococcosis 
(CE), are highly relevant for animal and human health issues, with somewhat lower importance of the 
sister species E. vogeli and E. oligarthrus [9, 10]. The fox tapeworm E. multilocularis has a sylvatic life-
cycle and its distribution in the northern hemisphere follows that of its natural host, the red-fox (Vulpus 
vulpus) [11]. In direct comparison to some satellite states of the former Soviet Union and the Republic 
of China, the infection rate of foxes in Europe is comparably high, although the prevalence of human 
AE is lower [12-14]. In contrast to Europe, the high transfer by domestic animals, predominantly dogs, 
and the reduced hygiene circumstances/situation are the main reasons behind the higher zoonotic 
infection rate outside of Europe [7].  
 
Figure 3.1.2 Distribution of the fox tapeworm Echinococcus multilocularis in Europe with 
endemic regions highlighted. Figure/Data based on Torgerson et al. (2010) [7]. 
Figure was modified from [15]. 
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In high endemic areas in central Europe, the transfer by domestic animals constitutes 10% of the 
infection rate and can be reasonably controlled through frequent deworming campaigns and higher 
hygiene standards. [16]. Efforts to conduct regular deworming campaigns of domestic and straying 
dogs are often not performed in Europe, Asia, Russia and especially in third world countries, due to 
the high costs of regular treatment [17]. A potential yet hitherto unclear infection risk for AE is also 
man-made, namely garbage collection. Non-regulated garbage collection in several countries offers 
new food sources for the red foxes in urban areas, which enables the possibility of contaminating the 
environment with infected eggs [18]. The lifestyles of humans in urban areas (and valleys) allows for 
the presence of red foxes, which can have a tendency to influence the rate of this zoonotic infection 
[19, 20]. An overview of possible preventions to reduce the infection risk is given in Fig. 3.1.3. 
 
Figure 3.1.3 Infection risks for alveolar echinococcosis and ways of prevention. Actions to 
prevent the infection with AE are indicated by anthelmintic treatment (red) and 
population management (blue). Lines (red/blue) are start- and endpoints, showing 
overall that one action can influence several central spots. Figure was modified from 
Hegglin et al. (2013) [16]. 
 
The red-fox population was influenced by the outbreak of rabies until 1990 in Europe, whereby the 
population gradually increased following a successful vaccination campaign [21]. Together with the 
recovery of the red-fox population, studies observed an increase in the local distributions of E. 
multilocularis infected red foxes in Central and Eastern Europe [7, 11, 19, 20, 22]. It is assumed that 
infection rates of humans in Europe will increase in the future due to the increasing rates of infected 
foxes. Indeed, first indications of a higher infection rate have already been observed in Germany 
(unpublished results), Switzerland and Austria [23-25]. An observation of new infection rates in 
Eastern Europe could not be estimate based upon incomplete data from previous decades [26]. 
Efforts to treat fox populations through baiting campaigns to reduce environmental contamination with 
E. multilocularis eggs are ineffective in the long run and the emergence of resistances are assumed 
[16, 27]. It has also been observed that the parasite population can recover within 24-36 months 
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following the end of the cost-intensive baiting campaign [16]. In contrast to the difficult-to-treat fox 
tapeworm E. multilocularis, the dog tapeworm E. granulosus is dependent on a man-made life cycle. 
Historical and cultural issues support the life cycle of the dog tapeworm. Administrative control 
campaigns have failed with far-reaching consequences, such as the current existence of the zoonotic 
disease in Europe [22, 24].  
 
3.2 The life cycle of the fox tapeworm Echinococcus multilocularis 
A common feature of all tapeworms is their complex life cycle, which is associated with two 
host changes. Species of genus Echinococcus are distributed worldwide within a wide spectrum of 
rodents and ungulates that act as intermediate hosts, whereas carnivores such as foxes, domestic 
dogs and cats act as definitive hosts [7, 9, 11, 18, 24]. The morphology and localisation of 
Echinococcus larvae in the intermediate host shows a species-dependent characteristic [28].  
In the case of the heterogeneous life cycle of the fox tapeworm E. multilocularis, two essential 
mammalian host changes are involved for the development of the intermediate host and the adult 
tapeworm. An overview of the life cycle of the fox tapeworm is given in Fig. 3.2.1. The adult worm of E. 
multilocularis is present in the intestine of carnivorous definite hosts such as the red fox (Vulpus 
vulpus), the polar-fox (Alopex lagopus) and the wolf (Canis lupus), among others [11, 29]. The adult 
tapeworm produces eggs in the intestine of the fox, which contain the first larval stage of the 
tapeworm, the oncosphere. 
 
Figure 3.2.1 Life-cycle of the small fox tapeworm Echinococcus multilocularis. Figure was 
kindly provided by Klaus Brehm.  
 
The infective eggs are released into the environment through the posterior segment of the tapeworm, 
the gravid proglottid. Natural intermediate hosts for E. multilocularis are usually rodents (especially 
Microtus arvalis and Arvicola terrestris), which acquire the infection through oral uptake of the infective 
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eggs. In rare cases, humans can become infected after accidental uptake of the infective eggs, and 
may subsequently develop the disease AE [6, 22]. When the infective eggs reach the stomach and 
intestine of the intermediate host, the oncosphere becomes activated by acidic pH and bile salts and 
subsequently hatches from the eggshell. By active penetration of the intestine wall, the oncosphere 
reaches the venous blood or lymphatic system, followed by passive transport through the body [30, 
31]. In most cases (~99%) the oncosphere undergoes a metamorphosis towards the metacestode 
stage within the liver of the intermediate host, driven by a population of pluripotent stem cells, namely 
germinative cells [32]. The molecular basis for the prominent organ tropism of E. multilocularis towards 
the liver is currently unknown, although it has recently been shown that host insulin serves as an 
important stimulus for parasite development in vitro [33, 34]. Since the highest insulin concentrations 
in mammals can be found in the liver, insulin-dependent parasite proliferation could contribute to the 
organ tropism towards the liver [35]. 
In both natural intermediate hosts and humans, the metacestode is characterised by an alveolar 
structure comprising numerous small vesicles [36]. This fluid-filled vesicle is surrounded by an 
acellular, laminated layer (LL) comprising mucins, to which the cellular so-called germinative layer 
(GL) is proximally attached [37, 38]. The metacestode vesicle is filled by a protein-rich liquid, the 
hydatid fluid. The E. multilocularis metacestode is capable of producing daughter vesicles in a 
budding-like mechanism and thus grows infiltrative, like a malignant tumour, into the surrounding liver 
tissue as a meshwork of interconnected tubes and vesicles [39-41]. The growth of the metacestode 
vesicle causes a reaction of the immune system in rodents and humans, although it does not cause a 
strong rejection of the forming tissue. Moreover, it has to be noticed that not all rodents are sensitive 
for an infection and growth of the metacestode vesicle; rather, several kinds of mice are resistant to 
infection [42]. Furthermore, humans do not represent a good host for the development of AE overall 
and it is assumed that the infection also depends upon the human immune status [43].  
The inner germinal layer opens towards the outside of the syncytial tegument. The nuclei of this 
syncytial tegument are localised in tegmental cell bodies connected to the tegument itself by thin 
cytoplasmic projections. Other cell types of the germinal layer are muscle, nerve, glycogen-storage 
and undifferentiated cells, like germinative cells [44-47]. At later stages of the infection, the germinal 
layer forms brood capsules in which the protoscoleces develop [28]. This larval stage already forms 
the scolex of the adult worm, but does not contain the proglottids as present in the adult worm. 
The infiltrative growth of the metacestode tissue in the liver gradually weakens the intermediate host. It 
is assumed that owing to their reduced fitness, infected rodents can more easily be caught by the 
definitive host. Upon ingestion of the infected rodent by the fox, the developmental process of the 
adult tapeworm is triggered in the intestine of the fox. Already in the intermediate host, the germinal 
layer of the metacestode vesicle forms buds towards the inside of the vesicle cavity into the hydatid 
fluid. These buds grow and develop vacuoles and stalks, which have been previously described as 
brood capsules [48]. These brood capsules are covered on the inside by a syncytial tegument, which 
is similar to the germinal layer. Following the syncytial tegument, the next larval stage proceeds, in 
which the protoscoleces develops [48]. The protoscolex has the head structure (scolex) of the adult 
tapeworm, but does not contain the proglottids. The scolex already has the four suckers and the 
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rostellum (hook ring), including a double ring of hooks, which are present in the scolex region of the 
adult worm [6]. In the metacestode vesicle, the protoscoleces are invaginated until the metacestode 
vesicle becomes digested by the fox [11]. This digestion process activates the protoscolex and 
stimulates the development of the adult worm within a period of 28 to 35 days. The adult worm is 
attached to the intestine wall of the fox and becomes segmented. The fox tapeworm is small 
compared to other tapeworms, with an adult size of 1.2 to 4.5 mm. The head region (scolex) of the 
tapeworm is directly followed by a distal proliferation zone, which produces the adjacent segments, the 
proglottids of the worm [28]. Given that tapeworms are hermaphrodites, which mean that each 
proglottid has female and male genitals, self-fertilisation generates the high reproduction rate of eggs 
in the terminal proglottid of the fox tapeworm. This terminal proglottid is finally released within the 
faeces of the fox.  
 
 
3.3  Alveolar echinococcosis - infection risk and clinical therapy 
   The accidental oral uptake of the oncosphere by humans as a dead-end host interrupts the 
natural passage between the intermediate host and the definitive host and causes the human 
endoparasitic zoonotic disease AE. If the infection is not detected through random medical screening, 
it takes 5 to 15 years until the first symptoms occur [11]. The early symptoms are abdominal pain, 
weight loss, anaemia, jaundice and hepatomegaly, which culminate in the dysfunction of the affected 
organ and can result in the patient’s death [22]. Beyond that, in later stages of the human infection, 
metastases can spread to other organs like the lung, bones or the brain. Human AE is often 
diagnosed in an advanced stage of the disease, when surgical removal of the parasite is no longer 
possible. After the detection of symptoms, the clinical diagnosis of AE is usually made by imaging 
(ultrasound, CT, NMR) [44], supported by serological tests. The serological tests allow detection with a 
sensitivity of 90-95% and a specificity of ~95% [30, 49]. After diagnosis, one option is radical surgery 
of the infected tissue, although this is only possible in some cases (20 to 40%) [11, 50]. Surgery is 
often combined with chemotherapy, which includes Benzimidazole carbamate derivatives (BZ) such as 
Albendazole (ABZ) and mebendazole (MBZ), which often have to be given lifelong [51]. It is not 
recommended to carry out a complete transplantation of the liver. A preceding radical resection of the 
parasitic mass before transplantation is difficult to complete and transplantation-associated immune 
suppression usually leads to massive growth of the residual parasite tissue and metastasised material 
[30, 52, 53].  
According to the recommendations of the WHO informal working group for echinococcosis, surgical 
treatment should be accompanied by chemotherapy. The current chemotherapeutics were originally 
used to treat intestinal worm infections in animals and humans [54]. Infection of the liver with AE 
mirrors a completely differentiated clinical setting. Although the orally-administered drugs reach 
parasitocidal acting concentrations in the patient’s intestine, they do not reach similar concentration in 
infected organs. The daily-administered dose of Albendazole is between 400-800 mg. It has been 
shown by in vivo studies of patients that the blood serum concentration of Albendazole is 0.65-3 µM 
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after four hours of treatment, which must be significantly lower than the unknown parasitocidal 
concentration in vivo and thus these drugs only act parasitostatic with drastic consequences and are 
not even guaranteed to cure the disease [22, 55]. In direct comparison to in vitro studies with 
Benzimidazole derivates like Mebendazol (MBZ) by Jura et al. (1998) and Albendazole Sulfoxide 
(ABZSO) and Albendazole Sulfone (ABZSN) by Ingold et al. (1999), parasitocidal effects (>0.1 μM of 
MBZ) and changes in the parasite ultrastructure tissue with changes in metabolites in vesicle fluids 
have been observed (≥0,03 µM ABZSO/ABZSN) [56, 57]. Accordingly, it should be theoretically 
possible to influence the parasite tissue with the given high blood serum concentrations in man after 
administering the drug. However, the low bioavailability in vivo is one essential factor that suppresses 
the drug’s activity. In addition, the protein targets of the current chemotherapy - the beta-tubulins (β-
tubulins) - have a high structural homology (>80% amino acid identity) between humans and the 
parasite. Albendazol acts on these β-tubulins by inhibiting the polymerisation of microtubuli in the host 
and the parasite [56, 58]. These circumstances cause side-effects such as urticarial or gastrointestinal 
disorders and neuronal deficits, often with toxic effects on the bone marrow, followed by reduced 
numbers of leukocytes and thrombocytes. Adverse events often have a patient-specific pattern and 
sometimes make it impossible to continue the administration of albendazol [55]. Furthermore, it is 
estimated that not all cell types of the parasite are affected by the drug, due to low cellular 
bioavailability. Previous studies have shown that the binding specificity of BZ is dependent on the 
amino acid sequence of the β-tubulin [58, 59]. It was assumed that a mutation in the amino acid 
sequence of the β-tubulin at position Phe 200 to Tyr 200 and Phe 167 to Tyr 167 might result in the 
development of resistance to BZ [58-60].  
 
 
3.4  Protein kinases and their characteristic features for the development of novel 
 chemotherapeutics  
 Many outstanding discoveries in science have been found as a side product, whereby their 
importance for possible future advancements was largely unknown at the time of their discovery. In the 
1950s, Krebs and Fischer (Nobel price 1992) researched possible regulatory mechanisms that are 
dependent on protein phosphorylation and discovered phosphorylating kinases [61]. At the time, they 
may have underestimated the wide influence of their accidental discovery and the future medical drug 
developments and applications of phosphorylating kinases on a cellular level as molecular switches 
[62-65]. Protein kinases are key factors in the regulation of cellular signalling and cell-cell 
communication and are well conserved among animals. Functionally, kinases carry out similar 
catalytic process by transferring the γ-phosphate of adenosine triphosphate (ATP) to a hydroxyl group 
of protein or non-protein targets. Overall, 518 kinases (representing ~2% of the genome) have been 
identified in the mammalian genome (not including splicing variants) and they show a range of 
similarities in their protein structure, the so-called sub-domains. A detailed characterisation of protein 
kinases was undertaken by Hanks and Hunter in 1988 [66, 67]. In their study, they described the 
conserved sequence motifs, the kinase core and the characteristics of 12 sub-domains that are 
required for the classification kinases, in a classification that still holds today [66].  
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Figure 3.4.1 Crystal structure of protein kinase with bound ATP molecule. The characteristic 
bilobal folded structure separates the kinase into two main functional domains, N- and 
C-terminal lobe. The ATP molecule (green) is indicated by an arrow the centre of the 
kinase domain. α-Helices are indicated in blue, β-Barrels in red. ATP competitive 
inhibitors (BI2536/BI6727) are drawn to indicate the variability of side chains in 
functional chemical compounds. Figure of the kinase domain was modified from Curtis 
Neveu [68]. Chemical structures have been drawn with www.chemspider.com. 
 
According to the classification system of protein kinases by Hanks and Hunter, we are now able to 
map amino acid sequences of kinases, leading to characteristic sequence motifs for each subdomain 
[66, 67]. Comparative studies on different types of kinases have shown that these structures are highly 
conserved over a broad range of eukaryotic organisms. All kinases are bilobal folded in an N-terminal 
(N-lobe) and C-terminal (C-lobe) part, producing a so-called hinge region in the middle, which is the 
binding side for the ATP molecule (Fig. 3.4.1). Binding of the ATP molecule and transfer of the 
phosphate is precisely regulated by elements in the N- and C-lobe in an activating process, including 
the activation and structural modification of the kinase core. Protein kinases are phosphorylated by 
other kinases in the core domain, which produces a conformational change to the active form. The 
phosphorylation takes place at the activation loop, which contains the amino acid threonine. The 
activation step leads to chemical modification of the central kinase domain and influences the folded 
structure by the negative charge of the phosphor ion. Depending on the kind of kinase, multiple 
phosphorylation sites can be present, which are not only located in the core region. In the cases of the 
mitogen-activated protein kinases (MAPKs) p38 (TGY), ERK (TEY) and JNK (TPY), two 
phosphorylation sites are present and p38α is a potential drug target for AE [69, 70]. In close 
correlation to the phosphorylation site in the activation loop or T-loop, other essential residues are 
present and relevant, such as the highly flexible region of the Asp-Phe-Gly (DFG) motif. The DFG-loop 
is necessary to bind an ATP molecule to a transported Mg-ion and plays an important role in the 
kinases activity. A structural modification in the activation process turns the DFG-motif from the “DFG-
motif in” position to the “DFG-motif out” position, which influences the activity state of the kinase and 
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its catalytic activity. Mutations in the DFG-motif have a negative effect on the kinase activity, leading to 
a dead kinase (mutant) version. A second important amino acid residue is the “gatekeeper”, which 
acts as a controlling factor of the chemical structure and size of the incoming ATP molecule. 
Depending on the size of the gatekeeper residue (large is comprised 77% of Leu, Met, Phe; small is 
comprised 21% of Thr, Val), variants of the ATP molecule are able to pass and bind in the 
hydrophobic centre of the core or not. The gatekeeper influences the design of novel 
chemotherapeutics, whereby many cancer drugs are designed to mimic the ATP molecule and work 
as a covalently-bound competitive inhibitor with the ability to produce displacing effects and longer 
resting times in the bound state [71]. Kinases are blocked in their activity by such inhibitors and the 
transduction of the downstream signal is inhibited. Mutations of the gatekeeper amino acid have 
significant physiological consequences; for example, the change of a small amino acid to a large 
amino acid at this position causes drug resistance through the interaction with the chemical structure 
of the side chains and a non-binding of the drug. For instance, the ATP competitive inhibitor imatinib 
only acts on the DFG-motif out version in the inactive state of the ABL-kinase. While this situation 
leads to disadvantages in the development of new drugs due to possible drug resistances, it offers a 
great target opportunity for therapies with chemical compounds that only need to target one type of 
kinases with their individual modifications. This individual drug design of ATP competitive inhibitors 
that bind in the hydrophobic ATP-pocket remains a fruitful approach, but new compounds are often 
generated in correlation to the activity state (DFG-motif out/in) of the kinase. In addition to the study 
and design of new drugs, it is important to invest time to understand the cellular functions of kinases 
and their importance for the regulation in the cellular mechanism. In summary, it can be said that both 
facts interact with each other and many cellular signal transductions are only discovered through the 
development of drugs. For instance, the understanding of the cell cycle with its fine-tuned regulatory 
functions executed and influenced by a battery of kinases is not possible without kinase inhibitors. 
One of the key players in the regulation of the cell cycle is the family of polo-like kinases, which will be 
discussed in the following section [72].   
 
 
 
3.5  Polo-like kinase 1 and their potential as anti-helminthic drug target 
 The search of novel therapeutic options to cure AE remains one major challenge of the next 
ten years in the field of parasitology. A successful implementation of a new drug will also show an 
impact on the treatment options of other parasitic cestodes and furthermore on the close related 
parasite S. mansoni. Today several drugs against E. multilocularis have been evaluated by in vitro and 
in vivo studies for their potential use against AE [73, 74]. Together with the comprehensive 
Echinococcus genome information and gene expression data a new area of drug discovery has 
started. The presents of a broad spectrum of anti-parasitic or anti-cancer drugs that are already 
marketed or in development, as well as the now much easier in silico analysis of ortholog pathways 
and essential enzymes of the parasite are very useful to identify novel drug targets against AE [60, 
75]. One of the essential enzymes is the Plk1, which belongs to the group of serine/threonine kinases 
(STK) and is part of a larger protein family. The Plk1 was first described in 1988 as a protein kinase 
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found to be associated with mitotic and meiotic defects in a D. melanogaster mutant named polo [72, 
76]. By genetic screening, orthologs of polo gene from D. melanogaster have been identified in 
several eukaryotes, with the exception of plants and apicomplexans. Several isoforms appeared in D. 
melanogaster, including a second polo-like kinase (sak), and are associated with a duplication of the 
genome [77]. In budding and fission yeasts, such as Saccharomyces cerevisiae and Saccharomyces 
pombe, the gene Cdc5 or plo1 is present and it was shown that both of them carried out similar 
cellular functions as polo in D. melanogaster [78]. Yeast strains only have one polo-like kinase gene, 
whereas higher bilateral eukaryotes have several isoforms, which emerged from the Plk 1 ancestor 
gene. The polo-like kinases are grouped into subfamilies and an overview of the distribution of polo-
like kinases is given in the following Tab. 3.5.1.  
Analysis of the function of the Plk1 in several organisms revealed their role as a key regulator of cell 
cycle progression, acting on the mitotic entry and exit as well as the formation of the spindle poles the 
activation of cyclin-dependent protein kinases (CDC) [72, 79]. Overall, five Plks of this family have 
been characterised in humans to date [77, 80]. The human Plks1-3 showed a high similar structure, 
comprising an N-terminal kinase domain that is relevant for the phosphorylation of the protein 
substrate and a C-terminal polo-box domain (PBD). The characteristic PDB are involved in the protein-
protein-interaction, relevant for phosphorylation of the substrate and furthermore involve in the 
subcellular localisation of the Plk [81]. A major focus where Plks are involved is the proliferation of 
eukaryotic cells. The cell cycle is controlled as fine-tuned mechanism, with defined steps and executed 
by protein kinases as the Plk1.  
 
Table 3.5.1 Evolutionary conservation of Polo-like kinases in eukaryotes. Polo-like kinases 
are separated into groups of subfamilies. The graphic was taken from Cácerer et al. 
(2011) and modified to include the parasitic helminths S. mansoni and E. 
multilocularis. Two orthologs of the Polo-like kinases are present; in the mentioned 
parasites they are Plk1 and SAK (Plk4) [77]. 
 
 
 
The functions of the Plk-family have been extensively analysed, particularly in mammals. Comparing 
all five Plks present in the mammalian genome revealed functional differences in their cellular action 
on the cell cycle as well as their protein sequences and domain structures. The differences in the 
protein structure arose from genomic duplication during evolution and mutations in the gene sequence 
[82]. Since this thesis concentrates on the Plk1 subfamily, the cellular functions of this Plk type will be 
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further outlined below. Plk1 is one of the most studied kinase and its respective inhibitors have been 
developed and shown promising effects in in vitro and clinical in vivo studies of cancer [83-85] . 
Human Plk1 is comprises of 603 amino acids and comprises two highly conserved domains. In the N-
terminal part, the 252 amino acid catalytic domain (Fig. 3.5.2, green,) is present. The kinase domain 
includes all the kinase-specific characteristic features described by Hanks and Hunter [66]. The 
gatekeeper residue at position 82 (K82) of the amino acid is highlighted, as well as the 
phosphorylation site at position T210. The kinase domain includes a nuclear localisation signal (NLS), 
which regulates the nuclear translocation of Plk1 (Fig. 3.5.2, orange) [86, 87]. At the end of mitosis, 
the Plk1 is ubiquitinated at the D-box side, indicated in red, leading to degradation of the kinase [88].  
 
Figure 3.5.2 Schematic representation of the human Polo-like kinase 1 highlighting 
characteristic protein features for this protein family.  
 
In the C-terminal region of the protein, two protein domains are present, namely the polo boxes (PB1 
& PB2). Together, these regions form the PBD. Studies have shown that the PDB-domain is 
responsible for the binding of the protein substrate by recognising the phosphopeptide-binding motif 
(Fig. 3.5.2, Phospho-selectivity). The phosphopeptide-binding motif has a strong substrate affinity for 
either phospho-Serine or phospho-threonine residues located in the consensus peptide Ser-
pSer/pThr-Pro [77]. Furthermore, the PBD regulates the subcellular localisation of the polo-like 
kinases [77, 89]. Both domains act together during the phosphorylation and activation of the Plk1. It is 
assumed that the PBD without a bound phosphorylated substrate folds back and blocks the kinase 
domain, leading to a regulation by molecular switching [80, 90].  
Activation via phosphorylation of the Plk1, during the G2 phase, is mediated by Aurora kinase A, a 
cellular serine/threonine kinase that binds to the Plk1/Bora protein complex. Aurora A kinase 
phosphorylates Plk1 at threonine T210 (Thr or T) in the kinase domain, but only in the complex with 
Bora. Bora serves as a relevant co-factor for the phosphorylation process and is also phosphorylated 
by the cyclin-dependent kinase 1 (CDK1), which is a downstream signal transduction substrate of the 
activated Plk1. No further detailed information is present about this Plk1/Bora pre-complex [91]. 
However, it has been shown by Förster Resonance Energy Transfer (FRET) that Bora is present in a 
cell cycle-dependent manner in the nucleus and cytoplasm [79]. Where and when the phosphorylation 
of Bora takes place and whether there is a correlation to the translocation of Plk1 is completely 
unknown [79]. In the next steps during mitosis are the nuclear envelope breakdown (NEB) and mitotic 
entry takes place. Bora is subsequently degraded from the Plk1/Bora protein-protein complex directly 
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after the mitotic entry. Like for the most proteins in the cell cycle also Aurora kinase A is regulated. 
During mitosis the co-factor Xklp2 (TPX2) takes over the regulation of Aurora kinase A and targets it to 
the mitotic spindle. Furthermore, it was observed that at later stages of the mitosis Plk1 is no longer 
Aurora kinase A-dependent. Drosophila studies show that Aurora kinase B and the Ste20-like kinase 
are also regulators of the activation of Plk1. The activation of the Plk1 by these kinases occurs at 
T182, the equivalent of the human T210. Plk1 subsequently triggers the downstream phosphorylation 
of the phosphatase CDC25. CDC25 adheres to the kinase complex of WEE1 and MYT1, which is then 
phosphorylated and inactivates the CDK1/Cyclin B1 complex, which promotes mitotic entry [92]. In 
addition to the activation of CDC25, Plk1 is also responsible for the inactivation of WEE1 and MYT1 
through phosphorylation. Finally, this leads to the onset of mitosis [91, 93]. 
 
Moreover, after the activation by phosphorylation of the Plk1, several proteins and cell cycle key 
factors interact with this kinase. A brief overview of Plk1 interaction partners is given in Fig. 3.5.3. An 
example of a typical feedback and forward loop in the cell cycle transition is given by the activation of 
the cyclin B/CDK1 complex. CDK1 is necessary for the activation of Bora via phosphorylation, which 
has a direct consequence of the activation of Plk1, after complex formation. Phosphorylated Plk1 in 
turn is necessary for the activation of cyclin B, which binds to CDK1. Overall, these kinds of feedback 
loops are relevant for the establishment of a bistable system that renders cell cycle transitions 
irreversible [79]. 
 
Figure 3.5.3 Schematic representation of some Polo-like kinases 1 protein interacting 
partners and the transduction of signal cascades during the cell cycle. Plk1 is a 
central player in the activation and inactivation of several protein factors acting on the 
transduction of the cellular progression. Figure was modified form Strebhardt et al. 
(2006) [84]. 
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Due to its importance in the cell’s entrance into mitosis and thereby cell proliferation, Plk1 is an 
interesting candidate for possible chemotherapy targets [85]. Several inhibitors for Plk1 have been 
identified in cancer cells, showing that Plk1 inhibition preferably kills cancer cells compared with 
normal cells, providing a potential therapeutic window for drug development [71, 83]. Besides the 
normal cellular proliferation, several cancers show a Plk1 up-regulation on transcriptional and 
translational level [83]. However, mutations in the Plk1 gene can occur and result in abnormal 
activation of the protein activity. It has also been shown that the up-regulation of Plk1 can be an 
indirect consequence of the cellular proliferation in cancers. In addition to this, it has also been 
reported that mutations in plk1 trigger a degradation of the protein rather than an increase of its activity 
[78, 94]. Based upon the fact that Plk1 is a protein kinase, several cancer studies have shown that 
ATP competitive inhibitors can inhibit its enzymatic activity [71, 83, 95, 96]. These ATP competitive 
inhibitors act by out-competing the cellular ATP molecule in the ATP binding pocket and thereby block 
the phosphor transfer of the kinases. The ATP binding pocket in the kinase domain demonstrates only 
small differences in the amino acid sequence between kinases, indicating a high evolutionary 
conservation. These small differences of molecular properties can be used to optimise the chemical 
structure of ATP competitive inhibitors to “personalise” the binding of the ATP binding pocket to the 
target kinases [65, 95]. Structure-based modelling, high throughput screening and chemical lead 
optimisation yielded two ATP competitive inhibitors, developed by Boehringer Ingelheim (Ingelheim, 
Germany), (BI 2536 and BI 6727 (second generation)), which belong to the dihydropteridinone 
substance class and bind to human Plk1 [95, 97, 98]. Both compounds show high selectivity for 
human Plk1 with more than 10.000 fold higher binding capacity to Plk1 than to other tyrosine or STK 
[95]. In vitro kinase assays for Plk1 showed half maximal inhibitory concentrations (IC50) of 0.83nM for 
BI 2536 and 0.87nM for BI 6727, underlining the high selectivity for this enzyme [95, 98, 99]. Although 
revealing a similar IC50 for Plk1 as BI 2536, the second-generation inhibitor BI 6727 has an improved 
half-life in vivo and a better accessibility to encapsulated tumour tissues [98]. Within the human polo-
like kinase family, BI 2536 shows an IC50 of 3,5nM for Plk2 and 9,0nM for Plk3. In the case of BI 6727, 
the IC50 is higher with 5nM to Plk2 and 56nM to Plk3. Several cancer cell lines were used to estimate 
the half-maximal effective concentration (EC50) in vitro for BI 2536, which reaches from 2-25 nM and 
for BI 6727 from 11-37 nM. Both inhibitors were able to induce mitotic arrest in proliferating cells, 
followed by apoptosis and significant cytotoxicity for stem cells was observed in the presence of micro-
molar concentrations [100, 101]. 
In addition to the promising effects of this inhibitor in clinical studies, this inhibitor has already been 
tested in S. mansoni and indicated inhibitory effects in the proliferation organs of the parasite [102]. 
The prediction of a Plk1 ortholog in E. multilocularis and the importance of this ortholog in the 
mechanisms of cellular proliferation prompted us to study the Plk1 of the fox tapeworm.  
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3.6  The invertebrate-specific family of Venus Flytrap kinases 
 Investigations on the presence of insulin receptor-like tyrosine kinases (TDKs) in S. mansoni, 
(Vicogne et al. 2003) discovered a structurally unusual member of the receptor tyrosine kinase family, 
SmRTK-1, with certain homologies to insulin receptor tyrosine kinases [103]. Insulin receptor-like 
tyrosine kinases are typically composed of an extracellular ligand-binding domain, located on the so-
called alpha subunit, which is connected to the beta-subunit via disulphide bridges [104]. The beta-
subunit of insulin receptors contains a transmembrane domain and an intracellular tyrosine kinase 
domain, and two typical members of this protein family are indeed present in S. mansoni [105]. By 
contrast, in SmRTK-1, the intracellular, insulin-receptor-like tyrosine kinase domain is connected to an 
extracellular domain with similarities to the Venus Flytrap module, which is typically found in 
periplasmatic binding proteins (PBP) of bacteria [106, 107]. Molecules employing this unusual 
combination of an extracellular Venus Flytrap module with homologies to those of GABA(B) receptors, 
connected to an intracellular RTK domain with homologies to insulin receptors, were later also 
discovered in insects and other invertebrates and the entire protein family was designated VKRs 
(Venus Flytrap Kinases) [108].  
 
 
Figure 3.6.1 Schematic representation of the Venus flytrap kinases receptor (VKR). The 
extracellular Venus flytrap module (VFTM) is connected by a single membrane 
spanning domain to similar insulin receptor tyrosine kinase domain. 
 
In bacteria, the VFT-containing PBP are involved in sensing sugars and ions as well as in the binding 
and the transport of amino acids. SmRTK-1 (now designated as SmVKR1) was shown to be activated 
by L-arginine [106, 108]. In a subsequent study, Vanderstraete et al. (2014) described a second S. 
mansoni member of the VKR family, SmVKR2, which was activated by calcium ions [109]. 
Furthermore, both SmVKR1 and SmVKR2 were shown to control reproduction in S. mansoni [109]. 
Since the tyrosine kinase domains (TKD) of schistosome VKRs share somewhat less homologies with 
the TKDs of human insulin receptors than the schistosome insulin receptors, the VKR family has 
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already been suggested as a promising target for drug design against schistosomiasis [103, 108, 110]. 
Furthermore, since schistosomes employ two members of the insulin receptor family and two VKRs 
that regulate important processes such as glucose uptake, metabolism, and reproduction, small-
molecule compounds that target all these enzymes simultaneously could prove effective in inhibiting 
several essential functions in these parasites [107]. Interestingly, one such compound, Tyrphostin AG 
1024, was shown to be a potent inhibitor of schistosome insulin receptors and the VKRs and affected 
the viability of both schistosomula and adult worms of S. mansoni in vitro [110] .  
 
 
3.7  In vitro culture of Echinococcus multilocularis  
   In vitro cultivation techniques are often essential to study parasite biology and host-parasite 
interaction mechanisms under defined laboratory conditions. For E. multilocularis larvae, the first 
cultivation methods were established by Hemphill and Gottstein in 1995 [111]. These authors 
introduced a culture system in which parasite material, isolated from infected rodents, was kept as 
tissue blocks in serum-containing medium. Tissue block-derived metacestode vesicles were 
morphologically similar to vesicles described in infected livers or other organs of patients [111]. In a 
second system, Jura et al. (1996) co-incubated rat hepatocytes with homogenised parasite material 
that was isolated from Mongolian jirds and embedded in a collagen matrix [112]. Although both 
systems were effective in the in vitro production of metacestode vesicles and demonstrated that 
parasite development depends on soluble host factors, they suffered from the fact that host cells were 
still present in the culture system. Hence, in the case of observed effects of host-derived factors or 
small-molecule compound inhibitors on parasite survival and development, it was unclear whether this 
involved direct effects on the parasite vesicles, or indirect effects on the co-cultivated host cells. 
To overcome the problems of the parasite-host cell co-cultivation systems, Spiliotis et al. (2004) 
developed the so-called ‘axenic’ E. multilocularis cultivation system [113]. In this system, metacestode 
vesicles are first generated through co-cultivation with host feeder cells (e.g. hepatoma cells) and are 
subsequently incubated for one week under a nitrogen atmosphere and with reducing agents in the 
medium [113]. These culture conditions were found to be important for parasite cultivation in the 
absence of host feeder cells since these obviously not only produce growth factors for the parasite, but 
also remove reactive (toxic) oxygen compounds from the medium upon incubation under an oxygen 
atmosphere [113]. After one week of incubation under ‘axenic conditions’ such cultures are free of host 
cells and can be maintained for longer periods of time provided that the reducing conditions are 
maintained and that host growth factors are constantly supplied, e.g. by adding ‘conditioned’ culture 
medium that has previously been incubated with host cells [113]. The authors also found that not only 
culture supernatant of hepatoma cells but also supernatant of many other cell lines could support 
Echinococcus development. However, hepatocyte-derived growth factors have been demonstrated to 
be the most effective.  
The axenic cultivation system subsequently facilitated the establishment of ‘pure’ parasite cell cultures. 
There have been several previous attempts to culture cestode cells in vitro, which all suffered from the 
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fact that parasite material of in vivo culture (i.e. from laboratory animals) had been used as a source 
for parasite cells [114-117]. Consequently, the cultivated parasite cells have always been overgrown in 
vitro by contaminating host cells, mostly fibroblasts [118]. By using axenically cultivated metacestode 
vesicles as a source for parasite cells (after trypsin digestion), it has been demonstrated that ‘primary 
cell cultures’ can be established that exclusively comprise parasite-derived cells [118, 119]. In the 
presence of suitable culture conditions (reducing environment; ‘conditioned’ medium), the parasite 
cells form aggregates within 2-3 days that contain actively proliferating parasite cells [118, 120]. After 
up to 6 weeks of culture, these aggregates form internal cavities, which later yield completely 
‘regenerated’ metacestode vesicles with a germinal layer surrounded by a LL [118-120]. When 
injected into laboratory mice, these vesicles resulted in large quantities of metacestode tissue with 
protoscoleces, indicating that the cultured parasite cells were at least pluripotent [121, 122]. Koziol et 
al. (2014) later showed that after 2 days of incubation the aggregates of ‘primary cultures’ were 
strongly enriched in parasite stem cells (the ‘germinative cells’; up to 80% of all cells) and that parasite 
development was exclusively driven by these stem cells [32]. The primary cultivation system has 
subsequently been extensively used for studies on host-dependent parasite development, on 
immunomodulatory activities of parasite excretory/secretory molecules, for studies on drug 
development and as a source for parasite mRNA in the Echinococcus genome project [33, 60, 70, 
123-126]. Interestingly, the morphology of developing parasite aggregates in the primary culture 
system closely resembles early stages of parasite development in oncosphere-infected laboratory 
mice [118]. Furthermore, parasite primary cell cultures show a gene expression profile similar to that of 
oncospheres [60]. It can thus be assumed that the parasite primary cell culture system closely mimics 
the oncosphere-metacestode transition as it occurs early during an infection of the intermediate host 
[59, 124].  
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3.8  Objectives 
   A recent publication by Koziol et al. (2014) showed that stem cells of the parasite E. 
multilocularis are relevant for proliferation and gave rise to all differentiated cells [32, 127]. This new 
information has a major impact also for the search of novel drug targets and should now been used 
together with the recently published genomic and transcriptomic data of the fox tapeworm to help to 
cure AE [60].  
In the last 10 years, efforts have been made to identify important cellular signalling cascades as 
potential drug targets, such as the mitogen-activated protein kinases (MAPK), the epidermal growth 
factor (EGF), the fibrinogen growth factor (FGF), the transforming growth factor β/Bone morphogenetic 
protein (TGFβ/BMP) and the insulin signalling pathways, which are involved in the proliferation and 
differentiation of cells, but a cell type specific action of the drug was not possible to show [33, 70, 126].  
Together with the current techniques available for the cultivation of E. multilocularis, which allow us to 
study the larval stages of this tapeworm in the laboratory, we want to test new inhibitors. In the first 
part of this work, the inhibitory action of the Plk1 inhibitor BI 2536, which should act on the cell cycle 
by suppressing the proliferation of cells, was evaluated [77, 118, 120, 128]. In the second part, we 
want to show that the specific action of this inhibitor BI 2536 is directly acting on parasite stem cells 
and try to validate the hypothesis that this cell type is expressing a β-tubulin isoform (tub-2), which 
shows limited affinity to benzimidazoles. Moreover, the study should finally show that the Plk1 is a 
fruitful target for further optimisations of the inhibitor BI 2536 and furthermore opens up a new 
approach for the treatment of AE and for the study of the role of stem cells in the larval stages of the 
metacestode vesicle. 
In the third part of this thesis, a novel receptor tyrosine kinase, the Venus flytrap kinase receptor 
(EmVKR) of E. multilocularis, was characterised. Members of this class of single transmembrane 
receptors were recently discovered in S. mansoni with an unusual receptor composition of 
extracellular and intracellular domains [103]. Moreover, this type of receptor has only been described 
in invertebrates to date [107]. The structural property - as well as the fact that this receptor type in this 
composition is not described for vertebrates - provides several interesting aspects for the study of the 
cellular functions in E. multilocularis and potentially as a new drug target for AE.   
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4  Material and Methods 
4.1 Material 
4.1.1 Equipment 
Bio-Rad Laboratories Universal Hood III 
for development of western blots 
RNA/DNA-agarose and protein gels        (Bio-Rad, München) 
 
Developer for radiographic films         (AGFA Graphics Germany, Düsseldorf) 
ELISA reader Multiscan Ex Primary EIA V.2.1-0    (Thermo Scientific, Braunschweig)  
Eppendorf Research Plus pipette set        (Eppendorf, Hamburg) 
Eppendorf Thermomixer Compact         (Eppendorf, Hamburg) 
Eppendorf Xplorer 15-300µl (41555AZ) Pipette     (Eppendorf, Hamburg) 
Gel documentation system: MidiDoc        (Herolab, Wiesloch) 
Gelelectrophoresis camber           (Bio-Rad, München) 
Heating Block: DB-3             (Techne, Cambridge, UK),  
Heizblock                (Liebisch, Bielefeld) 
Heating stirrer: Typ RCT            (Jahnke & Kunkel, Staufen i. Br.) 
HERA safe                (Heraeus, Thermo Electron, Langenselbold) 
Incubator: Heraeus             (Thermo Electron, Langenselbold) 
Leica IRB                (Leica Microsystems, Wetzlar) 
Leica TCS SP5 Confocal           (Leica Microsystems, Wetzlar) 
Leica Microtom 2065             (Leica Microsystems, Wetzlar) 
Mikro 200 table centrifuge           (Hettich, Tuttlingen) 
Micro scales: R160P             (Sartorius, Göttingen) 
Mini-PROTEAN II System           (Bio-Rad, München) 
MSC advantage laminar flow          (Thermo Scientific, Braunschweig) 
NanoDrop 1000              (PeqLab Biotechnologie, Erlangen) 
Neubauer chamber (0.1 mm, 0.0025 mm2)      (Hartenstein, Würzburg) 
Nuaire laminar flow             (Nuaire) 
Power Pack P24 and P25           (Biometra, Göttingen) 
Refrigerated Centrifuge 3K30          (Sigma-Aldrich, München) 
Scale: 10-1000 g              (Sartorius, Göttingen) 
Selectomat S2000 autoclave          (Münchner Medizin Mechanik, München) 
G24 shaking incubator            (New Brunswick Scientic, Edison, N.J.,  
                  USA) 
Spectrophotometer U-2000           (Hitachi, NY, USA) 
TECAN ELISA reader            (Tecan Group, Crailsheim) 
T-Gradient Thermocycler           (Biometra, Göttingen) 
TH30 shaking incubator            (Hartensein, Würzburg) 
Tricarb scintillation counter           (Packard) 
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Trio-ThermoblockTM heated lid         (Biometra, Göttingen) 
Trio-ThermoblockTM oil           (Biometra, Göttingen) 
Vacuum pumpt              (ILMVAC, Ilmenau) 
Vortex mixer: L46              (Gesellschaft für Laborbedarf, Würzburg) 
Zeiss microscope Imager Z1 AXIO        (Zeiss, Wetzlar) 
with AxioCam MRm   
 
4.1.2 Consumables 
 
96-well plates               (Sarstedt, Nuembrecht) 
48-well plates   (Greiner Bio-One International AG, 
 Kremsmünster Österreich) 
24-well plates               (Nunc, Roskilde, Denmark) 
12-well plates               (Nunc, Roskilde, Denmark) 
25 cm2                 (Sarstedt, Nümbrecht) 
75 cm2                 (Sarstedt, Nümbrecht) 
175 cm2                 (Sarstedt, Nümbrecht) 
Microtom sample adapter           (Rudens Plastinindusti, Hestra, Sweden) 
Microinjection cannula,            (Braun Melsungen AG, Melsungen) 
sterile 0.30 x 12mm BL/LB 30G x ½ “  
 
Nitrocellulose membran            (GE Healthcare, München) 
 
PD-10 column               (GE Healthcare, München) 
Radiographic Film              (Fujifilm Europe, Düsseldorf) 
Safe-Lock Tubes 0,5, 1,5 and 2 ml        (Eppendorf, Hamburg) 
Semi-micro cuvettes             (Sarstedt, Nümbrecht) 
Sterilfilter                (Nalgene, New York, USA) 
Sterile tubes, 15 and 50 ml           (Greiner, Nürtingen) 
Superfrost Plus slides            (Thermo Scientific, Braunschweig) 
Syringes and canula, sterile           (Braun Melsungen AG, Melsungen) 
Whatman blotting paper            (GE Healthcare, München) 
X-Ray film HyperfimTM -MP          (Amersham, Braunschweig) 
 
4.1.3 Chemicals, media, commercially available kits and Enzymes 
[14C]-D-Glucose              (Hartmann Analytic, Braunschweig) 
2’,5’-Dideoxyadenosine            (Sigma-Aldrich, München) 
3,3 Diaminobenzidine 4 Hydrochloride       (Serva, Heidelberg) 
5-Bromo-2-Deoxyuridine            (AppliChem, Darmstadt) 
Adenine hemisulfate             (Sigma-Aldrich, München) 
Agarose                 (Carl Roth, Karlsruhe) 
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Albumin fraction V (pH 7) Blotting grade (BSA)     (AppliChem, Darmstadt) 
Ammonium peroxodisulfate (APS),        (Carl Roth, Karlsruhe) 
Artemisinin 98% 361593-100MG         (Sigma-Aldrich, München) 
Aqua demin. (VE-water) 
Aqua B. Braun Spüllösung 1 Liter         (B. Braun Melsungen  AG, Melsungen) 
Ampuwa                (Fresenius, Bad Homburg) 
Ampicillin                (Sigma-Aldrich, München) 
Antarctic Phosphatase            (New England Biolabs Inc., Schwalbach) 
AS601245                (Calbiochem, Merck, Darmstadt) 
BA-6; BA-3-33, BA-3-35; BA-3-29;         (University of Siena) 
BA 3-61; BA 103; BA -126; BA 3-45  
Bacto agar                (Difco Laboratories, Augsburg) 
Bathocuproine disulfonic acid          (Sigma-Aldrich, München) 
BI 2536 Catalog No.S1109           (Selleck Chemicals, München) 
BI 6727 Volasertib Catalog No.S2235        (Selleck Chemicals, München) 
BIRB 796 Doramapimod Catalog No.S1574      (Selleck Chemicals, München) 
CIP                  (New England Biolabs Inc., Schwalbach) 
Chloroform                (Merck, Darmstadt) 
CloneJET PCR Cloning Kit pJET 1.2        (Thermo Scientific, Braunschweig) 
Color Plus Prestained Protein Marker (10- 230 kDa)  (NEB, Schwalbach) 
Colorimetric Cell Proliferation ELISA BrdU      (Roche, Grenzach) 
Complete Mini phosphatase inhibitor Mix       (Roche, Grenzach) 
Ciprofloxacin Kabi 2mg/ml- Infusionslösung     (Fresenius KABI Austria GmbH, Graz) 
Dimethyl sulfoxide (DMSO)          (Sigma-Aldrich, München) 
Dimethyl sulfoxide,             (Sigma Life Science, München) 
for inhibitors in cell culture (D8418-50ml)  
dNTP lyophilised              (Carl Roth, Heidelberg) 
DMEM- glucose free             (Biochrom, Berlin) 
DMEM- GlutaMAXTM (DMEM)          (Invitrogen, Darmstadt) 
DMEM no phenolred             (Invitrogen, Darmstadt) 
DO Supplement –Ade/–His/–Leu/–Trp       (Clontech, Heidelberg) 
DO Supplement –Leu/–Trp           (Clontech, Heidelberg) 
Entellan                 (Merck, Darmstadt) 
Eosine                 (Roche, Mannheim) 
Fetal Calf Serum (FCS)            (Invitrogen, Darmstadt) 
GW843682X 98% G2171-1MG          (Sigma-Aldrich, München) 
Haemalaun                (Roche, Mannheim) 
Hystidine HCL mono-hydrate          (Sigma-Aldrich, München) 
Imatinib-mesylate              (Enzo Life Sciences, Lörrach) 
Insulin, recombinant human           (Sigma-Aldrich, München) 
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K11777                 (By courtesy of Caffrey Conor, UCSF, USA) 
KOD Hot Start DNA Polymerase (71086-3)      (Merck KGaA, Darmstadt)  
L-Cystein                (Sigma-Aldrich, München) 
Lufenuron PESTANAL® 31662-100MG       (Sigma-Aldrich, München) 
Matchmaker Two Hybrid System 3        (Clontech, Heidelberg) 
β-Mercaptoethanol             (Sigma-Aldrich, München) 
2-Methoxyestradiol (2-MeOE2) Catalog No.S1233    (Selleck Chemicals, München) 
Mycophenolic acid M3536-50MG         (Sigma-Aldrich, München) 
NucleoSpinR Extract II            (Macherey-Nagel, Düren) 
NucleoSpinR PC100             (Macherey-Nagel, Dueren) 
NucleoSpinR Plasmid Kit           (Macherey-Nagel, Düren) 
Oligonucleotides              (Sigma-Aldrich, München) 
OmniscriptR RT Kit             (Qiagen, Hilden) 
Oridonin Catalog No.S2335           (Selleck Chemicals, München) 
pBAD/TOPOR ThioFusionTM Expression Kit     (Invitrogen, Darmstadt) 
PCR Cloning Kits              (Qiagen, Hilden) 
Penicillin/Streptomycin            (Invitrogen, Darmstadt) 
Pepsin                 (Sigma-Aldrich, München) 
PierceR BCA Protein Assay Kit          (Thermo Scientific, Braunschweig) 
PierceR ECL westen blot substrate        (Thermo Scientific, Braunschweig) 
Pierce ReactBindR             (Thermo Scientific, Braunschweig) 
ProBondTM Nickel-Chelating Resin        (Invitrogen, Darmstadt) 
Proteinase K               (AppliChem, Darmstadt) 
Phenytoin Zentropil®             (Sandoz Pharmaceuticals GmbH, Ismaning) 
RNAse A                (Roche, Grenzach) 
RNAseOut                (Invitrogen, Darmstadt) 
Peptone                 (Difco Laboratories, Augsburg) 
Phospho DetectTM Phosphoserine Detection kit    (Calbiochem, Merck, Darmstadt) 
PhosStop                (Roche, Grenzach) 
Polyethylene glycol             (PEG 3350, Sigma-Aldrich, München) 
PrimeScript RNA Polymerase          (Takara, Verviers, Belgium) 
Rapamycin                (Cell Signalling, NEB, Schwalbach) 
Resazurin                (Sigma-Aldrich, München) 
Restriction enzymes             (New England Biolabs Inc., Schwalbach) 
RotiphoreseR Gel 30 (37,5:1)          (Carl Roth, Karlsruhe) 
RotiphoreseR Gel 40             (Carl Roth, Karlsruhe) 
RQ1 RNase-Free DNase           (Promega, Mannheim) 
SmartLadder               (Eurogentec, Köln) 
SMARTTM RACE cDNA Amplification kit      (Clontech, Heidelberg) 
SOC                  (Invitrogen, Darmstadt) 
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Sodium taurocholat             (Sigma-Aldrich, München) 
Sodium hydroxide 306576-25G         (Sigma-Aldrich, München) 
SuperSignal West Femto Chemiluminescent Sub.   (Thermo Scientific, Braunschweig) 
T4 DNA Ligase              (New England Biolabs Inc., Schwalbach) 
Taq-Polymerase              (New England Biolabs Inc., Schwalbach) 
TAK-715 Catalog No.S2928           (Selleck Chemicals, München) 
TavanicR (Tava, active component        (Aventis) 
levofloxacin, 5mg/ml)  
Technovit 8100              (Heraeus Kulzer, Wehrheim) 
TEMED (N,N,N’,N’-Tetramethylethylendiamin)     (Merck, Darmstadt) 
TritonR X-100               (Sigma-Aldrich, München) 
TrizolR Reagent              (Invitrogen, Darmstadt) 
TOPO-TA CloningR KIT            (Invitrogen, Darmstadt) 
Trypsin/EDTA (0,05%/0,02% (w/v)/        (Biochrom, Berlin) 
PBS w/o Ca2+, Mg2+)  
TweenR 20                (Merck, Darmstadt) 
UlitmaGoldTM               (Perkin Elmer, Rodgau) 
Yeast extracts               (Difco Laboratories, Augsburg) 
Yeast nitrogen base w/o amino acids        (Difco Laboratories, Augsburg) 
Zeiss Immersol 518F Immersionsöl        (Zeiss, Wetzlar)  
 
All inhibitors were dissolved in Dimethyl sulfoxide (usable for cell culture, D8418, Sigma Aldrich), 
aliquoted into 0.5 ml tubes at concentrations for treatment (1000x fold higher) and stored at -80°C until 
usage. 
All buffers and solutions were made with commercial Aqua B. Braun sterile water. For RNA, either 
DEPC-treated or RNase-free water was used. For enzymatic reactions, double distilled and 
autoclaved water was used. 
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4.1.4  Oligonucleotides 
   A list of all genes specific Primers (AKO-Number/ASO-Number) used within this thesis is 
given in Tab. S1 in the supplement material. 
 
4.1.5  Plasmids 
Plasmid Sequencing Primer Sequence  
pDrive T7 (T7-Primer) GTAATACGACTCACTATAG 
SP6 CATTTAGGTGACACTATAG 
pBad/Thio-Topo® pBad fw (AKO-11) GCTATGCCATAGCATTTTTATCC 
pBad rev (AKO-12) GACTAAATTAGACATAGTCCG 
pJET1.2  
CloneJET  
pJetfw (AKO-95) CGACTCACTATAGGGAGAGCGGC 
pJetrev (AKO-96) AAGAACATCGATTTTCCATGGCA 
pSec-HygroA psecfw or T7 CTAGTTATTGCTCAGCGGTGG 
psecrev or   TAATACGACTCACTATAGGG 
pcDNA3.1 pcDNA3.1rev CTAGAAGGCACAGTCGAGGC 
T7 (T7-Primer) GTAATACGACTCACTATAG 
 
4.1.6  Antibodies 
   Primary antibodies: 
Antibody Dilution Source Company 
Elp 1:1000 5 % skim milk TBST Mouse Cell Signalling 
β-Actin 1:1000 5 % BSA TBST Rabbit Cell Signalling 
anti-Plk1 
(phosphor T210) 
1:500 5 % skim milk TBST Rabbit Abcam 
(ab12157) 
anti-Polo-like Kinase 
(Plk1) pT210 
1:1000 5 % skim milk TBST Rabbit Antibodies-online.com 
(ABIN129581) 
anti-PLK-1 1:500 5 % skim milk TBST Rabbit BioLegend (Catalog #/ 
618501; Clone Poly6185) 
 
Secondary antibodies: 
Antibody Dilution Company 
anti-mouse IgG–HRP 1:10.000 5 % skim milk TBST Jackson, ImmunoResearch 
anti–rabbit IgG–HRP 1:5.000 5 % skim milk TBST Jackson, ImmunoResearch 
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4.1.7  Echinococcus multilocularis isolates 
 
Isolate (Sample 
accession number) 
Origin of Isolate Year of infectionUsed for experiments 
H95 (ERS097684) Oral infection of jirds 
(Meriones unguiculatus) by 
oncospheres of from the 
intestine of a fox. 
1995 Co-culture of metacestode 
vesicles, isolations of primary 
cells. 
GH09 (ERS097686) Javaner Affe (Macaca 
fascicularis) intermediat 
host  
2009 Co-culture, isolation of  
protoscoleces and primary cells
Ingrid (G-Nr. 8292) Javaner Affe (Macaca 
fascicularis) intermediat 
host (female *19.06.1988 
ƚ14.09.2010) 
2010 Co-culture, isolation of 
protoscoleces and primary 
cells. The production of 
protoscoleces is reduced. 
J2012 (G-Nr. 8604) Javaner Affe (Macaca 
fascicularis) intermediat 
host (male *26.12.2003 
ƚ16.02.2012) 
2012  
 
Co- culture, isolation of 
protoscoleces and primary 
cells. DPZ 13 (G-Nr. 8785) Javaner Affe (Macaca 
fascicularis) intermediat 
host (female *13.07.2008 
ƚ30.01.2013) 
2013 
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4.2  Methods 
4.2.1  Working with nucleic acids 
4.2.1.1 Determination of nucleic acid concentrations and purity 
   Nucleic acid concentrations of RNA/DNA were determined photometrical at a wavelength of 
260nm with the spectrometer NanoDrop 1000. The protein, organic compounds and salt impurities of 
nucleic acids were analysed based upon the ratio of 260nm/280nm (protein; pure DNA, A260/280 is 1.8; 
pure RNA A260/280 is 2.0) and 260nm/230nm (salt; expected values for A260/230 are in the range of 2.0-
2.2). Concentrations of DNA fragments/bands were also estimated by comparison of the band 
intensity to the known DNA standard concentration given by the marker (e.g. SmartLadder, 
Eurogentec) in agarose gels. 
 
4.2.1.2 Isolation of total RNA from E. multilocularis larval stages 
 Parasite material (metacestode vesicles, primary cells and protoscoleces) were washed 
intensively with cold 1x PBS and centrifuged at 600g for 2 minutes (‘) at room temperature (RT). The 
supernatant was removed and 1ml of TRIzol® reagent was added. (The volume of parasite material 
should not be more than 10% of the total volume.) Parasite material was disrupted by re-suspension 
with a 1ml pipette and vortexed for 20 seconds (‘’), followed by 5’ of lysis at RT. Chloroform (200µl) 
was added followed by vortexing for 20’’and incubated for 5’ at RT. The sample was centrifuged at 
12000g for 15min at 4°C and the upper water phase was transferred to a new tube. For precipitation of 
the RNA, 0.7 Vol% Isopropanol was added and the tube was placed at -20°C for at least 2 hours (h) or 
overnight (O/N). Additional salts like the frequently used 10 Vol% of 2M sodium acetate 5.2 pH were 
not utilised based upon the already high salt concentration of TRIzol®. Nucleic acids were pelleted by 
centrifugation at 12000g for 10min at 4°C, the supernatant was removed and the pellet was washed 
with ice-cold 70% ethanol. An additional centrifugation step at 12000g for 5min at 4°C followed, 
whereby the supernatant was removed and the pellet was air-dried. The pellet was dissolved in DMPC 
treated water and the concentration was determined photometrical at the NanoDrop 1000. The quality 
of the RNA was analysed by an RNA-agarose gel. RNA was stored at –80°C or subsequently reverse 
transcribed into cDNA.    
 
4.2.1.3 DNase treatment of isolated total RNA 
 To remove co-precipitated genomic DNA from isolated total RNA samples, RNA was treated 
according to the commercial available protocol of RQ1 RNase-Free DNase (Cat.# M6101) from 
Promega. RQ1 DNase was heat inactivated for 10’ at 65°C. A second phenol-chloroform extraction 
was not carried out.    
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4.2.1.4 Reverse transcription of RNA into cDNA 
 Reverse transcription of RNA was carried out using PrimeScript™ Reverse Transcriptase 
from Takara (2680A, Clontech) or SuperScript® III Reverse Transcriptase from Life-technologies 
(18080044, Invitrogen). In both cases, the manufactures recommendation formula was used to 
reverse transcribe 1-2µg of total RNA. In addition to the reverse transcription protocol, 1µl of a 
recombinant ribonuclease inhibitor (10777-019, RNaseOUT™) from Life-technologies was added to 
the reaction. For all cDNA synthesis, the same oligo-dT-primer was used (AKO-cDNA) for 1h at 42°C 
of reverse transcription.  
 
4.2.1.5 Isolation and preparation of DNA from metacestode vesicles of E. multilocularis 
 Genomic DNA was isolated from metacestode vesicles (isolate H95). Metacestode vesicles 
were disrupted by pipetting and intensively washed with 1x PBS to remove the hydatid fluid. The 
metacestode vesicles were pelleted by centrifugation for 10’ at 5000g at RT. The supernatant was 
removed and the pellet was re-suspended in lysis buffer (100mM NaCl, 10mM Tris-HCL, pH 8.0, 
50mM EDTA pH 8.0, 0.5 % SDS, 20 µg/ml RNase A; 1.2 ml/100mg pellet) supplemented with 0.1 
mg/ml Proteinases K. To ensure a complete digestion of the metacestode vesicles an O/N incubation 
at 50°C was completed. On the following day, a phenol-chloroform extraction was performed followed 
by ethanol precipitation to concentrate the DNA (the exact protocol was established by Markus 
Spiliotis and includes the following steps), Briefly, an equal amount of phenol-chloroform-isoamyl-
alcohol (25:24:1) was added to the O/N treated sample solution. After centrifugation for 25’ at 2000g at 
RT, the upper aqueous phase was transferred into a new tube. This step was executed two times to 
ensure the remove of protein digestion products. The DNA was precipitated by adding of 0.1 Vol% of 
LiCl (stock 5M; pH 4.5) and 2 Vol% of 96% ethanol followed by incubation O/N at -20°C. On the 
following day, a centrifugation step for 30’ at 20000g at 4°C was carried out. The supernatant was 
removed and the pellet was washed with 70% ethanol followed by a second centrifugation step, the 
supernatant was removed and air-dried. The pellet was re-suspended in 1x TE buffer (10mM Tris, 
1mM EDTA pH 8.0).  
For concentration of DNA solutions (water based) 0.1 Vol% of the 3M sodium acetate pH 5.2 and 0.7 
VOL% of isopropanol (98%) or 2.5 Vol% of ethanol (96%) were added. After mixing the samples were 
incubated O/N at -20°C. The DNA was pelleted by centrifugation at 12000g for 30min at 4°C. The 
supernatant was removed and the pellet washed with 70% of ice-cold ethanol. After a second 
centrifugation step for 5’ at 12000g at 4°C, the supernatant was removed and the pellet was re-
suspended in water or 1x TE buffer (10mM Tris, 1mM EDTA pH 8.0).   
 
4.2.1.6 Amplification of DNA by DNA-Polymerase Chain Reaction (PCR) 
   All polymerase chain reactions were carried out with custom–made oligonucleotides from 
Sigma Aldrich (DNA oligos, PCR concentration 10µM) and included in the primer list (Tab. S1) in the 
supplemented material. The annealing temperature was estimated by the online software program 
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“Tm Calculator” on the New England Biolabs (NEB) webpage (https://www.neb.com/tools-and-
resources/interactive-tools/tm calculator). A calculation of the annealing temperature with the equation 
according to the Wallace rule Ta [°C] = 4x (G+C) + 2x (A+T) was not undertaken. The elongation time 
(Etime) was calculated with 1kb/min for the Taq DNA-Polymerase (NEB) with an elongation temperature 
(Etemp) of 72°C. For the proof reading KOD Hot Start DNA-Polymerase (Novagen) an Etime of 3kb/min 
with an Etemp of 70°C was used. PCR amplification was carried out to the manufacture protocol for 
both DNA-Polymerases (initial denaturation = ID; primer annealing time = AT; elongation time = Etime; 
final elongation = FE). To increase the primer specificity to a total PCR volume (50µl) 1µl MgCl2 
(25mM) or MgSO4 (25mM) was added additionally to the reaction in the case of the Taq DNA-
Polymerase (NEB).  
 
4.2.1.7 Purification of DNA from Agarose gels or enzymatic modifications of in vitro reactions 
   Agarose gels were used to separate enzymatic digested plasmids or PCR amplified DNA 
fragments by size under usage of electrophoresis. DNA bands of interested were excised and purified 
with the commercial available NucleoSpin® Gel and PCR Clean-up kit (Macherey-Nagel; REF 
740609.250). DNA samples that were enzymatic modified (e.g. restriction digest, poly-A-tailing, 
alkaline phosphatases treatment) in vitro have been purified with the same kit. In both cases, the 
manufacturer’s instruction were followed.  
 
4.2.1.8  Isolation of plasmid DNA from Escherichia coli  
 The isolation of plasmid DNA from E.coli stains was performed with the NucleoSpin® 
Plasmid Kit (Macherey–Nagel; REF 740588.250). A 5 ml O/N bacterial (LB Media, with antibiotic 
resistance) culture was inoculated with the bacterial stain of interest and 4ml of the O/N culture was 
used for DNA-plasmid isolation.  
 
4.2.1.9  Sequencing of plasmids 
 Isolated plasmids were sequenced by the company “Gesellschaft für Analyse-Technik und 
Consulting” (GATC in Konstanz, Germany). According to the company protocol for isolated DNA 
(plasmid 300ng-500ng; PCR product 200ng-300ng), 1µl of sequencing-primer (10µM) was added to 
the DNA in a final volume of 10µl.   
  
4.2.1.10  Semi-quantitative reverse transcribed polymerase chain reaction (RT-PCR) 
Total RNA was isolated from parasite material according to the isolation protocol for total 
RNA. Metacestode vesicles, primary cells of day 2, day 5 and day 11 isolated from metacestode 
vesicles as well as non-activated and in vitro activated protoscoleces obtained from gerbil material 
was used. Isolated RNA was DNase treated (RQ1 RNase-free DNase, Promega) followed by phenol-
chloroform extraction. RNA concentration was quantified spectrophotometricaly and 750 ng of each 
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stage were used for reverse transcription (RT) and used as a template for gene-specific PCR. Intron-
flanking, gene-specific primers were used to estimate the semi-quantitative expression profile by PCR 
employing a protocol of 32 cycles. The constitutively expressed gene elp (Primer AKO-36, AKO-037) 
served as a quantitative control. 
 
4.2.1.11 Colony PCR 
To prove the integration of amplified DNA fragment into the multiple cloning sites (MCS) of 
corresponding target plasmids, a colony PCR was carried out. A gene and a plasmid specific primer 
was selected and used for PCR with Taq DNA-Polymerase (NEB). A bacterial colony was picked from 
a PCR-tip and suspended in 30µl of sterile water. For PCR, 3µl of this bacteria-suspension were used 
under standard conditions for Taq DNA-Polymerase. The initial denaturation step of the PCR cycle 
programme was extended for 5’ to disrupt the bacterial cells. Bacterial colonies showing the right 
amplified PCR fragment size were used for a bacterial O/N culture followed by plasmid isolation.  
 
4.2.1.12 Agarose gel electrophoresis 
Separation of PCR amplified DNA products were carried out by agarose gel electrophoresis. 
Depending on the size of the DNA fragments, different concentrations of agarose were dissolved in 1x 
TAE Buffer (40mM Tris, 1mM EDTA, pH 8.0, 0.11% glacial acetic acid in 1liter of H2O, pH 8.5) and 
stored until use at 55°C. For the separation of DNA fragments larger than 4 kilo bases (kb), an 
agarose concentration of 0.7% was chosen. For DNA fragments in size of 0.2 to 7kb an agarose 
concentration of 1% was used. DNA fragments shorter than 0.5kb have been separated in 1.5% or 2% 
agarose gels. The overlapping DNA fragment size to the chosen agarose concentration is not strict 
and also depends on the biological question to be addressed. Agarose gels have been poured into a 
horizontal gel sleigh with loading wells left by a fitting comb. The DNA samples were mixed with 6x 
loading buffer, for agarose gels (0.25% bromophenol blue, 0.25% xylene cyanol, 40% saccharose and 
30% glycerol) and separated at a voltage of 80-140 volts for 20 to 45min. Visual observation of the 
electrophoretic separation was recognised by the two dyes bromophenol blue and xylene cyanol of the 
loading buffer. In a 1% agarose gel, the bromophenol blue band and the xylene cyanol dye 
correspond to a 0.3 kb and a 3kb DNA fragment. Ethidium bromid (EtBr) was used to stain separated 
DNA fragments; therefore, EtBr (0.2 mg/ml in 1xTAE) was dissolved and the agarose gel was 
incubated for 15min at RT. For visualisation of DNA fragments, UV light was used. In all agarose gels, 
a size marker was used to determine the size of the separated DNA fragment (SmartLadder, 
Eurogentec). In case of the electrophoretic separation of RNA in agarose gels, all materials used were 
treated with 2% peroxide solution (H2O2, 32% VOL) for at least 30’, followed by intensive washing with 
sterile water.     
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4.2.1.13 Addition of 3’ Adenosine overhang on PCR amplified DNA fragments (TOPO TA 
cloning) 
The Taq DNA-Polymerase automatically adds at the 3’-end of a PCR product an additional 
adenosine. This property can be used to clone the amplified DNA fragment into a plasmid supporting 
this so-called TA cloning. The plasmid “pDrive” (Qiagen) is a linearised plasmid with a tyrosine at its 
5’-end. The insert (DNA) and linearised plasmid were incubated following the manufactures 
instruction. Ligated plasmid was transformed into competent bacterial cells (E.coli TOP10). Selection 
of bacterial colonies was conducted by blue-white screen (X-Gal) and colony PCR.   
 
4.2.1.14 Bioinformatical and statistical analysis 
The E. multilocularis genome sequence assembly was used as available in GeneDB 
(http://www.genedb.org/Homepage/Emultilocularis). In addition to the basic local alignment search tool 
(BLAST) of GeneDB, the National Center for Biotechnology Information (NCBI) BLAST programme 
was used for amino acid comparisons (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Amino acid sequence 
and domain predictions were carried out using UniProt (http://www.uniprot.org/) and SMART 
(http://smart.embl-heidelberg.de/) software. Based upon the genomic sequence information, primers 
were designed to amplify the full coding sequence. Amino acid alignments were constructed with the 
programmes CLUSTA W(2) and MUSCEL, integrated in the software BioEdit (Version 7.1.11). 
Modification of the alignments - if needed - were carried out manually. 
All experiments were performed with at least three technical and biological replicates. Linear 
regression analysis was carried out using Microsoft Excel-2007. Error bars in figures represent 
standard deviation. Differences were considered significant for p-values below 0.05 (indicated by (*)), 
for p-values between 0.001 and 0.01 (**), and for p< 0.001 (***). For p> 0.5, differences were 
considered non-significant. 
 
4.2.1.15 Modification/restriction digests of DNA plasmids or amplified DNA fragments 
Restriction digest and modifications of purified or amplified DNA fragments was carried out 
with enzymes purchased from NEB. Re-ligation of plasmids was avoided by dephosphorylation of the 
plasmid by CIP- or antarctic phosphatase from NEB. All enzymes were used according to the 
manufactures recommendations. Restriction digests were carried out for 2h and CIP or antarctic 
phosphatase treatment for 45’ at 37°C. 
 
4.2.1.16  Ligation of DNA fragments into plasmids 
DNA fragments from plasmid or PCR amplification with or without restriction digest were 
ligated with T4 DNA-Ligase (NEB). The ligation reaction was incubated O/N at 16°C. In case of blunt-
end ligation of DNA fragments, the pJET1.2 CloneJET (Thermo Scientific) was used according to the 
manufactures instructions (20’ at RT). The (molar) concentration of the DNA was calculated as follow 
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(ngInsert = [(ngVector x kbInsert)/(kb Vectro) x Ratio]. For all ligations, a ratio of 3:1 - 5:1 of DNA 
insert to vector was used.   
 
4.2.2 Working with bacteria 
4.2.2.1 Bacteria strains and media used in this study 
E. coli DH5α Invitrogen F-Φ80dlacZΔM15 Δ(lacIZY-argF) U169 recA1 endA1 
hsdR17(rk-,mk-) phoA supE44 thi-1λ gyrA96 relA1 tonA 
E. coli TOP10 Invitrogen F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 
araD139 Δ(ara-leu)7697 galU galK rpsL (StrR) endAI nupG 
E. coli BL21 Amersham B F-, ompT, hsdS (rB-,mB-), gal, dcm 
 
4.2.2.2 Media for bacteria culture 
Luria-Broth (LB)  Invitrogen  
LB agar plates Invitrogen LB medium with 1.5% Bacto-Agar 
SOC Media Invitrogen  
 
All bacterial strains were grown on LB agar plates or in liquid culture under shaking conditions 
(225rpm) at 37°C. Bacterial culture media or agar plates were supplemented with antibiotics 
dependent on the transformed plasmid resistance (Ampicillin AmpR (AmpR 100µg/ml) Kanamycin KmR 
(KmR 50µg/ml) or Chloramphenicol CmR (CmR 50µg/ml)). 
 
4.2.2.3 Overnight culture of bacterial cultures 
Bacterial strains were on LB agar plates plated O/N and incubated at 37°C supplemented 
with antibiotics. A single bacterial colony was picked with a sterile plastic tip and a 5ml LB-liquid 
culture supplemented with antibiotic was inoculated and grown O/N under shaking conditions 
(225rpm) at 37°C. 
 
4.2.2.4 Bacterial liquid cultures of E. coli 
All bacterial liquid cultures were incubated at 37°C under shaking conditions of 225rmp. The 
culturing flask was chosen whereby one-fifth of the total volume was filled with LB media. Bacterial 
cultures were inoculated from O/N culture. For expression of proteins, a special flask “Schikanekolben” 
(DURANR) was chosen, namely an Erlenmeyer flask with four baffles on the bottom to interrupt the 
laminar flow to create a turbulent flow.  
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4.2.2.5 Chemical competent bacterial cells (E. coli) 
Uptake of extracellular DNA is a natural property of bacterial strains. An increase of DNA 
uptake could be observed by treatment of bacteria with calcium chloride (CaCl2) generating competent 
cells. Bacterial strains TOP10 of BL21 were treated as follows to make them chemically competed. A 
bacterial O/N culture of 1ml was inoculated and grown at 37°C and 225rpm. The O/N culture was 
transferred into 50ml of fresh LB media and further grown at 37°C and 225rpm until the OD600 of 0.5 -
0.7 was reached (~ 2-3 h). The bacteria were pellet by centrifugation for 10’ at 500g at 4°C. The 
supernatant was discarded and the pellet was re-suspended in 12ml of ice cold 100mM CaCl2 and 
centrifuged. The supernatant was discarded and the pellet was carefully re-suspended in 1ml of fresh 
100mM CaCl2 and incubated on ice for up to one hour. Glycerol (86%) was added in a final 
concentration of 20%. The bacteria were frozen on dry ice in aliquots of 50µl and stored at –80°C until 
use.  
 
4.2.2.6 Transformation of E. coli 
An aliquot of competent bacterial cells were thawed on ice and 5-10µl of ligated plasmid was 
added. The transformation reactions were incubated for 45’ on ice, followed by a heat shock of 90’’ at 
42°C and additional cooling on ice for 2’. In case of plasmid born antibiotic resistance with CmR or 
KmR to 250µl of SOC or LB media was added to the transformation suspension and the reaction was 
incubated at 37°C under shaking (225rpm) conditions for 2h. During this incubation time, the antibiotic 
resistance develops. Incubation in SOC or LB Media for by AmpR resistance is not necessary based 
upon the fact that AmpR only acts bacteriostatic and not bactericidal like KmR or CmR. The bacteria 
were centrifuged at 500g for 3’ at RT. 150µl of the supernatant was discarded, the bacterial pellet was 
re-suspended and the suspension was plated on LB agar plates supplemented with the antibiotic 
resistance. LB agar plats were incubated over night at 37°C. In case of the vector pDrive (Quiagen) 
40µl of X-Gal (40mg/ml) in DMSF) was plated additionally before plating the bacterial suspension.       
 
4.2.2.7 Dimethyl sulfoxide (DMSO) bacterial stocks (at -80°C) 
Bacterial strains with proofed sequences of plasmids were stored in DMSO-stocks at -80°C 
in cryo-caps. DMSO-stocks were made by 90%Vol (0.9 ml) of a bacterial O/N culture and 10%Vol (0.1 
ml) of DMSO. The DMSO stock was frozen immediately at -80°C. For inoculation of a bacterial culture 
of a strain or for streaking on a LB agar plate, a small portion was scraped of the frozen culture.   
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4.2.3 Working with eukaryotic cell lines 
4.2.3.1 Echinococcus multilocularis media used in the in vivo and in vitro cell culture 
Media and solutions Preparation 
Culture medium DMEM, 10% FCS, 1% PST, 4µl Levofloxacin (Tavanic) or 
Ciprofloxacin. 
A4 media Pre-incubation of 100ml culture medium for 7 days with 106 Rh- 
cells, sterile filtration and stored at -20°C until use. 
B2 media Pre-incubation of 100ml culture medium for 3 days with 2x107 Rh- 
cells, sterile filtration and stored at -20°C until use. 
cMEM Undefined conditioned medium (sterile filtered supernatant of Rh- 
cells from co-culture.  
Reducing agents 100µM L-Cysteine, 10µM Bathocuproine disulfonic acid,  
0.01% β-mercaptoethanol. 
 
4.2.3.2 Cultivation of feeder cells  
For in vitro cultivation of metacestode vesicles, feeder cells are necessary. Based upon 
several tests with different cell lines, the cell line of Reuber hepatoma cells (Rh-; ATCC No.: CRL-
1600) was selected. The cells were cultivated in 50ml of culture media in a 75cm² cell culture flasks 
and trypsinised once a week. After trypsinisation, the cells were counted with a Neubauer camber and 
106 cells were seeded in fresh media. Cells were cultivated at 37°C and 5% CO2 atmosphere with 
saturated humidity. 
 
4.2.3.3 Isolation and maintenance of in vivo parasitic material from Mongolian jirds 
The long-term maintenance of E. multilocularis metacestode is ensured by the repeated 
passages in the peritoneum of laboratory animals. Therefore, Mongolian jirds (Meriones unguiculatus) 
were infected with homogenised larval material of a single isolate by intraperitoneal injection to 
develop, secondary AE. Animals selected for this procedure were about three months old. By 
successful infection of E. multilocularis into the jirds secondary AE developed after approximately two-
to-three months. Isolate-specific characteristics of parasite material concerning the growth time and 
tissue material features could be drawn. Animals were scarified with CO2 and the parasite material 
was isolated under sterile conditions. Jirds were intensively washed with 70%Vol ethanol before 
parasite material was isolated. The isolated parasite tissue was cut into small pieces (0.5-1cm slices) 
and subsequently strained through a metallic tea sieve. The ground material was subsequently 
washed at least three times with sterile 1x PBS to remove host cells (blood cells). (At this point, 
different ways depending of the following experiments were able to choose.) The isolation of 
protoscoleces from smashed parasite material is described in chapter 4.2.3.6. For reinfection of jirds 
with parasitic material, the isolated material was incubated O/N at 4°C supplemented with 
Ciprofloxacin (5µl/ml) and Penicillin G/Streptomycin (10µl/ml). Parasitic material was washed with 1x 
MATERIAL AND METHODS  
 
44 
 
PBS the following day and syringes for reinfection of jirds were prepared (0.3-0.5ml/jird). Furthermore, 
the treated parasite material was used to set up new in vitro cell culture of metacestode larvae 
described in chapter 4.2.3.4.  
 
4.2.3.4 In vitro cultivation of Echinococcus multilocularis 
Isolated homogenised parasitic material was treated O/N with antibiotic as described in 
chapter 4.2.3.3. After intensive washing (3x) with 1x PBS, 1ml of parasitic material was used to set up 
a new 50ml co-culture. As previous described, no additional passing through a plastic tea sieve was 
carried out. The co-culture was supplemented with freshly trypsinised Rh- feeder cells (107). Media 
was changed weekly and new Rh- cells were added during each change. The parasitic material was 
passaged after reaching a certain number as per “reference” [113]. Parasite cells were cultivated at 
37°C and 5% CO2 atmosphere with saturated humidity. 
 
4.2.3.5 Axenic culture of metacestode vesicles of E. multilocularis 
Study cell type specific effects require the independence of possible side-effects reaching 
from other cell types. Rh- cell of the co-culture have to be removed by incubation under axenic 
conditions. Co-cultured metacestode vesicles were removed from supernatant and intensive washed 
with 1x PBS and carefully transferred into a new culture flask (75cm²). Pre-conditioned media (cMEM, 
A4, B2) with reducing agents was added and the atmosphere was changed to a nitrogen atmosphere. 
The lid of the bottle was always closed for cultivation under axenic conditions. Parasitic cells were 
incubated for 2-3 days at 37°C until use.  
 
4.2.3.6 Isolation and activation of protoscoleces 
Parasitic material was isolated from jirds as described in chapter 4.2.3.3. The material was 
transferred into a 50ml tube and diluted with 1x PBS to obtain a 1:4 suspensions and vigorously 
shaken for 10‘ to release the protoscoleces from the metacestode material. To isolate the 
protoscoleces from the rest of the parasitic material, the suspension was filtered by sieving through 
polyester gauze (pore size 150µm). The flow through was filtered by a second finer polyester gauze 
(pore size 30µm). The protoscoleces were collected on the top of the filter and transferred into a Petri 
dish (10cm). By horizontal-circular-rotation, of the Petri dish the protoscoleces were gathered in the 
middle. Protoscoleces were transferred into a 2ml tube for further applications. The residual white 
shadow on the ground of the Petri dish a calcium bodies with are separated from the protoscoleces by 
this method.  
For activation of the protoscoleces (1ml) the gastrointestinal passage was mimicked by adding of 
0.05% pepsin in DMEM (30ml) without FCS at pH 2 (200µl of 25% HCl). The tube was incubated for 
30’ at 37°C under shaking conditions (125rpm). The protoscoleces were washed with 1x PBS to 
remove the acid condition and stop the treatment with pepsin. The supernatant was decanted from the 
sediment protoscoleces and 30ml of 0.2% sodium taurocholate in DMEM without FCS was added. The 
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protoscoleces were further incubated for 3h at 37°C under shaking conditions (125rpm). Finally the 
protoscoleces were washed with 1x PBS and subsequently used for further experiments, like isolation 
of total RNA or setting up an in vitro culture.   
 
4.2.3.7 Cultivation of protoscoleces and live-dead staining 
Protoscoleces isolated from jirds were cultivated in A4-media under axenic conditions 
independent of an activation treatment. In a 12-well plate, approximately 200-400 protoscoleces were 
seeded. To observe the viability of protoscoleces especially after inhibitor treatment, a live-dead 
staining was carried out. Protoscoleces of one well were transferred into a 1.5ml tube washed with 1x 
PBS and stained with 0.03% of methylene blue (in 1x PBS). After 1’ of incubation at RT, the staining 
was stopped by three washing steps with 1x PBS. The protoscoleces were diluted 1:10 with 1x PBS 
and 100µl of the suspension was transferred on a cover side. Microscopic pictures of the 
protoscoleces were taken randomly and the live-to-dead ratio was counted by eye. Dead 
protoscoleces appeared blue, while healthy protoscoleces were not stained.   
 
4.2.3.8 Isolation and cultivation of primary cells from metacestode vesicles 
Metacestode vesicles that were co-cultivated for more than three months and showed a 
milky-white appearance with a thick laminar layer were transferred into a fresh culture flasket and 
axenised for three days. After intensive washing with 1x PBS the metacestode vesicles were 
transferred into a 50ml tube and destroyed by pipetting with a 10ml pipette. To remove the hydatid 
fluid the destroyed metacestode vesicles were sediment by gravity and the supernatant was decanted. 
Metacestode vesicles were pelleted by centrifugation for 3’ at 600g at 4°C. The supernatant was 
removed and four volumes of trypsin (0.05% trypsin, 0.02% EDTA in PBS) were added. An incubation 
time of 25’ at 37°C followed with a harsh shaking after 15min. After trypsinisation, the majority of 
metacestode vesicles were floating at the surface of the liquid (so-called “ghosts”). The suspensions 
was shaken vigorously again for 2min and directly filtered over a polyester gauze (pore size 150µm) 
on top of a glass breaker. The flow through was filtered by a second finer polyester gauze (pore size 
30µm). The flow through was collected in a 50ml tube and centrifuged for 2’ at 100g to remove the 
calcium bodies. The supernatant was transferred by decanting into a new 50ml tube. Primary cells 
were pelleted by centrifugation for 6’ at 600g at 4°C. The pellet was re-suspended in a total volume of 
2ml of pre-warmed A4 media. Subsequently, the cell density was measured at OD600, whereby 12.5 µl 
of the isolated primary cells were diluted in 1ml 1x PBS. An OD600 of 0.2 corresponds to 1Unit of 
primary cells [118, 119]. Ideal grow conditions were noticed with the following combinations of primary 
cells to chosen size of well and volume of A4-media. Primary cells were always cultivated under 
axenic conditions.  
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Plate (wells) Units A4-media (ml) 
6 500 2-2.5 
24 80-100 1.5-1.9 
48 30-50 1-1.4 
96 10-20 0.200-0.280 
 
4.2.3.9 Treatment of metacestode vesicles, protoscoleces and primary cells with inhibitors 
All experiments were performed using the isolate H95, Ingrid and GHO9 of E. multilocularis. 
Mongolian jirds (Meriones unguiculatus) were used for in vivo propagating of the parasite in the 
peritoneum as previously described by Siles-Lucas et al. 2002 [122]. Co-cultivation of parasite material 
in vitro, including metacestode vesicles and isolation of primary cells (stem cells), was carried out 
according to the protocol from Spiliotis et al. 2004 and 2008 [113, 118]. Metacestode vesicles than 
4mm were axenised and protoscoleces and primary cells were isolated as described before. All 
experiments were performed under axenic conditions. In case of inhibitor treatment with metacestode 
vesicles, a 6-well plate was used and 5-10 vesicles were transferred by pipetting and 5ml of A4-media 
was added. All inhibitors were dissolved in DMSO in a 1000 fold higher concentrated as the final used 
concentration, e.g. to a 5ml culture volume, 5µl of inhibitor was added. The A4–media was changed 
every second day by pipetting and fresh pre-warmed media with the final concentration of inhibitor was 
added. In case of inhibitors test in non-activated protoscoleces a 24-well plate with 2ml of A4 media 
was used and an amount of 80% confluence in the well covered with protoscoleces was used. 
Inhibitors were added according the final concentration and media was changed every second day.  
Primary cells were isolated as described before and 50 Units (15000 cells /Units, unpublished) of 
isolated primary cells were seeded in a 48-well plate with 1.0-1.3 ml of conditioned A4-media. The A4-
media was changed every second day and fresh inhibitor was added. All experiments were performed 
with technical and at least three biological replicates. In the case of protoscoleces and primary cells 
not the complete media could was able to removed, only 80%, based upon the biological fact that 
primary cells and protoscoleces are not adhered.  
 
4.2.3.10 Resazurin assay for monitoring viability of primary cells 
Resazurin (7-Hydroxy-3H-phenoxazin-3-one-10-oxide sodium salt) is a redox-sensitive dye 
that can be used for measuring the viability of living cells by absorbance or fluorescence of the cell 
culture media, without having a cell-toxic effect. We optimised the Resazurin assay for our cellular 
requirements based upon free online available protocols. Isolation of primary cells from metacestode 
vesicles was carried out according to the protocol described in detail in chapter 4.2.3.8. Overall, 10 
units of primary cells were seeded per well in a 96-well plate and pre-conditioned media (DMEM with 
phenol red) with rat hepatoma cells (A4-media) was added to a final volume of 200µl. After 24 hours of 
pre-incubation under axenic conditions the formation of cellular aggregation was controlled by light 
microscopy and inhibitors of interested were added to the wells with a 1/1000 dilution (generating their 
final concentration). 1% Triton (X-100) was used as a cytotoxic control. After 48h of further incubation, 
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20µl (1/10 of Vol/%) of Resazurin (Stock solution 20mg/ml in 1xPBS at -20°C; Diluted in 1:100 with 
1xPBS) was added with a final concentration of 0,018mg/ml to each well. The absorbance was 
measured at 570nm with a reference wavelength of 600nm (TECAN 2000 ELISA plate reader). The 
first measurement was directly taken after addition of the Resazurin solution (first measurement; zero 
hours) and after three hours of further incubation (final measurement).  
 
4.2.3.11 Injection of metacestode vesicles 
Metacestode vesicles were incubated under axenic conditions in A4-Media pre-conditioned 
media A4. All metacestode vesicles had a size of more than >0.5cm. After three days of axenic co-
culture, metacestode vesicles were wash intensively with 1x PBS transferred to a 25cm² cell culture 
flask and further in A4-media in the presents of BI 2536 (50nM). Treatment of metacestode vesicles 
was stopped and vesicles were further incubated for five more days to remove the releasing inhibitor 
BI 2536. Metacestode vesicles were transferred into a 24 well plate (1MC/well) at day five of recovery. 
The metacestode vesicles were totally covered by A4-media. Primary cells were isolated according to 
the primary cell isolation protocol chapter 4.2.3.8. Primary cells were re-suspended in 2 ml of pre-
warmed A4-media. For injection of primary cells into stem cell depleted metacestode vesicles, a 1ml 
tuberculin syringe with a fine cannula (Injection cannula, sterile 0.30 x 12mm BL/LB 30G x ½ “, Braun) 
was used. Injection was carried out in a 24 well plate including intact metacestode vesicle with 
covering media. Cannula was injected into metacestode vesicle with high sensitivity and with a soft 
tipping on the syringe. A volume of primary cells with A4 media that was injected into the metacestode 
vesicle could not be estimated. After injection, the cannula was removed with high sensitivity. 
Metacestode vesicles were further co-cultivated under axenic conditions. After five days of co-
cultivation, an EdU pulse experiment was carried out (50µM) for five hours to invest the integration into 
the germinal layer and proliferation of stem cells. As a negative control, metacestode vesicles were 
treated with BI 2536 (50nM) for 21 days. Metacestode vesicles were injected with A4-media without 
primary cells, non- injected and/or primary cells were added to the A4-media without destroying the 
vesicle integrity. EdU staining was carried out according to the previous described protocol [32].  
 
4.2.3.12 Labelling of proliferating cells in whole mount metacestode vesicles by EdU pulse 
staining 
Proliferation of stem cells was investigated by staining of newly-synthesised DNA using the 
Click-iT® EdU cell proliferation assay (Invitrogen, C10337). Metacestode vesicles from hepatocyte co-
culture were washed once with 1x PBS and carefully transferred into a 15 ml tube containing 3 ml A4-
medium. A final concentration of 50 µM EdU (Component A) was added and the metacestode vesicles 
and incubated for 5 h at 37°C (with gentle agitation every 20 min). For fixation, metacestode vesicles 
were transferred to a Petri dish and carefully opened with a syringe tip to remove hydatid fluid. After 
intense washing with 1x PBS, fixative (4% paraformaldehyde (PFA) in 1x PBS) was added and 
samples were incubated for 1 h at RT under shaking conditions. The samples were washed again (1x 
PBS) to remove the fixative, before being transferred to a 1.5 ml tube. The EdU labelling procedure 
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was carried out according to the manufacturer’s instructions (Invitrogen, C10337), but with extended 
incubation times. Metacestode vesicles were finally analysed by fluorescence microscopy. For long-
term treatment (21 days) with BI 2536, metacestode vesicles were cultivated in A4-medium for 21 
days with inhibitor (medium and inhibitor changed every second day), followed by three days recovery 
without treatment. As a control, a medium with an identical amount of DMSO (without inhibitor) was 
used. Randomly chosen metacestode vesicles (t = 4) were isolated and EdU stained as outlined 
above. For each metacestode vesicle, three randomly chosen sections of the GL were analysed by 
microscopy and EdU positive cells were counted. The number of EdU positive cells was calculated to 
cells per mm² of the GL. For short-time inhibitor experiments, metacestode vesicles were treated in 
vitro for 24, 48 and 72 hours with 50 nM or 100 nM BI 2536, followed by 24 h regeneration without 
inhibitor. EdU staining and the calculation of Edu positive cells per mm² of GL were subsequently 
performed as described above. 
 
4.2.3.13 In situ hybridisation of metacestode vesicles 
Metacestode vesicles of GHO9 with brood chambers were used for in situ hybridisation 
according to Koziol et al. (2013) [47]. A 1.3 kb long sequence of EmPlk1 was sub-cloned into pDrive 
cloning vector (Qiagen) using AKO-55 (CTCTCATGGAACTGCATAAGAG) and AKO-60 
(CGATCTATCATATCGTAGGCG). Digoxygenin-labelled antisense and sense RNA was in vitro 
transcribed using T7 or SP6 promotor of the linearised vector. 
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5.   Results 
5.1.  Cloning and characterisation of the Polo-like kinase 1 gene (EmPlk1) of Echinococcus 
 multilocularis  
 In silico analysis by BLASTP genome sequence mining of the available genome data for E. 
multilocularis (http://www.genedb.org/Homepage/Emultilocularis), using the full-length amino acid 
sequence of the human Polo-like kinase 1 as a query, identified a single orthologous gene, emplk1, 
(EmuJ_000471700.1; Echinococcus multilocularis Polo-like kinase 1, EmPlk1) encoding the protein 
EmPlk1 (e-value: 3.5e-161). A second hit in this BLASTP analyses, with much lower homologies (e-
value: 6.2e-52) identified an ortholog of the human Polo-like kinase 4 encoding gene, emplk4, 
(EmuJ_000104700.1; Echinococcus multilocularis Polo-like kinase 4, emPlk4) with, as in the case of 
human Plk4, only one predicted PBD. In both cases, iterative BLASP analyses using the deduced 
EmPlk1 and EmPlk4 amino acid sequences against the SWISSPROT database were carried out and 
confirmed highest homologies and similar domain structures of both proteins to human Plk1 and Plk4, 
respectively. Since currently available Polo-like kinase inhibitors are highly specific for Plk1, but not for 
Plk4, the E. multilocularis EmPlk4-encoding cDNA was cloned (ASS-057) and sequenced, but not 
further analysed in this thesis. The gene emplk1 spans a genomic region of 3174bp and is located on 
chromosome 3 (supercontig pathogen_EMU_scaffold_007614: 4512575-4515749). Analyses of the 
emplk1 exon-intron structure identified seven exons and six introns, which all displayed the canonical 
GT-AG dinucleotide sequences at the splice donor and splice acceptor sites, respectively (Fig. 5.3.1A) 
[129]. Trans-splicing or alternative splicing of emplk1 transcripts were not observed by analysing 
available RNA-deep sequencing transcriptome data [60]. The full-length emplk1 and emplk4 cDNAs 
were cloned from isolated total RNA of metacestode vesicles (isolate H95) using an RT-PCR strategy. 
The total length of the emplk1 open reading frame is 1833bp (cDNA; excluding poly-A tail), encoding a 
protein, EmPlk1, of 610 amino acids (aa) and a calculated molecular mass of 69.5 kDa. Analysis of the 
protein sequence by SMART software (http://smart.embl-heidelberg.de/) identified an N-terminal 
Ser/Thr protein kinase catalytic domain and a C-terminal protein binding domain (PBD), including two 
Polo boxes (PB), as shown in Fig. 3.5.2 and Fig. 5.1.2. The kinase domain of EmPlk1, spanning from 
aa-residue Tyr22 to Phe274, includes all invariable residues for protein kinases (Fig. 5.1.2) [66]. The 
amino acid sequence was further aligned using the Software MUSCLE (MUltiple Sequence 
Comparison by Log- Expectation) and a phylogenetic tree was constructed following the instructions 
of Phylogeny.fr “One click” (http://www.phylogeny.fr) [130]. 
 
Figure 5.1.1 Phylogenetic tree for Polo-like kinase 1 orthologs from different taxa. Amino acid 
sequences of Homo sapiens Plk1, Xenopus laevis Plx1, Drosophila melanogaster 
Polo, Schistosoma mansoni Plk1 (SmPlk1) and the Polo-like kinase 1 of Echinococcus 
multilocularis (EmPlk1) were aligned and graphically represented in a phylogenetic 
tree, constructed by Phylogeny.fr. Correlations are indicated by numbers (1 = highly 
correlated, red) and the size of the line [131]. 
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Figure 5.1.2 Structural features of EmPlk1. Multiple sequence alignment of Polo-like kinase 1 
orthologs from different taxa, highlighting similarities in conserved protein regions. The 
orthologous kinases of E. multilocularis (EmPlk1; GenBank accession number: 
HG931729), S. mansoni (SmPlk1; AY747306), Homo sapiens (Plk1; P53350), D. 
melanogaster (Polo; P52304) and X. laevis (Plx1; P70032) are aligned. Identical aa 
residues are shown in white on black background and. Kinase domains including the 
11 sub-domains of the kinases as defined by Hanks and Hunter (I-XI) [66] are boxed. 
The conserved threonine residue for activation of the kinase domain is marked by (T*) 
above the alignment. Residues for binding of phosphosubstrates in the PBD are 
marked by (#). BI 2536 interacting residues are indicated by grey dots.  
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A multiple sequence alignment of Plk1 like kinases of different organisms is shown in Fig. 5.1.2. The 
EmPlk1 kinase domain contains all 11 sub-domains (I-XI) that are characteristic of STKs as described 
by Hanks and Hunter [66]. Strong indicators for a STK kinase domain are particularly the amino acid 
sequence motifs HRDLKxxN and GTPNYIAPE, present in sub-domains VI and VIII. A third important 
and highly conserved motif in the kinase domain is the canonical GxGxxGxV motif for ATP binding. A 
characteristic variation of this motif is present in the Polo-like kinase family with the motif sequence 
GxGGFAxC (Fig 5.1.1). In mammals, activation of Plk1 during the cell cycle occurs in the activation 
loop (T-loop) with the major phosphorylation site at Threonine 210 (Thr210) [80, 90]. A similar 
phosphorylation site was found in S. mansoni at the corresponding Threonine residue 182 (Thr182) 
[102] and in E. multilocularis at Threonine 179 (Thr179) of the kinase domain (Fig. 5.1.2.)[132]. Within 
the kinase domain, EmPlk1 displayed 68% amino acid sequence identity to S. mansoni SmPlk1, 62% 
to human Plk1, 60% to D. melanogaster Polo and 60% to X. laevis Plx1. Plk1 protein-protein 
interactions and cellular localisation during the cell cycle is regulated by the C-terminal domain of the 
enzyme and involves a non-conserved linker region between the kinase domain and the PBDs. The 
two C-terminal Polo boxes (PB1 & PB2) of all Plk1-like enzymes that form the so-called PBD are also 
present in EmPlk1 and cover the region from Tyr378-Thr441 for PB1 and Cys476-Tyr545 for PB2. The 
three residues Trp388, His512 and Lys514, which are involved in Plk1-binding to the phosphorylated 
substrate [81], are also highly conserved in EmPlk1 (Fig. 5.1.2) [67]. Overall, EmPlk1 displayed 
significant homologies of 57% to S. mansoni SmPlk1, 47% to human Plk1, 43% to D. melanogaster 
Polo and 46% to X. laevis Plx1. Taken together, these structural analyses identified EmPlk1 as a 
typical member of the Plk1 protein family. 
 
 
5.2.  Structural analyses concerning binding of the Plk1 inhibitors BI 2536 and BI 6727 to 
 EmPlk1 
 In a previous study by Kothe et al. (2007) the crystal structure of the human Plk1 kinase 
domain together with bound inhibitor BI 2536 was analysed [95]. In this study, several important amino 
acid residues were identified that are essential for the binding of the drug. In addition to interacting 
amino acid residues involved in the binding process of the inhibitor, one essential determinant for 
inhibition of the kinase domain is the gatekeeper residue. The gatekeeper is often quite large and 
prevents large molecules from entering the site binding site in the kinase domain. In the human Plk1 
enzyme, the gatekeeper is present at position 132 in the amino acid sequence and represented by 
Leucin (Leu132). In direct comparison to other kinases of this protein family, this gatekeeper amino acid 
has a small amino acid side chain, which ensures the binding of BI 2536. The putative gatekeeper 
residue in EmPlk1 is also Leucine, at position 101 (Leu132). Interacting residues for the binding of the 
drug, according to the previous study by Kothe et al. (2007), are marked by grey dots in the alignment 
in Fig. 5.2.1 [95]. Based upon the amino acid alignment in Fig. 5.1.2, a comparison of the interacting 
amino acid residues with Plk1 inhibitors BI 2536 and BI 6727 are summarised in Fig. 5.2.1.  
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Figure 5.2.1 Schematic representation of the domain structure of EmPlk1 and amino acid 
residues for binding of the ATP competitive inhibitors BI 2536 and BI 6727. 
Amino acid sequences of Plk1-like enzymes were aligned from different taxa including 
E. multilocularis (EmPlk1; GenBank accession number: HG931729), S. mansoni 
(SmPlk1; AY747306), Homo sapiens (Plk1; P53350), D. melanogaster (Polo; P52304) 
and X. laevis (Plx1; P70032). Residues relevant for binding of the inhibitors BI 2536 
and BI 6727 [95, 97] were identified and outlined in an extra table. 
 
 
All amino acid residues important for binding of BI 2536 and BI 6727 to human Plk1 are highly 
conserved in EmPlk1 and in SmPlk1 of the related organism S. mansoni, for which a previous study  
has shown effective in vitro inhibition at micro-molar concentrations [102]. Based upon these results it 
was expected that BI 2536 and BI 6727 also exhibit inhibitory activities against EmPlk1. 
 
 
 
5.3  Expression of EmPlk1 in E. multilocularis larval stages 
 After the identification of a Plk1-like enzyme in the kinome of E. multilocularis, the expression 
profile of emplk1 in Echinococcus larvae was investigated. To this end, RNA-deep sequencing 
transcriptome data, obtained through the recently published E. multilocularis genome sequencing 
project [60] were used. The emplk1 expression profiles for primary cells after 2 and 11 days of 
development, as well as protoscoleces before and after activation by pepsin/low pH and metacestode 
vesicles from in vitro cell culture are shown in Fig. 5.3.1C. Relatively high expression in primary cell 
culture after day 2 and day 11, and a basal expression pattern in the activated/dormant protoscoleces 
and metacestode vesicles were observed. Since primary cell cultures are strongly enriched in parasite 
germinative (stem) cells when compared to metacestode vesicles and protoscoleces [32], these data 
indicated a stem cell-specific expression of emplk1. 
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Figure 5.3.1 Expression of EmPlk1 in E. multilocularis larval stages as assessed by RNA-
Seq. (A) Exon- intron structure of emplk1, spanning a genomic region of 3174bp. The 
exons (grey) and introns (blue) are matched to the RNA-deep sequencing 
transcriptome data according to the colours (B). Illumina read profile for emplk1 
(merge of all libraries analysed). (C) Larval stage expression profile for primary cells of 
day 2 (Pc_2d) and day 11 (Pc_11d), activated and dormant protoscoleces (Ps_non 
and Ps_act) and metacestode vesicles (Mc). Note that Illumina sequencing has been 
performed only once for each sample.  
 
 
Based upon the fact that the Illumina sequencing results shown above are based upon only one 
dataset, the results were validated by semi-quantitative reverse transcription polymerase chain 
reaction (RT-PCR). Total RNA was isolated from primary cells from cultures after day 2, day 5, and 
day 11 of development, as well as from activated and dormant protoscoleces and metacestode 
vesicles. Serial 10-fold dilutions of reverse transcribed RNA (cDNA) were subjected to emplk1 gene-
specific PCR. All larval stages clearly expressed emplk1, which was higher expressed in primary cells, 
in accordance with the expression profile obtained by RNA-Sequencing (Fig. 5.3.2). 
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Figure 5.3.2 Expression profile of emplk1 in E. multilocularis larval stages. Total RNA was 
isolated from primary cell cultures (Pc) from day 2, 5 and 11 (d2, d5, d11), dormant 
(Ps_non), and activated protoscoleces (Ps_act), as well as in vitro cultivated 
metacestode vesicles (Mc). Equal amounts of isolated RNA were reverse transcribed 
to cDNA and subjected to gene-specific (RT)-PCR for emplk1. The house keeping 
gene elp [133] was used for normalisation. The generated cDNA was 10-fold diluted in 
1, 1:10 and 1:100 for PCR. Genomic DNA (gDNA) served as a positive control and 
purity of DNA contamination during RNA isolation. Non-reverse transcribed RNA was 
used as a purity control for DNA contamination during RNA isolation. Marker sizes are 
indicated on the left. (1,5% Agarose; EtBr stained). 
 
 
Taken together, the RT-PCR experiments verified the prominent expression of empk1 in in vitro 
cultivated primary cells, which again indicated the possibility of a stem cell-specific expression pattern 
of emplk1.  
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5.4.  Expression of EmPlk1 in the heterologous Xenopus oocytes system triggers germinal 
 vesicle breakdown (GVBD), which can be blocked by the Plk1 inhibitor BI 2536 and BI 
 6727 
 The Xenopus oocyte system has frequently been used for studying enzymatic activities of 
heterologously expressed protein kinases [102]. In a previous study, Long et al. (2010) analysed the 
functions of the Plk1-like enzyme of S. mansoni with this system, using active, inactivated and dead 
kinase mutant forms of SmPlk1 [102]. In the present work, similar studies were carried out with 
EmPlk1. In addition to wild type EmPlk1 (EmPlk1WT), an activated (mutant) version (EmPlk1T179D) was 
generated by replacing Thr-179 through phosphomimetic Asp. An inactivated version was created by 
replacing Thr-179 by Val (EmPlk1T179V) and two “kinase dead” versions of EmPlk1WT and EmPlk1T179D 
were generated by replacing the D163FG motif of the active loop through D163SV165, yielding versions 
wtKD and T179DKD, respectively. As shown in Tab. 5.4.1, expression of EmPlk1WT and the inactive 
version EmPlk1T179V in Xenopus oocytes did not induce GVBD, which was only observed with the 
activated form EmPlk1T179D in a similar way as through the natural stimulating factor progesterone 
(PG). The kinase dead versions of the enzyme, wtKD and T179DKD only induced a low basal activation. 
 
Table 5.4.1 Xenopus oocytes serving as a heterologous system for the expression of 
EmPlk1. Microinjection of in vitro transcribed RNA constructs of wild type (EmPlk1WT) 
and mutant forms (EmPlk1T179D, constitutively active; EmPlk1T179V, non-active; wtKD, 
T179DKD, kinase dead mutants) of EmPlk1 were expressed in Xenopus oocytes. 
Progesterone (PG) served as a natural inducer (positive control) for G2/M transition and 
induction of germinal vesicle breakdown (GVBD). Overall, 20 oocytes per setting were 
used. Germinal vesicle breakdown (GVBD) assays were performed in the presence of 
different concentrations of BI 2536 as indicated to the left. Listed are the percentages of 
Xenopus oocytes that underwent GVBD in the different experimental settings (mean of 
three independent experiments). ‘-’ indicates that this condition has not been tested.  
 
BI 2536 PG EmPlk1 (wt) T179D T179V EmPlk1 (wtKD) T179DKD 
0nM 90 0  90 0 0 10 
1nM - - 90 - - - 
5nM - - 80 - - 0 
10nM 90 - 20 - - - 
20nM - - 10 - - 0 
50nM - - 0 - - - 
100nM 80 - 0 - - 0 
 
As revealed in the Xenopus oocyte experiments, the active version of EmPlk1T179D was able to induce 
the G2/M transition in the Xenopus system, which resulted in germinal vesicle breakdown (GVBD). 
Furthermore, an effective inhibition of EmPlk1 at 20 nM concentrations of the inhibitor BI 2536 and the 
second-generation inhibitor BI 6727 (data not shown in Tab 5.4.1) was observed. Regarding the first 
generation inhibitor BI 2536 (20 nM) this concentration lead to a 90% reduction of GVBD and 80% 
reduction in the case of the second generation inhibitor BI 6727. Overall, it was noticed that BI 6727 
inhibited the EmPlk1 kinase activity about 50% less than BI 2536 at similar molar concentrations. No 
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change in GVBD was observed with and without inhibitor for the wild type version EmPlk1T179D, the 
inactive kinase domain version EmPlk1T179V and “kinase dead” version of the enzyme wtKD. The 
observed basal activity of the double mutated version of T179DKD was blocked at the lowest 
concentration of 5 nM with BI 2536. Unaffected by even high concentrations of BI 2536 and BI 6727 
was GVBD induced by the natural stimulating factor progesterone. Taken together, these data 
indicated that EmPlk1 is a functional kinase with binding affinity to the inhibitors BI 2536 and BI 6727 
at a low nanomolar range.  
 
 
5.5.  BI 2536 inhibits the formation of metacestode vesicles from parasite primary cells  
 As already shown above, the Plk1 inhibitors BI 2536 and BI 6727 affected the activity of 
EmPlk1 when expressed in the Xenopus system. Furthermore, emplk1 showed highest expression 
levels in parasite primary cell cultures and displayed an expression pattern in WMISH that is typical for 
stem cell-specifically expressed genes [32, 132]. To test effects of Plk1 inhibitors on parasite 
germinative cells, the primary cell culture system was used, which - as recently shown - is highly 
enriched in germinative cells and leads to the formation of mature metacestode vesicles within 2-3 
weeks [32]. As shown in Figs. 5.5.1 and 5.5.2., BI 2536 treatment showed a statistically significant and 
concentration dependent inhibition of the formation of metacestode vesicles within two weeks of 
treatment. At concentrations of 25, 50 and 100 nM, vesicle formation was almost completely 
abolished, parasite cells were only loosely aggregated and central cavities, which eventually should 
result in vesicles, were not observed [118, 123, 132]. Even at concentrations as low as 5 and 10 nM, 
only about 50% and 25%, respectively, of mature vesicles were formed when compared to the control. 
Taken together, these data indicated that parasite stem cell proliferation and/or differentiation, which 
eventually results in the formation of mature metacestode vesicles in the culture system employed, 
can be effectively inhibited by BI 2536 [118]. 
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Figure 5.5.1 BI 2536 affects the formation of metacestode vesicles from primary cell culture. 
Primary cells were isolated from intact metacestode vesicles and seeded in a 48-well 
plate format. Metacestode vesicle formation was observed by light microscope in non-
treated and treated wells with different concentrations (10 nM, 25 nM, 50 nM, 100 nM) 
of the Plk1 inhibitor BI 2536. ‘Mock’ indicates cultures with DMSO (without inhibitor). 
Experiments with primary cells were performed in A4-media. A4-Media with freshly 
added inhibitor was changed every second day. Pictures were taken on day 14. Size 
is indicated by a white bar on the bottom right corner of each picture. 
 
 
 
 
In addition to the two inhibitors BI 2536 and BI 6727, belonging to the chemical substance class of 
Dihydropteridinone, a third Plk1 inhibitor GW843682X was tested on metacestode vesicles and in the 
primary cell culture system. GW843682X is a thiophene benzimidazole ATP competitive inhibitor for 
human Plk1 and Plk3 with nanomolar acting concentration of IC50 of 2.2 nM and 9.1 nM, respectively. 
Several studies on cancer tissues showed that this inhibitor is acting in a micro-molar concentration 
and it was also tested in S. mansoni acting on SmPlk1 [85, 102, 134].  
 
Figure 5.5.2 Formation of E. multilocularis 
metacestode vesicles from primary cells are 
inhibited by BI 2536. Primary cell cultures were 
established from intact metacestode vesicles and 
incubated under ideal growth conditions (A4 medium) 
treated with different concentrations (5 nM, 10 nM, 25 
nM, 50 nM and 100 nM) of BI 2536 or non-treated 
Control and ‘Mock’ indicating cultures with DMSO 
(without inhibitor). The formation of mature 
metacestode vesicles (with laminated layer) was 
observed by light microscopy and counted on day 14. 
All conditions were assessed at least in three different 
biological replicates with at least three technical 
replicates. *(p,0.05); **(p = 0.001–0.01) (Student’s t-
test). 
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Similar to the previous experiment with the BI 2536 inhibitor, primary cells were treated with 
GW843682X. A concentration dependent inhibition in the formation of metacestode vesicles from 
primary cells was observed, statistically significant at an inhibitor concentration of 0.5 µM. Taken 
together, these data indicated that several different Plk1 inhibitors are able to inhibit the formation of 
metacestode vesicles from parasite primary cells in a concentration dependent manner. 
 
 
 
 
 
 
 
 
 
 
 
5.6  In vitro effects of BI 2536 on E. multilocularis metacestode vesicles  
 Parasite material was isolated from Mongolian jirds (Meriones unguiculatus) and grown in 
the in vitro cultivation system for at least three months in the presence of rat Rheuber hepatoma (Rh-) 
feeder cells. Feeder cells were subsequently removed and mature vesicles were incubated for up to 
three weeks in conditioned medium (A4-Media) in the presence of different concentrations of BI 2536 
(5 nM, 10 nM, 25 nM, 50 nM and 100 nM). Subsequently, structurally intact vesicles were counted by 
visual inspection. Interestingly, even after three weeks of incubation at a concentration of 100 nM BI 
2536, no significant reduction in structurally integer vesicles were observed (Fig. 5.6.1A). However, as 
shown in Fig. 5.6.1B, BI 2536 treated vesicles were consistently smaller than control vesicles, 
indicating that inhibitor treatment had impaired growth and proliferation capacity of the metacestode 
vesicles.  
Figure 5.5.3 Formation of E. multilocularis 
metacestode vesicles from primary cells are 
inhibited by GX843682X. (B) Primary cell cultures 
were established from intact metacestode vesicles 
and incubated under ideal growth conditions (A4 
medium) treated with different concentrations (0.5 
µM, 1 µM, 2.5 µM, 5 µM) of GW843683X or non-
treated Control and Mock indicating cultures with 
DMSO (without inhibitor). Formation of new 
metacestode vesicles was observed by light 
microscopy and counted on day 14. (A, B) All 
conditions were assessed at least in three different 
biological replicates with at least three technical 
replicates. *(p,0.05); **(p = 0.001–0.01) (Student’s t-
test). (A, B) ‘Mock’ indicating cultures with DMSO 
(without inhibitor). 
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Figure 5.6.1 In vitro effects of BI 2536 on E. multilocularis metacestode vesicles. (A) 
Cultivated metacestode vesicles under axenic conditions were treated in vitro over 
21days in the absence (Control) and presences of the Plk1 inhibitor (BI 2536, 100 
nM). A4-Media with fresh added inhibitor was changed every second day. (B) Co-
culture flasks after 21 days of treatment with Control and treated metacestode vesicles 
with BI 2536 (100 nM). (A) The experiment was performed in three independent 
biological replicates (n=3).  
 
Furthermore, a second inhibitor, GX843682X was tested in micro-molar concentrations on 
metacestode vesicles over 10 days. An effect on the vesicle integrity or a particular a phenotype, 
showing abnormalities in the laminated or germinal layer by light microscopy was not observed (Fig 
5.6.2).  
 
 
Figure 5.6.2 In vitro effects of GX843682X on E. multilocularis metacestode vesicles. 
Metacestode vesicles were cultivated over 10 days in the absence (Control, Mock) 
and in the presence of increasing concentrations of the Plk1 inhibitor GX843682X (0.5 
µM, 1µ M, 2.5 µM, 5 µM). Metacestode vesicle integrity was observed by light 
microscope. A4-Media with fresh added inhibitor was changed every second day. The 
experiment was performed in three independent biological replicates (n=3).  
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To address the question whether parasite stem cells were affected in the structurally intact 
metacestode vesicle after treatment with the inhibitor BI 2536, a Click-iT EdU cell proliferation assay 
(EdU (5‐ethynyl‐2´‐deoxyuridine; Invitrogen, C10337) pulse experiment was carried out. This assay 
provided an overview of whether proliferating cells remained present after a defined time of treatment 
with this inhibitor (Chapter 5.7).  
 
 
 
 
 
5.7. Stem cells of metacestode vesicles are affected by treatment with BI 2536, visualised by 
a Click-iT EdU cell proliferation assay  
The experiments outlined above highlighted that BI 2636 inhibited the growth of metacestode 
vesicles and the formation of mature metacestode vesicles from primary cells. Metacestode vesicles 
are the chemotherapeutic target in infected patients and thus the main focus for the development of 
new lead compounds in drug development.  
As shown above, the treatment mature metacestode vesicles with 100 nM BI 2536 over 21 days did 
not lead to structural disintegration or vesicle collapse. Interestingly, in a recent study carried out by 
Koziol et al. (2014), hudroxyurea (HU) at high concentrations was used to successfully eliminate 
germinative (stem) cells in metacestode vesicles, which remained structurally intact for several weeks 
in culture. Hence, in the present study it was indeed possible that BI 2536 had similar effects as HU. 
To test this hypothesis, a Click-iT EdU cell proliferation assay on BI 2536 treated vesicles was carried 
out. Labelling of proliferating cells in treated and untreated metacestode vesicles was performed as 
previously described by Koziol et al. (2013) [47]. Metacestode vesicles were cultivated under axenic 
conditions in A4-medium and treated with increasing concentrations (from 10 nM to 100 nM) of BI 
2536 for 21 days. After 21 days, treatment was stopped and followed by three days of recovery, 
(without further inhibitor treatment) to allow surviving stem cells to re-enter the cell cycle. Proliferating 
cells were subsequently labelled using an EdU pulse approach. All metacestode vesicles were intact 
and did not show any phenotypic variation after these 21 days of treatment and three days of 
recovery. Microscopic analysis of inhibitor-treated metacestode vesicles vs untreated samples showed 
significant differences in the number of proliferating EdU positive cells (Fig. 5.7.1). In particular, the 
treated samples showed a drastically reduced number of EdU positive cells (Fig. 5.7.1A). A statistical 
analysis by counting EdU positive cells (cells/mm²) demonstrated that the remaining proliferating cells 
in the treated metacestode were highly significantly reduced by treatment with concentrations of 25 nM 
BI 2536 and higher (Fig. 5.7.1B). Overall, only two EdU positive cells/mm² were found in the sample 
treated with 100 nM BI 2536. The observation of less proliferating cells was in line with the 
suppression of growth in metacestode vesicles and the suppressed regeneration capacity of in vitro 
cultivated primary cells. 
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Figure 5.7.1 Elimination of proliferating germinative cells in metacestode vesicles after 
treatment with BI 2536. Metacestode vesicles were cultivated under axenic 
conditions over 21 days with different concentrations (10 nM, 25 nM, 50 nM and 100 
nM) of the Polo-like kinase 1 inhibitor BI 2536 and without (Control, Mock (DMSO)), 
followed by three days of recovery without inhibitor. On day three of recovery, an EdU 
pulse [EdU (5‐ethynyl‐2´‐deoxyuridine)] experiment was performed. Three out of ten 
labelled metacestode vesicles were randomly chosen for the EdU staining and 
microscopically counting of EdU positive cells. (A) Microscopic pictures of the germinal 
and LL (GL) of BI 2536 treated (10 nM, 25 nM, 50 nM, 100 nM) and non-treated E. 
multilocularis metacestode vesicles after staining with EdU (red; proliferating cells) and 
DAPI (blue; nuclei). Scale bar (white, bottom right corner) represents 25 µm. (B) EdU 
positive cell counts per mm2 of GL. ‘Control’ indicates vesicles cultivated in A4 
medium alone. ‘Mock’ indicates the DMSO control. ***(p, 0.001) (Student’s t-test). 
Please note that the specific examples shown in (A) display slightly different total cell 
numbers but that the overall cell numbers in metacestode vesicles were not altered by 
drug treatment. 
 
 
 
Figure 5.7.2 Short-term treatment of E. 
multilocularis metacestode vesicles with 
the Polo like kinases 1 inhibitor BI 2536 
reduced proliferating stem cells. 
Metacestode vesicles were treated for 24, 48 
or 72 hours (h, as indicated) with 50 nM (light 
grey) or 100 nM (darker grey) of BI 2536, 
followed by one day of recovery without 
inhibitor treatment. EdU labelling for 5 hours 
with 50 µM EdU reagent was carried out and 
labelled cells were microscopically counted. 
Identified EdU-positive cell were counted per 
mm2 of germinal and laminated layer (GL). 
‘Control’ indicates vesicles cultivated in A4-
medium alone. ‘Mock’ indicates the DMSO 
control. ***(p,0.001) (Student’s t-test). 
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Besides the long-term treatment over 21 days with the inhibitor BI 2536, the question of the effectivity 
of short-term treatment with the same inhibitor was addressed. To this end, a short-time treatment 
over 24, 48 and 72 hours with concentrations of 50 nM and 100 nM of BI 2536, followed by one day of 
recovery and EdU pulse approach, was carried out. EdU stained positive cells were counted as before 
(cells/mm²) and graphically represented in Fig. 5.7.1. After 24 hours and particularly 48 hours of 
treatment with the lowest concentration of 50 nM, the number of proliferating cells in the metacestode 
vesicles was drastically reduced. Even higher reduction was observed upon incubation with 100 nM BI 
2536. Hence, short-term incubation of metacestode vesicles with high concentrations of BI 2536 was 
effective in eliminating large parts of the stem cell population, which could prove valuable for future 
studies on stem cell dynamics or stem cell-specific gene expression in E. multilocularis.  
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5.8  Attempts towards elucidating the crystal structure of the Polo-like kinase 1 of E. 
 multilocularis (EmPlk1) 
 The design of new lead compounds in drug development takes into account several factors 
such as the accessibility of the inhibitor to an organism, direct interactions between drug and protein 
target, as well as the acting drug concentration, which is relevant concerning adverse side-effects. 
Based upon these facts and that the two tested Polo-like kinase 1 inhibitors BI 2536 and BI 6727 
passed phase II of the clinical trials [98, 99] we decided to go one step further and tried to optimise 
these inhibitors for the inhibition of EmPlk1. Our in vitro experiments on metacestode vesicles, primary 
cells and in the heterologous expression in Xenopus oocytes clearly showed that the inhibitors act on 
EmPlk1 and inhibit the proliferation of these cells. Targeted drug design is greatly facilitated by the 
availability of crystal structures of the respective protein target. In collaboration with the Kisker group 
at the Rudolf-Virchow-Centre for experimental Biomedicine, the crystallisation of EmPlk1 (with and 
without inhibitors) was thus attempted. For this purpose, and similar to such previous approaches for 
the crystallisation of human Plk1, the EmPlk1 regions encoding amino acids 8 to 296 of the EmPlk1 
kinase domain were chosen for cloning, expression, and purification [95]. Respective clones were 
generated for wild type EmPlk1WT, for the mutated, active form EmPlk1T179D and an inactive version, 
EmPlk1T179V. As a vector system for cloning and bacterial expression, pETM-14 was used. Several 
crystallisation conditions were tested, which remains an ongoing process for optimisation with and 
without inhibitors. To date, small crystals have only been seen in the wild type form of EmPlk1WT 
without inhibitor (data not shown). The questions that we want to address from this approach concern 
(I.) whether there is a binding correlation of the inhibitors compared to the human Plk1, (II.) what are 
the differences in the binding of BI 2536 and BI 6727 to EmPlk1 and do they correlate with the better 
inhibition as seen in experiments with BI 2536, and (III.) whether it is possible to optimise the chemical 
structure of BI 2536 or BI 6727 for binding to EmPlk1 [135]. 
 
 
5.9.   Expression patterns of E. multilocularis β-tubulin genes. 
 The current chemotherapy of AE is based upon benzimidazoles, such as mebendazole or 
albendazole (Chapter 3.3), which target the cellular β-tubulins of E. multilocularis. β-tubulins are 
usually highly conserved between helminths and mammals and only a few amino acid sequence 
differences account for a higher affinity of benzimidazoles to helminth β-tubulins than to mammalian β-
tubulins. The most important amino acid in this context is residue 200, which in helminth β-tubulins is 
usually Phe, whereas in mammalian isoforms it is typically Tyr [59]. In a previous study, three different 
β-tubulin isoforms (tub-1, tub-2, tub-3) that are expressed by E. multilocularis had been identified and 
of these, Tub-2, was shown to contain Tyr at position 200, indicating that it might represent an isoform 
with diminished affinity to benzimidazoles [58]. Since it was unclear whether Tub-1, Tub-2 and Tub-3 
represented the entire set of Echinococcus β-tubulins, the available E. multilocularis genome 
sequence was utilised in the present study for BLASTP analyses using the already-characterised 
Echinococcus β-tubulin sequences as queries [60].  
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Figure 5.9.1 β-tubulins from E. multilocularis. Multiple sequence alignment of the β-tubulins 
from E. multilocularis. Identical aa residues are shown in white on black background 
and captioned by upper-case letters. Similar amino acid residues are shown and in 
black on grey background. Position 200 of the proteins is indicated by a red star. 
Gene designations according to GeneDB are indicated to the left. 
 
As shown in Fig. 5.9.1, a total of ten β-tubulin encoding genes were thus identified, of which four 
encoded a protein with Tyr at position 200. During the E. multilocularis sequencing project extensive 
RNA-Seq. data have been obtained for several parasite developmental stages, and as listed in Table 
5.9.1, tub-1(EmuJ_000202600), tub-2(EmuJ_000672200), and tub-3(EmuJ_000202500) were indeed 
the highest expressed β-tubulin genes of the parasite, at least in the larval stages [60]. 
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Table 5.9.1 Expression of E. multilocularis β-tubulin genes in different developmental 
stages 
 
 
Interestingly, and as depicted in Fig. 5.9.2., tub-2 showed an expression profile that is highly 
reminiscent of genes specifically expressed in the parasite’s germinative cell population. According to 
the analyses made by Koziol et al. (2014), such genes should show highest expression in primary 
cells after 2 days of incubation, somewhat lower expression levels in primary cells after 11 days, and 
the lowest levels in metacestode vesicles and protoscoleces. Of all three highly expressed β-tubulin 
genes of the parasite, this could only be observed for tub-2, indicating that it might be specifically 
expressed in germinative cells (Table 5.9.1, Fig. 5.9.2.).  
 
 
Figure 5.9.2 Expression of β-tubulin genes in E. multilocularis larval stages as assessed by 
RNA-Seq. Larval stage expression profile for primary cells of day 2 (Pc_2d) and day 
11 (Pc_11d), dormant and activated protoscoleces (Ps_non and Ps_act) and 
metacestode vesicles (Mc). Note that Illumina sequencing has been performed only 
once for each sample. 
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Figure 5.9.3 Expression of tub-1, tub-2 and tub-3 in E. multilocularis larval stages. Total RNA 
was isolated from primary cell cultures (Pc) after day 2, and 11 (d2, d11) of incubation, 
dormant (Ps_non) and activated protoscoleces (Ps_act), as well as in vitro cultivated 
metacestode vesicles (Mc). Equal amounts of isolated RNA were reverse transcribed 
to cDNA and subjected to gene-specific (RT)-PCR for tub-1, tub-2 and tub-3. The 
house keeping gene elp was used for normalisation. The generated cDNA was 10-fold 
diluted in 1, 1:10 and 1:100 for PCR. Genomic DNA (gDNA) served as a positive 
control and purity of DNA contamination during RNA isolation. Non-reverse 
transcribed RNA was used as a purity control for DNA contamination during RNA 
isolation. Marker sizes are indicated on the left. (2% Agarose; EtBr stained). 
 
To verify the results obtained through RNA-Seq. RT-PCR analyses for tub-1, tub-2, and tub-3 were 
carried out in the present study. As shown in Fig. 5.9.3., an expression of all three genes was indeed 
found in primary cells (2 and 11 days of incubation), in metacestode vesicles and in protoscoleces. 
The results again indicated that tub-2 is highest expressed in primary cells after 2 days of incubation, 
although due to the method used (RT-PCR), expression differences could not be determined to an 
extent comparable to RNA-Seq. data.  
 To further investigate possible stem cell-specific expression patterns of Echinococcus -tubulins, RT-
PCR experiments were carried out on metacestode vesicles after treatment with BI 2536, which - as 
outlined above - leads to a specific elimination of the germinative cell population. To this end, 
metacestode vesicles were treated with BI 2536 (50 nM) for 21 days, followed by 5 days of recovery 
without further treatment, to ensure that the inhibitor is dissociated. Total RNA was isolated from 
treated and untreated metacestode vesicles and used for a semi-quantitative RT-PCR. As shown in 
Fig. 5.9.4., no change in the expression of tub-1 was observed for treated and untreated vesicles and 
in the case of tub-3, expression levels were even higher after BI 2536 treatment. By contrast, the 
expression levels of tub-2 were greatly reduced after BI 2536 treatment, indicating that it is indeed 
specifically expressed in the germinative cell population. Hence, the most important cell type for 
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parasite proliferation and development, the germinative cells, most probably express a -tubulin 
isoform with diminished affinity for benzimidazoles. 
 
 
Figure 5.9.4 Expression of tub-1, tub-2 and tub-3 in BI 2536 treated E. multilocularis 
metacestode vesicles. Total RNA was isolated from in vitro cultivated metacestode 
vesicles (Mc) treated or non-treated with the Polo-like kinase 1 inhibitor BI 2536 
(50nM) for 21 days followed by 5 days of recovery without treatment. Equal amounts 
of isolated RNA were reverse transcribed to cDNA and subjected to gene-specific 
(RT)-PCR for tub-1, tub-2 and tub-3. The house keeping gene elp was used for 
normalisation. The generated cDNA was 10-fold diluted in 1, 1:10 and 1:100 for PCR. 
Genomic DNA (gDNA) served as a positive control and purity of DNA contamination 
during RNA isolation. Non-reverse transcribed RNA was used as a purity control for 
DNA contamination during RNA isolation. Marker sizes are indicated on the left. (2% 
Agarose; EtBr stained). 
 
Previous unpublished experiments had shown that primary cells were insensitive to even very high 
concentrations of Albendazol (50 µM, 100 µM) (Sarah Hemer, Doctoral thesis, 2012), indicating that 
parasite stem cells could indeed be insensitive to benzimidazoles. To further investigate these effects, 
experiments were carried out in this work to verify that albendazole-treated metacestode vesicles 
indeed still contain viable stem cells. To this end, metacestode vesicles have been treated for one 
week with high albendazole concentrations (50 µM, 100 µM) leading to structural disintegration and 
collapse of the vesicle (Fig. 5.9.5). Primary cells were subsequently isolated and the formation of 
metacestode vesicles was measured.  
RESULTS  
 
69 
 
 
Figure 5.9.5 Inhibitor effects on the regeneration capacity of metacestode vesicles. 
Metacestode vesicles were treated with 50 µM and 100 µM of albendazole (ABZ) or in 
combination of 50 µM ABZ and 50 nM BI 2536 for one week under axenic conditions. 
(A) Primary cells were directly isolated from treated metacestode vesicles and 50 
Units were co-cultivated for regeneration without any further treatment. (B) Pictures 
were taken after 14 days of the primary cell regeneration process. (C.) Colour change 
of the media was photographed as an indicator for active cellular metabolism. Sizes 
are indicated (white) at the bottom right corner (A) 100 µm (B) 200 µm.  
 
In the case of the non-treated sample, aggregate formation and formation of metacestode vesicles 
could be observed as expected (Fig. 5.9.5 B, Control). However, independently of the concentration of 
ABZ or combinatory treatment, no formation of aggregates or mature vesicles was observed for the 
inhibitor-treated samples (Fig. 5.9.5 B). A cellular monolayer of cells covered the bottom of the 48-well 
plate in all treated samples. Metabolic activity was similar until 10 days after primary cell isolation. The 
first change in media (colour) was observed on day 14 (Fig. 5.9.5) and only occurred in samples 
deriving from non-treated metacestode vesicles. Taken together, these experiments indicated that 
treatment with high concentrations of albendazole is effective in eliminating the proliferation and 
regeneration capacity of metacestode vesicles. 
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6.0  Injection of isolated primary cells into metacestode vesicles treated with the Polo-like 
 kinase 1 inhibitor BI 2536. 
   The experiments outlined above revealed that long-term BI 2536 treatment of metacestode 
vesicles leads to (largely) stem cell deprived vesicles that are otherwise structurally intact. This led to 
the interesting question whether stem cell deprived vesicles could be repopulated by stem cells upon 
introduction via injection. Such a system would prove highly valuable in tracking stem cell dynamics in 
their natural niche, e.g. by injecting fluorescently labelled stem cells. Furthermore, once transgenic 
techniques for stem cells are established, these could not only be used for vesicle generation in the 
primary culture system but for vesicle ‘transformation’ in the metacestode culture system.  
This new method is in my opinion a promising new technique that can be utilised to study genetically 
manipulated primary cells in our in vitro cell culture system and might also be useful for further 
experiments. The present situation of a technique to genetically manipulate primary cells of E. 
multilocularis is still not given today, although efforts have been undertaken. The usage of the current 
in vitro cell culture technique for primary cells is not trivial and has to be improved for working with 
genetically manipulated primary cells. Independent of the outcome of the preliminary experiments, a 
technique that will finally be able to generate transgenic cells of E. multilocularis needs a method to 
further in vitro cultivate these cells. Primary cells of E. multilocularis are not adherent, which goes 
along with problems in the basic cell culture technique in direct comparison to several human cell 
lines. Furthermore, to protect these “stressed cells” from the environment and cultivate them in an 
optimal natural condition, the idea was to inject these cells were into a “physical intact metacestode 
vesicle” in our in vitro cultivation system. This new method is supported by the fact that the 
metacestode vesicle mimics the most natural environment for the transformed primary cells, while this 
method offers us a much easier handling of the non-adherent cell type; moreover, the influence of 
stress by change of the media is reduced. I suppose that the survival chance of genetically 
manipulated parasite stem cells is even higher in a “natural environment” compare with the current 
primary cell culture method. To this end, metacestode vesicles (isolate H95) were first deprived of 
stem cells by BI 2536 treatment for 21 days, followed by injection of stem cells from primary cells 
(isolate H95) as outlined in Fig. 6.0.1.  
According to the experimental approach described in Fig 6.0.1, metacestode vesicles (H95) were 
selected by size (>0,5cm) and vesicle integrity (microscope), followed by treatment with BI 2536 for 21 
days (Fig. 6.0.1 A-B). After five days of recovery without inhibitor treatment, fresh isolated primary 
cells (H95) were injected (Fig. 6.0.1 B-C- D). The injection process and handling of the metacestode 
vesicles were carried out carefully, resulting in ~25% of the injected vesicles surviving the approach. A 
picture of metacestode vesicles after the injection process is given in Fig 6.0.1 F. The picture shows 
metacestode vesicles before EdU staining and some metacestode vesicles that were seriously 
damaged during the injection process, as indicated by a change of the colour in the hydatid fluid (Fig. 
6.0.1.F). Damaged metacestode vesicles were removed and EdU staining of the remaining 
metacestode vesicles followed. The EdU staining was carried out as before and described in Koziol et 
al. (2014) [32]. 
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Figure 6.0.1 Schematic representation of an experimental approach to repopulate stem cell 
depleted metacestode vesicles. (A.-B.) Metacestode vesicles (>0.75 cm) were 
treated over 21days with 50 nM BI 2536. ,(D.) Primary cells in A4-Media suspension 
were injected by syringe into intact BI 2536 treated metacestode vesicles. (E.) EdU 
staining for the detection of proliferating and integrated stem cells was carried out. (F.) 
Injected metacestode vesicles before EdU staining [32]. 
 
 
 
Figure 6.0.2 Repopulation of stem cell deprived metacestode vesicles with primary cells. 
Metacestode vesicles were treated over 21 days with BI 2536 (50 nM) followed by five 
days of recovery without treatment. Freshly isolated primary cells of non-treated 
metacestode vesicles were used for injection into stem cell depleted metacestode 
vesicles. ‘Control (positive)’ is non-treated metacestode vesicles; ‘Control (negative)’ is 
treated vesicles without injection of primary cells. Primary cells were injected in the 
sample ‘injected Pc’ whereas in the sample ‘added Pc’ the primary cells are simply 
added to the A4-media for co-culture. EdU (50 µM) staining was carried out for 5 
hours, 5 days after injection. Proliferating cells are labelled red. DAPI staining (blue) 
was used for labelling of nuclear DNA. 
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As can be seen in Fig. 6.0.2., BI 2536 treatment for 21 days was effective in eliminating proliferating 
stem cells in metacestode vesicles. After injection of primary cells (stem cells) and an incubation time 
for 5 days, the GL appeared completely repopulated by proliferating cells (Fig. 6.0.2). To exclude that 
the injection process itself led to an activation of ‘dormant’ stem cells, vesicles were also injected with 
A4 medium alone (Fig. 6.0.2. Control neg.). When the stem cells were only added (from outside) to the 
vesicles, no repopulation occurred (Fig. 6.0.2 added Pc). However, like in the negative control (Fig. 
6.0.2) no positive signals were obtained for vesicles how have only been punctuated by a needle 
(mechanical stimulation, data not shown). Taken together, these experiments indicated that it is 
indeed possible to successfully repopulate stem cell deprived metacestode vesicles using the injection 
technique. 
In addition to the repopulation of stem cell depleted metacestode vesicles with isolated primary cells of 
the same genetic background (Isolate H95; i.e. same parasite isolate), injection experiments with 
primary cells of other parasite isolates were performed (isolate GH09, Ingrid, J2012). To this end, 
metacestode vesicles of the isolate H95 were stem cell depleted and repopulated with primary cells of 
isolates GH09, J2012 or Ingrid. In all cases, the stem cells integrated into the stem cell depleted 
germinal layer of the metacestode vesicle and underwent proliferation (data not shown).  
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6.1  Additional inhibitor studies on E. multilocularis  
 Several other approaches on potential target proteins of E. multilocularis have been tested. 
All of the listed inhibitors have been tested for one week on metacestode vesicles and primary cells in 
A4-media under axenic conditions. All inhibitors have been used in a first trial in the following 
concentrations of 50 µM, 25 µM, 10 µM and 1 µM. 
 
Name CAS number Protein target Metacestode 
vesicles 
Primary cells 
Artemisinin 63968-64-9 target is not yet 
identified 
neg. neg. 
BA-6; BA-3-35; BA-
3-29; BA 3-61; BA 
103; BA 3-45 
University of 
Siena (Marco 
Radi) 
DDX3, a DEAD-
(Asp-Glu-Aal-
Asp)-box RNA 
helicase [136] 
neg. neg. 
BIRB 796 
(Doramapimod) 
285983-48-4 p38alpha MAPK 
(human) 
neg. neg. 
Lufenuron 103055-07-8 chitin production 
and influences the 
exoskeleton 
production in 
many insects 
neg. neg. 
2-Methoxyestradiol 
(2-MeOE2) 
362-07-2 Cellular 
microtubule 
depolymerisation 
[137] 
It was shown in a former study on E. 
multilocularis that metacestode 
vesicles treated with 2-ME2 (2–10μM) 
showed an adverse effect in the 
viability on the parasite [138]. These 
results could not be validated in my 
experiments, also for primary cells. 
Mycophenolic acid 24280-93-1 5’-Inosine 
monophosphate 
dehydrogenase 
(human) 
neg. neg. 
Oridonin 28957-04-2 AML1-ETO (AE) 
fusion protein 
neg. neg. 
Phenytoin, Zentropil® 
from Sandoz 
Pharmaceuticals 
GmbH 
57-41-0 Blocking of 
voltage-
dependent and 
voltage-gated 
sodium channels 
(human) 
neg. neg. 
TAK-715 303162-79-0 p38alpha MAPK 
(human) 
neg. neg. 
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6.2  Characterisation and cloning of a Venus flytrap kinase receptor gene (emvkr) of E. 
 multilocularis  
 The first member of the invertebrate-specific family of VKR was identified in the blood-
dwelling fluke Schistosoma mansoni in 2003 [103]. Features of this new family of Tyrosine kinases 
receptor (RTKs) are the presence of an extracellular VFTM with homologies to similar modules in 
GABAB receptors, which is connected via a single transmembrane domain to an intracellular TKD that 
is related to the TKD of Insulin receptors (IR-TKD). This kind of RTKs have only been described in 
invertebrates to date, with the feature that the extracellular insulin receptor domain (IR) are more 
distantly related to human IR-TKD than the TKD of invertebrates. This fact opens up the possibility to 
study the function of those RTKs and their potential role as a new protein targets for the development 
of drugs.  
In S. mansoni, two VKR are already described (SmVKR1 (SmRTK1) and SmVKR2) [103, 109] and the 
published protein sequences (SmRTK1 Smp_019790 (previously known as Sm00.scaff00045.0290) 
supercontig Schisto_mansoni.SC_0136: 209761-238744) were used in this work to identify VKRs in E 
.multilocularis. In silico analysis, BLASTP genome sequence mining of the available genome data of 
E. multilocularis (http://www.genedb.org/Homepage/Emultilocularis) using the full-length amino acid 
sequence of the S. mansoni SmVKR1 (SmRTK1; AAL67949 (EMBL) Q8WSM2 (UniProtKB)) identified 
a single orthologous gene (EmuJ_000619800.1; supercontig pathogen_EMU_scaffold_007728: 
4664450-4691242) encoding the protein EmVKR, with highest homologies to SmVKR1 (e-value 4.5e-
256). A second hit by BLASTP analysis identified the ortholog of the insulin growth factor 1 receptor 
beta (EmuJ_000981300, supercontig pathogen_EMU_scaffold_007780: 4236535-4260814) of E. 
multilocularis (e-value of 1.8e-34 to SmVKR1), which was recently characterised and designated 
EmIR2 [33]. Hence, in contrast to the situation in S. mansoni, where two VKR-encoding paralogs are 
present, E. multilocularis only appears to encode one ortholog of the VKR family. 
The EmVKR-encoding gene, emvkr, spans a genomic region of 26.792 bp. Analysis of the exon-intron 
structure of the gene emvkr structure identified 17 exons and 16 introns that displayed the canonical 
GT-AG dinucleotide sequence motifs at the splice donor and acceptor sites, respectively (Figure 
6.2.1A). Trans-splicing and alternative splicing of this gene was not observed in analyses of the RNA-
deep sequencing transcriptome data (data not shown). Further analysis of the RNA-deep sequencing 
transcriptome data represents the expression values of emvkr in all larval stages (Fig. 6.2.1 B) No 
significant differences between the larval stages are observed. The gene emvkr shows a similar 
expression profile in all larval stages also in the semi-qualitative RT-PCR approach (Fig. 6.2.1 C). The 
emvkr cDNA was cloned from total RNA isolated from metacestode vesicles (isolate H95) using RT-
PCR. The total length of the open reading frame of emvkr was 5.112 bp (excluding poly-A tail), 
encoding a protein of 1703 amino acids and a calculated molecular mass of 190.5 kDa. Analysis of the 
protein sequence by SMART software (http://smart.embl-heidelberg.de/) identified an N-terminal ANF-
receptor domain (aa 386-722), described as an extracellular ligand-binding domain present in many 
bacterial amino acid binding proteins and of a wide range of receptors as well as GABAB receptor 
[139]. The identified amino acid sequence showed similarities to VFT-Motifs. Furthermore, a 
transmembrane helix region (aa 928-950) was identified, followed by a C-terminal TKD (aa 982-1256). 
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Figure 6.2.1 Transcriptome expression pattern of emvkr in E. multilocularis larval stages. (A) 
RNA-deep sequencing transcriptome data represents the expression values of emvkr 
in all larval stages from primary cell cultures (Pc) from day 2, and 11 (d2, d11) , 
dormant (Ps_non), and activated protoscoleces (Ps_act), as well as in vitro cultivated 
metacestode vesicles (Mc). Untranslated regions (UTR) in the 5’ and 3’ end are 
highlighted by blue boxes, like the exon- intron structure (boxes and lines) of the gene 
emvkr spanning over a genomic region of 26792bp. (B) emvkr expression profile in 
parasite larvae was given in a graphical view by expression pattern in percent based 
upon fpkm (fragments per kilobase of exon per million fragments mapped; merge of all 
libraries analysed). (C) RT-PCR analysis of emvkr expression in parasite larvae. Total 
RNA was isolated from larval stages as indicated for (A). Equal amounts of isolated 
RNA were reverse transcribed to cDNA and subjected to gene-specific (RT)-PCR for 
emvkr. The house keeping gene elp was used for normalisation. The cDNA was 
diluted 10-fold in 1, 1:10 and 1:100 for PCR. Genomic DNA (gDNA) served as a 
positive control and purity of DNA contamination during RNA isolation. Non-reverse 
transcribed RNA was used as a purity control for DNA contamination during RNA 
isolation. Marker sizes are indicated on the left. (1% Agarose; EtBr stained). Note 
Illumina sequencing were only performed only once for each sample. 
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Figure 6.2.2 Amino acid sequence comparisons for EmVKR VFT- and TKD-domains. Multiple 
sequence alignment of two highly conserved regions in the VKR, the VFTM (VFT-
module) and the TKDs from VKR of different taxa. Orthologous proteins of the Venus 
flytrap receptor were identified by BLASTP in E. multilocularis (EmuJ_000619800.1), 
S. mansoni (AAL67949.1), Aedes aegypti (DAA06509.1) and C. sinesis 
(GAA27163.2). Amino acid sequence was analysed by the SMART programme and 
orthologous regions containing the VFT-module and the Tyrosine kinases were 
extracted and aligned by ClustalW. Identical amino acid residues are shown in white 
on black background. Similar amino acid residues are shown and in black on grey 
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background. The two Lobes of the extracellular VFT-module are indicated (I. & II.), 
interrupted by three flexible regions (L1, L2, L3). Asterisk (red) in the alignment 
indicate residues important for substrate binding in known GABAB receptors [103, 140, 
141]. The intracellular TKD includes the 11 sub-domains of the kinases as defined by 
Hanks and Hunter (I-XI) [66]. Relevant residues in the amino acid sequence for ATP 
binding domain (GxGxxGxV) and its stabilisation (VaVkX16E), the catalytic loop for the 
phosphor transfer (HRDXARN), the Mg2+-binding side (DFG) and the consensus 
sequence for tyrosine kinases (PVRWMXPE) and the present juxtaposed 
autophosphorylation site (YY) is subscribed in the alignment by grey bold letters. 
 
Orthologous proteins of the Venus flytrap receptors from E. multilocularis (EmuJ_000619800.1), S. 
mansoni (AAL67949.1), A. aegypti (DAA06509.1) and C. sinesis (GAA27163.2) were identified by 
BLASTP search using S. mansoni as the initial amino acid sequence [108]. In all orthologous proteins, 
the N-terminal region of the receptor VFT-module (ANF-receptor, 386-722 aa), with similarities to the 
extracellular human GABAB receptor was identified. This external domain is linked by a single 
transmembrane region to an intracellular tyrosine kinase that showed similarities to the tyrosine 
kinases of human IRs. The originally described and characterised Venus flytrap kinase receptor of S. 
mansoni (SmVKR1) showed an overall identity of 33.9% when compared to the full amino acid 
sequence of EmVKR. Analysis of the two major conserved protein regions gave an identity of 32.9% 
for the extracellular VFT-module (Similarities: 0.4822335 Similarity Matrix: BLOSUM62) and an identity 
69.7% for the intracellular Tyrosine kinases domain (Similarities: 0.7970480 Similarity Matrix: 
BLOSUM62) between EmVKR and SmVKR1. Further analysis of the sequence of the two major 
conserved domains, containing the extracellular VFT-module and the intracellular TKD have been 
used for a multiple sequence alignment to identify identical and similar aa residues. As indicated in the 
aligned sequence of the VFT-module important regions (Lobe I. & Lobe II.) of the extracellular domain 
were identified and residues known to be essential for the substrate binding for GABAB receptors were 
identified in EmVKR (indicated by asterisk in Figure 6.2.2).  
The TKD of EmVKR contains all 11 sub-domains (I-XI) representative for RTK as described by Hanks 
and Hunter in 1995 [66]. Strong indicators for a RTK domain are particularly the amino acid sequence 
of H1115RDXARN1123 and P1160VRWMXPE1167, present in sub-domains VIb and VIII. A third important 
motif in the kinases domain is the canonical G989xGxxGxV996 motif, necessary for ATP binding and the 
stabilisation residues for ATP binding (V1010aVkX16E1030). In addition, the existence of the D1135FG1137-
motif involved in the Mg2+-binding is an essential factor that is also present in the kinases subdomain 
VII flanked by two hydrophobic amino acids G1134 and L1138. Furthermore, in some RTK, an additional 
motif was characterised that was also described for IR tyrosine kinases domains, the juxtaposed 
autophosphorylation site (Y1150 Y1151).  
The Venus flytrap kinase of E. multilocularis have been previously mentioned by Vanderstraete et al. 
(2013), in a genome wide screen for identifying orthologs of this receptor type in other organisms 
[107]. Within this study, I have been able to show that the Venus flytrap kinase showed all essential aa 
residues belonging to this new RTK family [103, 107]. In future experiments, it should be investigated 
whether EmVKR is suitable to be expressed in Xenopus oocytes and can be activated by amino acids 
like L-arginine and blocked by the previously-described inhibitor AG1024 [108, 110]. 
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6.3.  AG1024 (Tyrphostin), a potential Venus flytrap kinase inhibitor 
 Insulin-like growth factor receptors are cellular membrane receptors that dimerise after 
binding of external stimulating factors (such as insulin or IGF). Dimerisation of the intracellular 
Tyrosine kinase receptor leads to a so-called ligand-stimulated receptor autophosphorylation and 
activation of the kinase domain. Due to this activation, binding sites are formed for intracellular adaptor 
proteins that transduce the extracellular signal downstream in the cascade and often promote cell 
survival and cell proliferation. Suppressing the activation steps for autophosphorylation is a common 
drug target strategy and used in many cancer studies [142]. The synthetic protein tyrosine kinase 
inhibitor AG1024 (Tyrphostin) was initially identified to block the autophosphorylation of the insulin-like 
growth factor 1 (IGF-1) receptor [143]. In several studies, AG1024 inhibited the proliferation of the cell 
cycle and induced apoptosis in a human breast cancer cell line MCF-7 in a time-dependent manner 
[144]. In addition to the inhibitory action of AG1024 on IGF-1R, blocking of IR was also noticed [110].  
 
 
Figure 6.3.1 AG1024 does not affect the integrity of metacestode vesicles but inhibits the 
formation of metacestode vesicles from primary cell cultures. (A) Metacestode 
vesicles were co-cultivated over 10 days in the absence Control, Mock and in the 
presences of increasing concentrations of the inhibitor AG1024 (0.01µM, 0.1µM, 1µM, 
10µM). Metacestode vesicle integrity was inspected by light microscope. (B) Primary 
cell cultures were established from intact metacestode vesicles and incubated under 
ideal growth conditions (A4 medium) treated with different concentrations (0.01 µM, 
0.1 µM, 1 µM, 10 µM) of AG1024 or non-treated Control and Mock indicating cultures 
with DMSO (without inhibitor). Formation of new metacestode vesicles was observed 
by light microscope and counted on day 14. (A, B) All conditions were assessed in 
three different biological replicates with at least three technical replicates. *(p,0.05); 
**(p = 0.001–0.01) (Student’s t-test). (A, B) ‘Mock’ indicating cultures with DMSO 
(without inhibitor). 
 
In both organisms S. mansoni and E. multilocularis two types of IRs have already been described 
[105] [33]. In addition to presences of the family of IRs, the discovery of the uncommon VKR 
(SmVKR1 and SmVKR2) with the containing intracellular tyrosine kinase (TK) domain similar to that of 
IRs represents a new class of RTK. In E. multilocularis one of the VKR (emvkr) could be identified as 
part of this work. This class of RTK are interesting candidates for the development of novel drugs, 
based upon the conserved intracellular TKD and the availability of chemical compounds acting on IR-
TKD. In a previous study by Vanderstraete et al. (2013), several inhibitors for the TKD of IRs like 
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AG1024 and HNMPA(AM) 3 were tested for their ability to inhibit the enzymatic activity of S. mansoni 
SmIR1, SmIR2, SmVKR1 and SmVKR2 using the Xenopus oocyte expression system [110]. These 
authors were able to show that AG1024 and HNMPA(AM)3 are able to inhibit GVBD in low micro-
molar concentrations (<10 µM). Furthermore, treatment with AG1024 induced apoptosis in 
schistosomula and impairing of adult worms as well as a decrease of egg laying in a dose and time-
dependent manner [110]. Within this study they were also able to show that AG1024 acts upon the IRs 
(SmIR1 or SmIR2) and the VKRs (SmVKR1 or SmvKR2), with slight differences in the number of 
oocytes that underwent GVBD [110]. Moreover, the study observed a similar inhibitory effect with 
another inhibitor HNMPA(AM) 3, which was tested in parallel in E. multilocularis [33]. It was assumed, 
that this inhibitor is acting on the two present IRs (EmIR1 and EmIR2) in E. multilocularis, but other 
inhibitory effects could not be excluded within this study.  
To investigate possible anti-Echinococcus effects of AG 1024, the compound was tested on 
metacestode vesicles and primary cells. As shown in Figure 6.3.1 AG-1024 does a not show lethal 
effect on metacestode vesicles under axenic condition within 10 days of treatment (Fig. 6.3.1A). 
However, in case of the primary cell culture system, treatment with AG1024 showed a statistical 
significant inhibition in the formation of metacestode vesicles at nanomolar concentrations (10 nM and 
100 nM) (Fig. 6.3.1B). In summary, an inhibitor effect of AG1024 could be observed in the formation of 
metacestode vesicles. If AG1024 is active against the IRs or the Venus flytrap kinase receptor could 
not be addressed by this experiment, but likely, since it also affects both types of receptors in 
Schistosoma [110].  
 
 
6.4  Further work on VKR 
   The full coding sequence of the VKR (EmuJ_000619800.1; 5112bp) was sub-cloned into the 
storage plasmid pJET1.2/blunt Cloning Vector (Fermentas) (ASP-054) and the expression vector 
pSecTag2/HygroA (Invitrogen) (ASP-055). The latter vector can be used for expression of the fusion 
protein in mammalian cells like human embryonic kidney 293 (HEK 293) cells for purification and 
detection. In a previous study by Ahier et al. (2009) focusing on analysing the functions of the Venus 
flytrap kinase receptor of Apis mellifera (AmVKR; ACF34409.1), the VKR was expressed in 
mammalian cells (immunoprecipitated from detergent lysates of HEK293) and Xenopus oocytes 
(TKD). Through this method, we want to ascertain what is the stimulating factor of EmVKR according 
to the previous experiments by Ahier et al. (2009) [108]. Newest experimental data suggest that 
EmVKR does not bind to the amino acid Arginine, as was shown for Venus flytrap kinase of the S. 
mansion. It seems very likely that EmVKR utilises another ligand, perhaps specific to Echinococcus. 
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7.   Discussion 
7.1  Overview 
 In the past decades, cellular signalling cascades have been studied intensely in metazoan 
organisms. Findings arising from these studies influenced medical applications and helped to 
understand some basic aspects of cellular biology [65, 69, 145, 146]. Metazoan cells are frequently 
influenced by extracellular signals that bind to their surface, followed by either an activation or 
inhibition of responsive signalling cascades. A variety of respective cell signalling pathways are highly 
conserved across all metazoan taxa and several of these pathways have been identified in parasitic 
helminths [33, 105, 126, 147-153]. For example, in the past ten years, cell signalling pathways of the 
Mitogen‐activated protein kinase (MAPK) cascade, as well as Transforming Growth Factor TGF-β, 
Fibroblast growth factor (FGF), Epidermal growth factor (EGF) and Insulin signalling have been 
identified in the tapeworm E. multilocularis [33, 70, 126, 149].  
Many signal transduction processes are carried out by protein kinases, which are responsible for the 
transfer of a phosphate to the downstream substrate. In mammalian cells, there are approximately 518 
protein kinases (1.7% of the human genome) present in different cell types and most of them have an 
influence on signal transduction pathways. In particular, cell proliferation and differentiation are 
mechanisms that crucially involve protein kinases [154-156]. Thus, many studies have shown that 
kinase signalling mechanisms are affected in cancer cells, often resulting in a constitutive activation or 
inactivation of the pathway, while it has been further observed that such signalling processes can be 
blocked by small-molecule inhibitors [157, 158]. The first respective inhibitors were derived from 
natural sources such as bis-indoylmaleimide staurosporine, which acts upon protein kinase C (PKC) 
[142]. Further investigations showed that staurosporine is not acting specifically on one single protein 
kinase but rather has a broad inhibitory effect on >90% of all kinases [142]. This lack of specificity 
prompted further investigations on the molecular action of staurosporine. It thus emerged that 
staurosporine acts as an ATP competitive inhibitor by out-competing the high cellular concentration of 
ATP from the highly conserved ATP binding pocket of the protein kinase. Today, most kinase 
inhibitors are designed with a greater specificity for binding in the kinase pocket with remarkable 
results on cancer therapy [65]. Based upon the plethora of inhibitors generated in human cancer 
research, it was possible to show in several studies with ATP competitive inhibitors that these drugs 
have an inhibitory effect on the orthologous proteins of the tapeworm E. multilocularis [33, 70, 123]. 
These studies suggest that inhibitors against human proteins, or modifications thereof, could be a 
viable strategy for searching for new chemotherapeutic options against AE. 
 
 
7.2  Limitations of the current chemotherapy against alveolar echinococcosis 
   The human parasitic infection AE is linked to an asymptomatic incubation period of 5–15 
years until the first symptoms appear. AE development of the primary tumour-like lesions is driven by 
the asexual growth of the larval stage, the metacestode, which in most cases affects the liver of the 
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patient [30, 159]. The current treatment options in AE chemotherapy rely on benzimidazole derivates, 
such as Albendazol (ABZ) and Mebendazol (MZ) [30, 49]. Despite intense research into alternative 
anti-parasitic drugs, no reliable alternatives to ABZ and MZ are currently available [55, 73]. 
Furthermore, the chemotherapeutic treatment by Albendazol and Mebendazol in patients is difficult to 
evaluate given that no methods exist to determine whether all parasite cells are killed during the 
treatment. The urgent need for alternative chemotherapy is underscored by the fact that ABZ 
chemotherapy is associated with adverse side-effects, is parasitostatic, associated with high 
recurrence rates and often has to be given lifelong [49, 55, 57, 159]. The main reason for adverse 
side-effects of the drug is the high conservation of the protein targets, the β-tubulins, between host 
and parasite (>80%) [58, 59]. The high similarities of parasite and host β-tubulin are the reason why 
ABZ, can only be applied in parasitostatic doses to the patient. In addition, the drug – which is orally-
administered in most cases – shows a low bioavailability, based upon the fact that it is poorly 
resorbed. A consequence of the low doses of ABZ is an ineffective AE chemotherapy, which only 
reaches parasitostatic concentrations [55, 127].  
In mammalian tissues, multipotent stem cells are responsible for the development of different tissue-
specific differentiated cells. In cestodes, a population of pluripotent stem cells (also called germinative 
cells or undifferentiated cells) are responsible for the development of all differentiated cell types and 
for infiltrative growth and metastasis formation of Echinococcus larvae within the host organs [40, 41, 
44]. A recent publication by Koziol et al. (2014) showed that the primary cell culture contains up to 
80% of stem cells of the parasite [32]. Moreover, these authors showed that the germinative cells 
exhibit a typical stem cell character by expressing several genes from the argonaute and nanos family 
[32]. Indeed, the expression of these genes is a typical component of the germline multipotency 
programme (GMP) of metazoan stem cells, but some of otherwise highly conserved GMP 
components, such as vasa, are absent or highly modified in parasitic flatworms [60].  
In in vitro studies for the development of novel anti-parasitic drugs, the chemical lead compounds are 
often tested on protoscoleces, metacestode vesicles and in primary cell culture [33, 70, 120, 123, 
160]. It was observed that the current anti-AE chemotherapy is ineffective in eliminating the stem cell 
population of the parasite, which leads to remission of parasite growth as soon as therapy is 
discontinued. Unpublished data showed that these stem cells are almost unaffected at high 
concentrations of ABZ in a cell-killing assay in the first days after primary cell isolation (Sarah Hemer – 
Doctoral thesis, 2012). ABZ did not affect the cellular integrity of primary cells when treated over a 
short time (48 hours) in our primary cell culture system, which is a model system for the early 
development of metacestode vesicles.  
The limited activity of benzimidazoles on the parasite stem cells have also been indirectly observed in 
previous in vitro studies by Ingold et al. (1999) and Stettler et al. (2003) [57, 161]. In addition to the in 
vitro studies by Ingold and Stettler a recent publication by Küster et al. (2013) also supports the low 
bioavailability of ABZ of orally treated mice in vivo, which underlines the assumption of a primary cell 
insensitivity to ABZ, where ABZ has low effects on stem cells and ABZ plasma concentrations are low 
[162]. They showed with a new in vivo approach that the growth of a secondary subcutaneous 
infection with AE can be supressed with ABZ (parasitostatic effect) but a complete cure of AE was not 
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observed, which indicates the low in vivo activity of ABZ on the parasite´s stem cells [162]. Thus, 
these results are in line with the results of the in vitro primary cell culture and indicate that the growth 
of metacestode vesicles in vivo is supressed but simultaneously the survival of stem cells during the 
treatment by ABZ is not affected. Long-term experiments within this new in vivo mice model system 
have not been carried out [162]. It would be interesting to observe whether the parasitostatic effect of 
ABZ is abolished after the interruption of the treatment and if recurrence of metacestode vesicle 
growth is generated by surviving stem cells, which remained relatively unaffected. 
We now want to address the question derived from this experimental approach as to what is causing 
the insensitivity of parasite stem cells to benzimidazoles. Phenotypes of benzimidazole resistance 
have been previously observed in other parasites, such as Haemonchus contortus, although the 
reason for the resistance in this parasite is based upon a genetic mutation of a β-tubulin gene [163]. 
Suggestions for a benzimidazole insensitivity of stem cells of E. multilocularis base on a specific 
expression of a β-tubulin isoform (tub-2). Brehm et al. (2000) verified by a genomic a transcriptomic 
analysis that three isoforms of β-tubulins are present (Tub-1 (EmuJ_000202600), Tub-2 
(EmuJ_000672200) and Tub-3 (EmuJ_000202500)) [58, 127]. All three β-tubulin gens have 99% 
identical amino acids, as shown in Fig. 5.9.1. As indicated in Fig. 5.9.1 (red star), Tub-1 and Tub-3 
contain the same amino acid motif at position 200 (Phenylalanine). In direct comparison, Tub-2 shows 
a Tyrosine at this position. It has previously been reported that this specific change at this amino acid 
position is most likely the reason for the insensitivity of Tub-2 to benzimidazoles [58, 59, 127, 132]. 
This suggestion is supported by the fact that a higher binding affinity of benzimidazoles to β-tubulins 
was observed by a Phenylalanine at this position [59, 127]. At present, the binding side on β-tubulins 
to benzimidazoles is not known. Could this natural change in the amino acid sequence of β-tubulins be 
the reason for the infectivity of primary cells (e.g. stem cells) to high concentrations of benzimidazoles, 
further causing regeneration of the parasite tissue in patients?  
Further in silico analyses indicate the presence of ten β-tubulin genes in E. multilocularis (Fig 5.9.1). 
The ten β-tubulin genes include the three genes already characterised by Brehm et al. (2000), namely 
tub-1, tub-2 and tub-3, which show a high expression profile in the larval stages (Tab. 5.9.1) [58]. The 
expression pattern of the β-tubulin genes in each larval stage was further analysed by RNA-
Sequencing data, which showed that tub-2 has a high expression in primary cell cultures at day 2 and 
day 11 (Fig. 5.9.2) [60], known to be enriched by parasite stem cells (80%) [32]. Overall, the semi-
quantitative RT-PCR approach was not sufficiently sensitive to detect the finely regulated genetic 
expression between all larval stages, as identified in the RNA-Deep sequencing data (Fig. 5.9.3) [60].  
As previously shown by Koziol et al. (2014) is it possible to deplete of stem cells from metacestode 
vesicles by treatment with Hydroxyurea (HU) [32]. A similar effect was observed with the Plk1 inhibitor 
BI 2536 acting on parasite stem cells, and will be discussed in a following paragraph; a long-term 
treatment over 21 days should eliminate stem cells from metacestode vesicles. If Tub-2 is specifically 
expressed in stem cells, we assume to observe an expression profile change in the RNA transcription 
pattern. We observed a salient contrast in metacestode vesicles, which were treated over 21 days with 
BI 2536 (50nM) (Fig. 5.9.4). The treatment with the inhibitor BI 2536 does not influence the presence 
of cells expressing tub-1 and tub-3, although the expression of tub-2 was supressed (Fig. 5.9.4). We 
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assume that, in correlation to the staining of proliferating cells by an EdU pulse experiment, all stem 
cells have been depleted (Fig. 5.7.1). These results are confirmed by the RNA-Sequencing data of 
Uriel Koziol (unpublished, personal communication), in which stem cells were shown to have been 
depleted from metacestode vesicles by treatment with HU. While this experiment highlighted that the 
expression of tub-2 is related to stem cells, it also provides evidence why stems cells with the 
described protein modification of the β-tubulin show benzimidazole insensitivity. 
Finally, the identification of a new potential drug target against AE is a crucial issue and newly found 
inhibitors should target the parasite´s stem cells, given their relevance for disease progression and 
resurgence [75, 127].  
 
 
7.3  Targeting of parasitic stem cells by inhibition of the Polo-like kinase 1 (emplk1) 
   Aware of the importance of parasite stem cells and their decisive influence on growth and 
development of the parasite tissue, we focused within this work on a new druggable enzyme that plays 
a key function in the proliferation and differentiation of cells. Similar to extracellular signal transduction, 
the cell cycle is regulated by kinases that execute the transmission of molecular switches. One of the 
best-studied kinase families involved in the cell cycle is the Polo-like kinase family [72, 77, 80, 90, 
156]. One sub-member of this family is the Polo-like kinase 1 (Plk1), which triggers the G2/M transition 
[79, 93, 164]. Several cancer studies showed that an increase of enzymatic activity by these kinase 
force the growth of cancer tissue by influencing the proliferation of cells [165]. Often this observation of 
a higher expression of plk1 is secondary effect, caused by a higher proliferation rate of the tumour. 
Due to this central function, inhibitors have been designed to inactivate this kinase in several types of 
cancers tissues [71, 85, 96, 128, 134, 166]. By analysing the E. multilocularis genomic and high 
throughput RNA-Sequencing data, an ortholog of plk1, emplk1 (EmuJ_000471700) was identified, 
showing a higher expression level in primary cells, which is likely to be correlated to the expression of 
Plk1 in proliferating cells (Fig. 5.3.1). This was confirmed by an RT-PCR showing a high expression of 
the gene in the primary cell culture at day 2, day 5 and day 11 (Fig. 5.3.2). In direct comparison to 
other parasite flatworms like the trematode S. mansoni the Plks have also been studied intensively 
[102, 167, 168]. S. mansoni, SmPlk1 showed considerable homologies to the mammalian Plk1 [102]. 
Long et al. (2010) demonstrate a high expression of the gene in female vitelline cells, oocytes and in 
male spermatocytes. These results indicate that SmPlk1 has a prominent role in the proliferation cells 
like neoblasts with a key role for schistosome mitosis and/or meiosis [102, 168]. In this context Koziol 
et al. (2014), was able to demonstrate that mitotically active parasite stem cells are distributed 
throughout the germinal layer, brood capsule, protoscolex buds and at the base of developing suckers 
[32]. These experiments have been carried out by an in situ hybridisation (WMISH) experiment that 
was recently established on metacestode vesicles and protoscoleces [32]. Furthermore, Koziol was 
able to show that the specific expression of emplk1 in metacestode vesicles is obtained in regions of 
parasite larvae that typically contain large numbers of proliferating stem cells, such as germinal layer 
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cells, early brood capsules and developing protoscoleces [132]. In summary, these data strongly 
indicate that emplk1 is specifically expressed in parasite stem cells. 
Regarding the analysis of amino acid structure of EmPlk1, all relevant amino acid residues that are 
typical for protein kinases and the Plks could be identified (Fig. 5.1.2) [66]. However, the presence of 
relevant amino acid residues in the sequence EmPlk1 alone does not confirm their activity in a cellular 
context. Based upon previously-described protein-interaction partners in humans that are involved in 
the activity of the Plk1, in silico analysis has been carried out to identify upstream interaction partners 
[79, 93]. One of these interacting proteins is the Aurora A kinase, which acts as an initial activation 
kinase for Plk1 [91, 93]. Together with a co-factor protein Bora A, the kinase Aurora A binds to the 
Plk1 and activates the kinase by phosphorylation on T210 (T179 in E. multilocularis; Fig. 5.1.2) [91]. In 
E. multilocularis, Aurora A (EmuJ_001059700) and Bora A (EmuJ_000804300) have been identified 
by a BLASTP search. Furthermore, the presence of upstream activating proteins for EmPlk1, such as 
the cyclin B-bound cyclin-dependent kinases 1 (CDK1; EmuJ_001070150), was identified [77, 80]. 
These proteins are important downstream factors published as M-phase inducer phosphatase 
(Cdc25c; EmuJ_001174300) and act as a phosphorylating substrate for EmPlk1. We conclude from 
the in silico analysis of the genome data that a similar regulatory pathway of ortholog proteins in E. 
multilocularis exist. 
The second gene identified during the BLASTP search was EmPlk4 (EmuJ_000104700; emplk4), 
which is also expressed in primary cells, but this protein does not have such a high importance within 
this study based upon the fact that an effective inhibitor for Plk4 is missing. In a previous study by 
Long et al. (2010) it was already described that a similar set of Plks, SmPlk1 and SmPlk4 (SmSAK) 
exists in the closely related invertebrate S. mansoni [102]. Moreover, these authors showed in a 
second study a co-expression of both kinases SmPlk1 and SmPlk4 in female ovary and vitelarium and 
were able to validate a protein-interaction by in vivo and in vitro experiments, indicating a synergistic 
effect during meiosis of S. mansoni [168]. However, an inhibition of SmPlk4 was not observed by 
currently available Plk-inhibitors [102, 168]. In addition, a detailed study of the function of EmPlk4 at 
this time seems irrelevant for the development of novel drug targets against AE. The clinical 
manifestation of schistosomiasis depends on sexual reproduction in comparison to the infiltrative 
asexual growth by metacestode vesicles in case of AE.  
Our structural analysis of EmPlk1 indicate that all protein domains and catalytic residues are present 
at the corresponding positions and typical for the Plk1-like subfamily, but they do not demonstrate the 
in vitro activity of the kinase. By heterologous expression in Xenopus oocytes, we were able to show 
by in vitro data that an active version of EmPlk1 in Xenopus oocytes is able to induce meiosis and 
GVBD (Tab. 5.4.1). This system was also used to validate whether BI 2536 is able to bind and inhibit 
EmPlk1, as it was previously shown for SmPlk1 in S. mansoni [102]. 
One of the best-studied ATP competitive inhibitors of Plk1 is BI 2536, which acts at low nanomolar 
concentrations [128, 169, 170]. In several studies of clinical phase I and phase II, this inhibitor was 
well tolerated by patients [99, 169, 171]. The inhibitor BI 2536 was tested on several cancer cells in 
vitro with IC50 ranges of 5 to 175 nM [128, 169, 172]. These concentrations are in the same order of 
magnitude as the measured plasma concentrations of cancer patients ranging from 20 to 200 nM after 
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48 hours of orally given doses [99, 169, 171]. Based upon the amino acid sequence and the presence 
of all eight amino acid residues involved in the binding of the inhibitor, we assumed that BI 2536 and 
the second generation BI 6727 are able to bind to EmPlk1 (Fig. 5.2.1) [95, 97, 98].  
In combinatory experiments with the active version of EmPlk1T179D and with increasing concentrations 
of the inhibitor BI 2536, we observed an inhibitory effect at concentrations of 20 nM (Tab. 5.4.1). This 
ATP competitive inhibition was concentration dependent and, at higher concentrations of 50 nM and 
100 nM, EmPlk1 was no longer able to induce GVBD (Tab. 5.4.1). Taking into account that all 
necessary amino acid binding residues involved in the inhibitor binding are present, we assume that BI 
2536 acts against the orthologous protein EmPlk1 in a similar way as against S. mansoni SmPlk1 
[102].       
Having shown that BI 2536 is suitable to inhibit the activity of EmPlk1, inhibitor effects on primary cells 
and metacestode vesicles have been analysed by the following experiments. In the case of the 
primary cell culture, a clear inhibitory effect in the formation of metacestode vesicles was observed 
(Fig. 5.5.1; Fig. 5.5.2). Even at concentrations as low as 25 nM BI 2536 (a concentration in the same 
range as the plasma concentrations of patients after 48 hours of oral treatment [99]) the regeneration 
of metacestode vesicles from primary cells was affected. At higher concentrations of 50 nM and 100 
nM, only a few metacestode vesicles were formed within 14 days (Fig. 5.5.2). This data suggest that 
BI2536 has profound effects on Echinococcus stem cells. Regarding the effects of BI 2536 on 
metacestode vesicles, direct killing was not observed within a week of treatment as compared to other 
inhibitors like ML3403 or Imatinib (Fig. 5.6.1) [70, 123]. However, long-time treatment over 21 days 
showed that metacestode vesicles were unable to grow in size (Fig. 5.6.1). To analyse whether the 
observed reduced growth of metacestode vesicles depends on the inhibition of proliferating stem cells, 
an EdU pulse approach was carried out according to Koziol et al. (2014) [32]. EdU labelling 
investigates how many proliferating stem cells remain in the tissues of the metacestode vesicle. 
Metacestode vesicles were treated for 21 days with concentrations of 50nM and 100nM of BI 2536. 
After five days without treatment, the proliferating cells – stem cells – in the intact metacestode vesicle 
were stained using an EdU pulse approach (Fig. 5.7.1). Upon further cultivation, these treated 
metacestode vesicles did not resume growth and their GL was no repopulated by residual (surviving) 
stem cells. In addition, primary cell cultures isolated from inhibitor-treated vesicles did not develop into 
metacestode vesicles. A short-term treatment of metacestode vesicles with BI 2536 at 50 nM and 100 
nM was also performed (Fig. 5.7.2). After 24 hours of treatment followed by one day of regeneration, 
we observed that the proliferation rate is significantly reduced within such a short time of inhibitor 
administration. However, we assume that a short-time treatment even at high concentration of 50nM 
and 100nM is not sufficiently effective and that proliferating cells were simply blocked and kept 
probably in mitotic arrest until dissociation of the inhibitor. An experimental approach of isolating 
primary cells from these short-time treated metacestode vesicles to demonstrate the hypothesised 
formation of regeneration has not been carried out to date. These results are in line with existing 
studies; indeed, as previously mentioned, SmPlk1 shows a high expression rate in reproducing organs 
and morphological changes in testes and ovaries with significant effects on oogenesis and 
spermatogenesis in adult worms by inhibition of SmPlk1 with 100 nM of BI2536 [102]. The inhibitory 
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action of the Plk1 inhibitor BI 2536 has been originally observed in several cancer tissue cell lines at 
low nanomolar (2–25 nM) concentration (EC50) values [100, 128]. Based upon the observation of 
cancer cell lines, Long et al. (2010) already discussed that BI 2536 led to a mitotic arrest in gonads of 
S. mansoni and cells are forced into apoptosis [102, 128]. Similar effects have been observed in 
cancer cell lines that have been treated with the second generations of this inhibitor class BI6727 
[128, 169]. We conclude that BI 2536 is able to arrest the proliferating cells in the mitosis or cause 
killing by mitotic arrest followed by apoptosis of parasite stem cells but the metacestode vesicles can 
apparently survive for longer periods without much cell renewal.  
Inhibitory effects in the parasite cell culture have also been observed with two other Plk1 inhibitors in 
preliminary experiments. In addition to the inhibitor BI 2536, we tested the second generation of this 
kind of inhibitor class, BI 6727, which also acts at nanomolecular concentrations, as well as a third 
ATP competitive inhibitor, GW843682X (ATP competitive), which acts at micro-molar concentrations. 
Similar to the previously tested inhibitors, metacestode vesicles do not show a phenotypic effect over 
a short time of treatment (GW843682X Fig. 5.6.2; BI 6727 data not shown). The formation of 
metacestode vesicles from primary cells was suppressed, but the inhibitor concentrations have been 
up to 1000-fold higher, which depends on the fact that this inhibitor belongs to another inhibitor class 
(GW843682X Fig. 5.5.3; BI 6727 data not shown). The reason for a lower binding affinity of 
GW843682X to EmPlk1 could not be analysed, potential side changes residues of the drug are 
responsible for the less binding activity. The inhibitor was previously tested on 18 cancer cell lines 
showing an inhibitory effect at concentrations ranges from 0.02 to 11.7 µM [173]. An effect at 
nanomolar concentrations could not be observes on Echinococcus cell lines. Further experiments with 
the inhibitor GW843682X are currently not planned.  
Regarding the further development of anti-echinococcosis drug, we intend to increase the specificity of 
derivatives of BI 2536 for its parasitic protein target EmPlk1. In comparison to the second-generation 
inhibitor BI 6727 for Plk1, we observed 50% less activity at the same nanomolar concentration, 
concerning the formation of metacestode vesicles from primary cells and GVBD in Xenopus oocytes 
experiments (data not shown). Concerning all three tested inhibitors acting on Plk1 it has to be 
mentioned that side-effects by these drugs cannot be excluded due to the strong similarities between 
the human and parasite protein target. 
Therefore, we are currently in the process of crystallising the protein structure of EmPlk1 in 
combination with both inhibitors BI 2536 and BI 6727 (Chapter 5.8). Having the crystal structure with 
the bound inhibitor would allow us to identify other chemical lead compounds or estimate which 
chemical modifications can be made to optimise the chemical structure of BI 2536 or BI6727 for 
binding to EmPlk1. Overall, it must be possible to specify the inhibitors BI 2536 or BI 6727 for the 
EmPlk1 enzyme based upon the fact that the amino acid identity to the human Plk1 is only 62%. 
Compared to the current treatment with benzimidazols this is a great advantage, because the β-tubulin 
of humans and parasites share more than 80% identity.  
Having shown that the Plk1 inhibitor BI2536 is acting on the parasite stem cells we want to validate the 
previous data (Sarah Hemer – Doctoral thesis) and show that parasite stem cells are insensitive to 
benzimidazoles. A further question that we investigated was whether a combinatory treatment in vitro 
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of metacestode vesicles with benzimidazole (ABZ) and BI 2536 would be sufficient to inhibit the 
regeneration process after primary cell isolation (Fig. 5.9.5). During the regeneration time, formation of 
new metacestode vesicles in treated samples was not observed but metabolic activity was detected by 
colour change of the culture media (Fig. 5.9.5C). The formation of intact metacestode vesicles could 
not be observed after seven days of primary cells isolation (Fig. 5.9.5B). Moreover, a suppression of 
aggregate formation during the regeneration process was also not seen, as visible in the control 
samples and previously-described studies [33, 70, 118, 123]. Therefore, it can be concluded that 
primary cells are able to survive a short time (2 days, Sarah Hemer – Doctoral thesis) of high 
concentration of ABZ, owing to differences in the expression pattern of Tub-2 as undifferentiated cells. 
However, we assumed that the regeneration process is also related to differentiated cells, such as 
muscle and nerve cells, which might have an influence on the regeneration process (personal 
communication Uriel Koziol). We propose that differentiated cells are unable to proliferate but instead 
trigger stem cell proliferation as described for other free-living flatworms [174-176]. Finally, the actual 
function of the differentiated cells in the regeneration process is unknown and should be further 
analysed regarding the signal cross communication of cells [32].  
Taken together, we herein present a new inhibitor BI 2536 acting on EmPlk1 and directly affect the 
stem cells of E. multilocularis. The inhibitor is orally-administered and acts at a nanomolecular 
concentration in range of the measured plasma concentration of cancer patients. Although the human 
and the parasite kinases have a high homology of 62%, they are more divergent than the current drug 
for AE treatment. In conclusion, BI 2536 should act as a lead compound and the structural differences 
of the amino acid can further be used to optimise the chemical structure for a parasite specific drug.  
 
 
7.4  Injection of primary cells into metacestode vesicles 
   The current cell culture of metacestode vesicles is carried out with several isolates of E. 
multilocularis showing different phenotypes during there “life in co-culture”. For example, some of the 
isolates that have been kept in co-culture over several years, such as the isolate H95, show fast 
growth of metacestode vesicles but does not produce any protoscoleces. Younger isolates such as 
GHO9, J2012 or DPZ grow slower but remain able to form brood capsules. The question arises as to 
what triggers the formation of protoscoleces at a certain point in the metacestode vesicle development 
and whether isolates like H95 have been genetically handicapped by mutations over the decades of 
co-culture. 
With the herein presented new method of injection of primary cells into stem cell depleted 
metacestode vesicles and further co-cultivation, I propose that some of the questions can begin to be 
answered. Furthermore, with further experiments, it might be possible to gain information of the 
genomic stability (e.g. epigenetic modifications) and influencing factors of stem cells, like regulation 
protein factors. Does this mean that the possible “regulating protein factor” for the formation of 
protoscoleces is generated by differentiated cells types such as nervous cells, which are released in 
the stem cell depleted metacestode vesicle, or is the start point triggered by the parasite stem cell? 
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Through stem cell depletion of several isolates of E. multilocularis and cross-injection of isolate 
different primary cells, I propose addressing the initial questions concerning what the difference in 
stimulating the formation of protoscoleces in long-term in vitro cultivated metacestode vesicles might 
be, starting with first experiments on the method of injection of primary cells into stem cells depleted 
metacestode vesicles.  
As previous studies have shown in other organisms such as free-living flatworms, a single stem cell 
can repopulate a whole organism by proliferation [177-180]. The organisms have previously been 
treated with ionising radiation, which eliminates all proliferating cells (mainly stem cells, such as 
neoblasts and germinate cells). In this thesis (Chapter 6), it has been shown that a similar principle in 
the metacestode vesicle is possible, leaving an intact shell of a metacestode vesicle without any 
further proliferating cells.  
Generated data showing that a long-term treatment of metacestode vesicles with the inhibitor BI 2536 
directly affects the survival of proliferating cells and suppresses the growth of metacestode vesicles 
gave rise to further questions. What happens with a metacestode vesicle, which is depleted from stem 
cells, when isolated primary cells are injected into the hydatid fluid? Are parasite stem cells able to 
integrate in to the stem cell depleted germinal layer? Is it possible to repopulate a stem cell depleted 
metacestode with stem cells of another isolate (e.g. H95 with GHO9) of E. multilocularis? In an 
experimental approach, I tried to generate some preliminary data to address some of the above-
mentioned questions. Concerning the question of reintegration of stem cells into stem cell depleted 
metacestode vesicles I used a previously-described EdU pulse approach to stain proliferating cells 
(Fig 5.7.1). Primary cells were isolated as before from different isolates of E. multilocularis. Stem cell 
free metacestode vesicles were generated by treatment over 21 days with the inhibitor BI 2536 and 
primary cells were injected followed by an EdU pulse approach carried out five days later  
Initial results showed that the injected primary cells were able to reintegrate and proliferate within the 
germinal layer of the metacestode vesicle (Fig. 6.0.2). In addition, I could observe that the integration 
was possible with stem cells of isolates of different genetic background. However, at this experimental 
point, we are unable to exclude that muscle or nerve cells were also able to reintegrate into the 
germinal layer, although we know that only proliferating cells such as the parasite stem cells are able 
to proliferate. Furthermore, we saw that the injection of primary cells had a local distribution at one 
side of the depleted vesicle. This observation could be caused by the fact that the primary cells were 
injected from the top of the metacestode vesicle and the sedimentation in the hydatid fluid was forced 
by gravity. According to the preliminary results, it can be concluded that firstly the reintegration of 
primary cells (stem cells) into stem cell depleted metacestode vesicles is possible, and secondly, the 
reintegration is independent from the specific isolate that was used. Nevertheless, this method has to 
be improved and it will be necessary to use a commercially available micro-injector for further 
experiments. In further experiments, this method might also be interesting because injecting 
transgenically manipulated primary cells into the hydatid fluid can reintegrate into the GL of the 
metacestode vesicle proliferately and form a genetic manipulated metacestode vesicle. I assume that 
even a single transgenic stem cell of E. multilocularis is able to repopulate a whole metacestode 
vesicle, as indicated by Koziol et al. (2014) after treatment with HU [32]. 
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7.5  The Venus flytrap kinase receptor of E. multilocularis 
   The VKR represent a novel family of receptor tyrosine kinases (RTK) that are specific for 
invertebrates, as originally described in the parasitic platyhelminth S. mansoni [103]. The RTK 
superfamily is characterised as being involved in cellular and developmental processes, including cell-
cell communications and tissue organisations in several metazoan organisms [181]. The growth of the 
parasite by cellular mitogenesis is dependent upon growth factor receptors and hormones, such as 
IRs, according to mammalian cells [103]. At present, it is already known that growth factors are 
stimulated by interacting the cellular surface and are relevant for the host-parasite and male and 
female communication, although less is known about ligands and receptors involved in this process in 
S. mansoni [103]. To date, no IR has been characterised in S. mansoni and efforts have been made to 
identify one of these essential receptors types [105]. Unexpectedly, Ahier et al. (2003) identified one 
uncharacterised membrane receptor that has an extracellular ligand-binding domain connected by a 
single membrane domain and one IR (previously named SmRTK-2) with an intracellular TKD 
(SmRTK-1) [103, 105]. This characteristic is typical for RTK showing an extracellular ligand-binding 
domain, linked to an integral single membrane protein domain to an cytoplasmic ligand-sensitive 
tyrosine kinases domain [181]. The biological function of SmRTK-1 (SmVKR1) remains unknown, 
although previous studies have observed that this receptor type is expressed in reproducing organs of 
parasites, like S. mansoni and other invertebrates, mainly insects [108]. A genome-wide analysis 
highlighted that no vkr gene was detectable in vertebrate genomes, which means that this receptor 
type is invertebrate-specific. In S. mansoni, two receptor types of this class have been characterised 
overall (SmVKR1, SmVKR2) and in Turbellaria genomes a putative truncated version of vkr in the 
planarian Schmidtea mediterranea (GenBank: AAWT01078636.1) has been detected [108]. 
Furthermore an existing gene of vkr in E. multilocularis was previous mentioned in a study by 
Vanderstraete et al. (2013) using the recently-published genome data of the four tapeworms by Tsai et 
al. (2013) [60, 107]. We now wanted to study the characteristics of this novel RTK in E. multilocularis 
to address the question of what might be the biological role and what are the activating ligands for this 
receptor. The study of this new receptor might essentially help to understand the development and 
differentiation of Echinococcus cells from larval stage to the adult worm, including the morphological 
changes necessary also to adapt to changes in the environment.   
Analysis by BLASTP genome sequence identified one ortholog receptor type of the VKR 
(EmuJ_000619800.1; emvkr) in the genome of E. multilocularis. The gene emvkr is constitutively 
expressed over all larval stages as indicated by analysis of the RNA-Sequencing data (Fig 6.2.1B). 
Moreover, no unusual gene expression pattern caused by alternative splicing or trans-splicing was 
observed (Fig. 6.2.1A). Deeper analysis of the two domains (the extracellular VFTM (VFT-module) and 
the intracellular tyrosine kinase) was performed by a structural alignment of the amino acid sequences 
(Fig. 6.2.2). Furthermore, the amino acid homology of the VFT-module to SmVKR1 and EmVKR 
identified a similarity of 48%. Phylogenetic analysis identified that the extracellular domain has high 
homologies to GABAB receptors (drug receptors) and the intracellular TKD confirmed similarities to IR 
catalytic domains [103, 139-141]. We were also able to identify previously-described amino acid 
residues involved in the binding of extracellular ligands from GABAB receptors [139-141]. Overall, we 
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expected that the extracellular domain of the VKR might be involved in the binding of amino acids, 
such as L-arginine, as it was previously identified in the ortholog receptor of the honey bee [108]. 
However, first experiments by expressing EmVKR in Xenopus oocytes suggest that L-arginine is not 
the binding ligand and activation factor of this receptor (personal communication - Colette Dissous). In 
further experiments, efforts have to be made to identify the stimulating factor of EmVKR, whereby 
possibly another ligand - perhaps specific to Echinococcus - is used. To analyse this cell culture, 
supernatant and hydatid fluid has to be tested. 
In case of the intracellular domain, we obtained homologies to the TKD (TDK) of the previously 
identified IRs in E. multilocularis [33]. This data was further validated by the amino acid alignment of 
the TKD in ortholog VKRs (Fig. 6.2.2). We were able to show that this kinases domain fruit fills all 
typical protein domains and catalytic residues for this enzyme family at the corresponding positions 
[66, 67]. In direct comparison to the tyrosine kinases domain of SmVKR1, a similarity of 80% was 
estimated. Moreover, all essential motifs for a dimerisation and autophosphorylation are present as 
previously describe of the VKR of Apies mellifera (AmVKR) [108].  
In conclusion, we showed that the extra- and intracellular domain of the herein presented Venus 
flytrap kinases inhibitor of E. multilocularis are functional. Further studies in the activity and potential 
binding substances on the extracellular domain are under investigation. So far, a second gene of this 
receptors class that has previously been observed in invertebrates was not identified in E. 
multilocularis [108]. The question of why S. mansoni has two VKR and E. multilocularis only has one 
gene could not be answered and remains open; indeed, it might be an evolutionary question of “keep 
or loss” of gene in general in some species [107].  
The characterisation of the unusual Venus flytrap kinase receptor, its specification to invertebrates and 
its role in the development of the parasite, suggests its ability as a potential new drug target [110]. The 
presence of a high similarity to the TKD of human IRs opens the possibility to test cancer drugs acting 
specifically in this domain of the receptor. In a recent study the IR inhibitor, Tyrphostin AG1024 (ATP 
competitive) was tested to inhibit the VKR. Vanderstraete et al. (2013) were able to show that this 
inhibitor was able to block the functions of the VKR at micro-molar concentrations [110]. Furthermore, 
they observed alterations of reproductive organs and apoptosis in a concentration dependent manner 
following treatment with AG1024. A disadvantage of this study is that they were unable to show that 
this inhibitor is only acting in the two VKR in S. mansoni. An inhibition of the two IRs in S. mansoni 
was also given [105, 110]. A second tested IR inhibitor in this study was HNMPA(AM) 3, which has 
previously been tested in E. multilocularis [33]. In E. multilocularis this inhibitor suppressed the 
formation of metacestode vesicles in the primary cells culture and decreased protoscolex viability [33]. 
A high potency in the killing of metacestode vesicles was not observed [33]. Independent from the 
chemotherapeutic studies of S. mansoni and the knowledge of the synergistic effect of AG1024 on IRs 
and the VKR, we tested AG1024 in our cell culture on primary cells and metacestode vesicles. 
Treatment over 10 days does not show any phenotypic effect on the integrity of metacestode vesicles 
(Fig. 6.3.1A). A concentration dependent inhibitory effect on the regeneration of metacestode 
formation from primary cells was observed (Fig. 6.3.1B).  
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Comparing the results from S. mansoni and the present experiments in E. multilocularis, it is unclear 
whether AG1024 and HNMPA(AM) 3 only target the IRs and VKRs. In S. mansoni, it was observed 
that AG1024 acts upon both receptors, which suggests that the inhibiting effect in the present study E. 
multilocularis is comparable [110]. The observed effects in the inhibition of the estimated protein 
targets could be generated by the IRs or the VKR. Unpublished results from RNA-Seq. data of stem 
cell depleted metacestode vesicles indicate that the VKR (emvkr) is not stem cell-specifically 
expressed (Personal communication – Uriel Koziol). These first observations from E. multilocularis are 
in line with the results from S. mansoni and show that an inhibition by AG1024 of the VKR affects the 
proliferating cells in the reproduction organs of the parasite [110].  
The exclusive expression of the VKR in invertebrates makes this kind of receptor an interesting target 
for the development of novel drugs for AE. Moreover, resistances have also been observed in the 
current chemotherapy for the parasite S. mansoni. One reason for this is the mass-use of the single 
drug Praziquantel (PZQ) [182, 183]. Independent from the identification as VKR as new potential drug 
target, a more specific inhibitor of the AG1024 or HNMPA(AM) 3 compounds would help to study the 
biological role of this new type of receptor class in both parasites. 
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A   Sequences 
   Start-, stopcodons are highlighted in grey. 
 
EmPlk1 CDS (EmuJ_000471700; supercontig pathogen_EMU_scaffold_007614 : 4512575-4515749) 
 
1    ATGGATAAGT CAAAAGCGAA GGAGGTTCCC GCTATTGTGC ATGACAAGTC AAACGGTAAA ACGTATGTGA GAGGGAGGTT 
 
81   TCTTGGAAAA GGAGGCTTCG CTCGCTGTTG GGAGTTGAGT GACCAAGACA CCGGTGTAAA GTATGCGGGA AAAGTTGTTG 
 
161  CAAAATGCGA TATCCTCAAG CCCTCCCAGC GTCAGAAGAT GCAGCAAGAA ATTACAATTC ATGCTTCATT GAAGCACGAA 
 
241  AATATTGTCG GTTTTCACAG GTCTTTTGAG GATGAAGCCA ACATATACAT ACTGCTCGAG CTGTGCCCAA GGCGGACTCT 
 
321  CATGGAACTG CATAAGAGAC GTCGACAAGT TACTGAGCCA GAAGCCCGGT ACTTTATTAG GCAAATCGTC ACCGGATGTC 
 
401  AATATCTGCA CCTTAATAAC ATAATTCATC GCGATCTTAA ACTGGCCAAT CTGTTTTTAA ATGATGACAT GATTGTAAAG 
 
481  ATCGGGGATT TTGGTTTGGC CTCTAGAATT ACTAAAGAAG GTGAAATGAA GAAGACATTA TGTGGGACGC CAAACTATAT 
 
561  TGCTCCTGAG ATTCTCTGCA AACATGGCCA CAGCTTTGAG GTAGATTCGT GGTCCGTGGG TTGCATTTTG TACACTCTTC 
 
641  TTGTGGGTCG TCCGCCTTTC GAAACGTCGA GTTTGCATGA CACATATGAA AAAATAAAGA AGAACGATTA CCTCGTTCCT 
 
721  GGTAACATCA GCATAGCAGC CACAAACTTG ATTCGCGCCT TTCTTAACTC TGATCCACAA AAGCGGCCGA GCATGTTCAG 
 
801  TGTGATGGAC CACAGTTTCT TTAAAGGATT TACTCCCACC GGTCTCCCTG TCAGTGCACT AACCACCTGT CCCCGATTCG 
 
881  ACAATCTTGC TCGCAATCCC TCCGACAGAC GACCACTCTC TGTTATTGAT GCTAATCTAA ATGATGTATC AACAGTCAGT 
 
961  ACAGAGGCGA ATAAAGATTA CACTACAGAC GATTGCTGGC TTACAGTTTT GTTTGAGAAG TTAGGAGAAC TACTACATGC 
 
1041 ACCCGTACTG CAAGCAACCT CCATAACCGC AATGGAAGAG AGCGAAGATC CAGCATGTGT TCCCATTTAT TGGGTCTCTA 
 
1121 AGTGGGTGGA TTATTCGGAC AAGTATGGCA TTGGTTATCA TCTGTGTGAT TTCTCGAACG GTGTTCTTTT TAATGATGAT 
 
1201 ACACGCTTAA TCTTCACTGC GAACAAAGAG AACCTCCAAT ATATTGAAAG TGGTGGCAAA GAGCACTTGT ATACCAAGAA 
 
1281 TGACTACCCC GCTACACTCA AAAAGAAAGT AACATTACTT ACTTGCTTCA CTAGTTACAT GCAGGAAAAT CTGCTTCATG 
 
1361 CCGGAGAGAA CATTGTGCGT CGGGAATCAG ATAGCATGGC CAGACTTCCC TTCCTCCGAA GCTGGTGTCG AACCCGCGTC 
 
1441 GCAATCGTGC TTCATCTCAG CAATGGAACA TTGCAACTCA ATTTCTTCGA CGATCACTCC AAAATCATCC TCTGCCCTTT 
 
1521 GATGGAGGCT GTTACTTTTA TTGACCCGAG TCGTAATTTC AAAACCTTTC GTTTCAATTT GCTCAGGAAA TATGGCATTA 
 
1601 CTGATGACTT AATAAAGCGA TTGAAGTACG CCTACGATAT GATAGATCGC AAGCTCTTGC AACGGCAGTC TGAATCCCAC 
 
1681 GCGCGTTGCA CTGGCGCAAA GAATAAAAAA GGTTCTCGAG AGGCAGTTCC ACATCCAGCC ATTGCTCCAA TGAAAGAAGA 
 
1761 AGATCCTGTT AGTGCAGCCG TTGGCGCAAG GAAGCAAGAC GCTCCAAAGG TTGATGTTCT GAAACACAAA TAA 
 
 
 
EmPlk1 Protein sequence 
 
 
1   MDKSKAKEVP AIVHDKSNGK TYVRGRFLGK GGFARCWELS DQDTGVKYAG KVVAKCDILK PSQRQKMQQE ITIHASLKHE   
 
81  NIVGFHRSFE DEANIYILLE LCPRRTLMEL HKRRRQVTEP EARYFIRQIV TGCQYLHLNN IIHRDLKLAN LFLNDDMIVK   
 
161 IGDFGLASRI TKEGEMKKTL CGTPNYIAPE ILCKHGHSFE VDSWSVGCIL YTLLVGRPPF ETSSLHDTYE KIKKNDYLVP   
 
241 GNISIAATNL IRAFLNSDPQ KRPSMFSVMD HSFFKGFTPT GLPVSALTTC PRFDNLARNP SDRRPLSVID ANLNDVSTVS   
 
321 TEANKDYTTD DCWLTVLFEK LGELLHAPVL QATSITAMEE SEDPACVPIY WVSKWVDYSD KYGIGYHLCD FSNGVLFNDD   
 
401 TRLIFTANKE NLQYIESGGK EHLYTKNDYP ATLKKKVTLL TCFTSYMQEN LLHAGENIVR RESDSMARLP FLRSWCRTRV   
 
481 AIVLHLSNGT LQLNFFDDHS KIILCPLMEA VTFIDPSRNF KTFRFNLLRK YGITDDLIKR LKYAYDMIDR KLLQRQSESH   
 
561 ARCTGAKNKK GSREAVPHPA IAPMKEEDPV SAAVGARKQD APKVDVLKHK *  
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EmPlk4  CDS (EmuJ_000104700; contig pathogen_EMU_contig_62145 : 542458-548585) 
 
1    ATGTACGTTC AACCAAACCT AAAGGGGTTA GGGTCCTCAA AGGATGATTT TCAGGTTTTT GAACTCCTCG GCCGTGGGGG   
 
81   CTTTGCGCAA GTATATAGAG CCAAGTCGGT CATCACTGGT CAGGAGGTTG CAATCAAAAT GATTGATAAA AAATATATGC   
 
161  ATCAACATGG CCTCACTCAT CGCGTTCAAC GAGAGGTCGA AATCCACAGT CGTTTGAAGC ATCCTGCGGT TCTCGAGTTA   
 
241  TACACATGCT TTGAAGATGC AAACTACGTT TACTTGGTCC TCGAATTTTG TGACAATGGG GAGCTACAGG CTTACATTCG   
 
321  GCAGAACGGA TCTGTTTCGG AGGACATGGC TCGTCACTAT ATGAAGCAAA TCATCAGTGG CTTGCTCTAC CTTCATTCAC   
 
401  ACAACATCCT TCACAGGGAT CTCACTTTGG CTAACCTTCT GCTGACAAAG GACATGAAAG TGAAAATTGC TGACTTCGGC   
 
481  CTCGCGACCA AAATTGAGCC TGGTGAAGAT CACACCACCA TGTGTGGCAC ACCTAATTAC ATCTCACCTG AGGTGGCAAG   
 
561  TCGAGGTCAC CAGGTTCTGG AGACGGACGT TTGGTCTCTT GGTTGCATGC TCTACACCCT AGTGGTGGGT CATCCTCCAT   
 
641  TTGATACGCG CGAGGTCAGA AGTACCCTGA GTCGAGTAAT CGCCGGGGAT TATGAAATGC CTGAACATCT CTCTCCCGAT   
 
721  TGCTCTGATC TCATTGCCAA ACTCCTGCGG AAGCAACCGC AGGATCGTAT CAAACTCTCC GATATGATCA GACATCCCTT   
 
801  TATCACTAGG AGCACAACAC CTCGACGTAA AATGGAGCAC TCCAGAGACA GTGGGATCGA TTCGATGTCG CGTACACCCA   
 
881  CCATTGGAAT GCAGTCAAAC TCACTCACTG CAACAACAAC CACTACAGCT GCCACTGCAA ACAGTCGTCA CTCCCTGCCT   
 
961  TACCGACCGG GTGCGAGCAT TCTGCCTCCA CGTGCAGCCT CCCGCCTGTC AGTGGATATG CATCGTTCGA CGCAGAACCA   
 
1041 GCAATCTGGT CACCAGACGC CTCTGACCCC CTTCGATTCT AGAGGTCACC AACCGCCAAC TTCTGCCACG CGACTGCGTG   
 
1121 GTGGCTCTCT ACAACACCTT CTTCCTCCTT CAAAGAGTAT GTCAGGCCTA TCTCTTGCGA CCTCATCGCC TTCTCCTTGT   
 
1201 CGTTCCGCCT CAGTGGGAAA TCTTCAGCGC ACCTCACATC AGCCGAGCCT CTCACCTCTC TGTACCTGTC GCCTGCGCCC   
 
1281 AATGCGCACA GTCACACGGA TGGCAGTGAT CAACATTCTC CCTGATGAGT CGGTTTGTTT GGAGTTTTTT GACCCGCAGG   
 
1361 TGAATCAACA GAAGCTCGTC GTTGAAGTGA TGGGCATCTC GGCTGATGGA CAGGAGGTGA TTATCTATCA TCCTAATGGA   
 
1441 GGACGTGGAG TGCCTCCAAA TACGAACAGC CCGGTAGCAG CCCGCTCTGG CGATACGTAT GGAGTATATA GACTTGCTCA   
 
1521 GCTCCCTGAG AAGTACTGGA AGAAGTATCA GTTTGTGTCC AAATTCATAA ATATGGCCAA GGCTCATACA CCCAAAGTGA   
 
1601 CGCTGTACAC ATCGCGAGCA AAGTGTATTC TAATGGAGAA GGTGGAGCCT CAGGCGGACT TTGAGATGGA GGTGCTTACA   
 
1681 GACGGTAGTC GGGTTATCTG TCTCGGTGGT GAGGCAGCCG GAACGGTGCA GGTCATTACA CAGACCAACG GCACCGTTAC   
 
1761 TGTTGATCGC AAACAGCCTT TGGACAATCT GCCAACTGCC ACCCGGGAAC TCATTTCCTA CGCAGAAAGA TGCCGACGTC   
 
1841 GCTGTCTGGA GGTTGAAAGT TCACTGGAGA AGTTTAATGT TGCCCTATCT CCGCTGGATG CAGAAGTTTC CTCGCCTTTC   
 
1921 CCCGTAATAA TTGGTCGTCG ATCTTGCGCC GCTTCTAAAA CCTCGTCCAA AGGCCCCGTC TCATCCGCAT GCCTCTCTCA   
 
2001 GCTCGTGGCT AGCTGCGGTA CCTCGGTCAG CGATAGTCAG CCGCGCTCTT TCTCGCGCCA CTACGATCCT GTATTTGTTC   
 
2081 CCTCCGTTGG GTGGGTCTCA CAGTCCTCTC CGGAGGAGTT GCAAGTTCAA TTCAACGACG GCGCCCGACT TGTAGTTGTT   
 
2161 TACTCCACAG CGACAGTCCA CAGCATCCGC TACCATCCAC CGGCAATAGC TGGAGAGGAG GAAGAGGAGC AGGTCTACTC   
 
2241 GACTGCATCA TCGTCCACAC CTCTGCCAGC CGAAGTGCGG AGCCGTTTGG AGGTCATTCC AAAAGTTGTT AAATGTCTCC   
 
2321 GTTCGAGGTC TAAAACTCCA CCCTGA  
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EmPlk4 Protein sequence 
 
1   MYVQPNLKGL GSSKDDFQVF ELLGRGGFAQ VYRAKSVITG QEVAIKMIDK KYMHQHGLTH RVQREVEIHS RLKHPAVLEL   
 
81  YTCFEDANYV YLVLEFCDNG ELQAYIRQNG SVSEDMARHY MKQIISGLLY LHSHNILHRD LTLANLLLTK DMKVKIADFG   
 
161 LATKIEPGED HTTMCGTPNY ISPEVASRGH QVLETDVWSL GCMLYTLVVG HPPFDTREVR STLSRVIAGD YEMPEHLSPD   
 
241 CSDLIAKLLR KQPQDRIKLS DMIRHPFITR STTPRRKMEH SRDSGIDSMS RTPTIGMQSN SLTATTTTTA ATANSRHSLP   
 
321 YRPGASILPP RAASRLSVDM HRSTQNQQSG HQTPLTPFDS RGHQPPTSAT RLRGGSLQHL LPPSKSMSGL SLATSSPSPC   
 
401 RSASVGNLQR TSHQPSLSPL CTCRLRPMRT VTRMAVINIL PDESVCLEFF DPQVNQQKLV VEVMGISADG QEVIIYHPNG   
 
481 GRGVPPNTNS PVAARSGDTY GVYRLAQLPE KYWKKYQFVS KFINMAKAHT PKVTLYTSRA KCILMEKVEP QADFEMEVLT   
 
561 DGSRVICLGG EAAGTVQVIT QTNGTVTVDR KQPLDNLPTA TRELISYAER CRRRCLEVES SLEKFNVALS PLDAEVSSPF   
 
641 PVIIGRRSCA ASKTSSKGPV SSACLSQLVA SCGTSVSDSQ PRSFSRHYDP VFVPSVGWVS QSSPEELQVQ FNDGARLVVV   
 
721 YSTATVHSIR YHPPAIAGEE EEEQVYSTAS SSTPLPAEVR SRLEVIPKVV KCLRSRSKTP P*  
 
 
 
Emvkr CDS (EmuJ_000619800; supercontig pathogen_EMU_scaffold_007728 : 4664450-4691242) 
 
1    ATGAATGCAA TGGTGGCGTT TGTTCACTTG ACATTTCTAC TATGTACTGT GTCTTTGTGC GTTCTTGCCA AACAAGGCCT   
 
81   TGATTTAAGC GAAAGTTGTC TTGCAGCTAA AGAAAAAGCA AAATGGATAA GAAGTCTTCA CTTCAATAAT AAGTCTTTTT   
 
161  CCCTCAATGT TGAGGTGAAC GATAGGCCTT CCCACTGGAT CATAAACTAC ATATTTGAGA TACTTATTCG AGAGCGTTTT   
 
241  GGGTACAGAA ATATCAATTT TATCTACACT CCATGGGATT CCTCTTCGAA TGCGATCAAT CGTCTCAATT GTGAAAAGTC   
 
321  CAATGATTGT TCTTGCCCCC CGCCCATTCA TGTTAATCTG GAATTATGGC TTCGCACTGG AGAGCAAGCT TCGGATTATG   
 
401  CACCGCCACA TCGTGTAAAC ATGAACGGAC CGCTTGGTCC GATAACGCGA TGGGGCCTCT ATACCAATGA GGAATTAGTA   
 
481  GGTCGTCAGG CTCCACAGCT TAGTACTGAC CCGAGGATCT CCCAGGATGT TCACCCAAGC CAGTCCTTTG GCGAAGGTGT   
 
561  ACTCTTTTAC GACCGCCCAT CTATGCTGAA GGCCTACAAG ACCCTCCTCT CGGAGGATGG CATGTCAATG GAGATGCATG   
 
641  TAGAGCAGCG TCCAACCCAG TTCCTGTGGA ACCTTACCAC ACAGGCCCCA CGCTTCCCCA TCCTCCTTAA TTGGTACCCC   
 
721  AATACTCTGA CGCTCAAGTC ACGACTGGTA CGCCTTGGTG TGCCCGACTG TGTTGCTCTC CGTGCCCGCA CTCCCGTCGA   
 
801  CTCCTCCGTC GACTCCACTT GCGCTTTCGA GGTCAATCAA CTAGTAAAGG TCTCCTGGGC CGGCCTCGCG GAGGCAGCTC   
 
881  CTCTTGTCAC CCAGCTAATT AATCGATTTC ATATCAAGCA GACTGACTAC ATTCAACTCC TCCGCCGTGT TAGCCCCAAC   
 
961  CTCCTAAACT ACACCGATGC AATCGAACGA GGCGAGGAGA AGCAGTTTCG TGCACGTTTT CGCGAAACGG CCTGTTGGTG   
 
1041 GCTGCGAATG CATCGATCGA GGTGGGAACA GTGGACTGAG GGATGGAACG TTAAGAAAGA GATCATCATT GGGGGCATGT   
 
1121 TCACCTTCGC GGGCACCGAG GAGTTCAAAG ATTTGGCTCC CAATGCCTTC CATGCAGTGG ACGTTCTGAA CGGTGACGAG   
 
1201 AAGTACTTTG GCAACTCGGA GTTTGCCATT CGTCTTCAAA TTCGCAATCT TACTTGCTCT CAGAATGTAG TGCTCAACGA   
 
1281 TTTCTTCAAT TTCCTCACCG TCAACCCTAA CAATGAAAGC ATCCTTGGCG TGATCCTTGC CCTCTGCCCC GATGCCATTG   
 
1361 AGGCGACTGT GCGGTTGGCG AACCTACGTC GGGTGCTTGT CATCTCGCCC ACTGTGGAGT CTGCCTCCTT CCTGTGGCAG   
 
1441 AAACATTACA AGTTCTTCTT TCGCACCATT CCCTCCGCCT ACACTGCCAG CTTCATCTTC ATCCGCCTGT TCCAGCAGTG   
 
1521 GCAGTGGAAG CGGGTCACGA TGTTCCGGAA GGATGACCAC TATTTTTATC GCGATGCCTT CACCGCAAAT AACATTACCC   
 
1601 TGGTGGACGA CTTTGAAGTG AAGGAGTCTA TGCTCACCTA TGCTGTTGCT CAAAAGAACG TCATGTCGGT GAAACAGCGC   
 
1681 AATGGACGAA TCATAATCGT GGATCATTCG GCTGCGGCAA CCGCTATTAT CCTTTGCGCC GCTTTTCATC TGAACATGCG   
 
1761 CGCTGAGAAG GGTTACGTGT GGTTCCTCAG CCCTTGGCTC TCCAAGAACT TCTGGGAGTC GCCGGAAGTG ATTCCTCCCG   
 
1841 AGTGCAGTGC CAATGATCTC AAGGTCATGC ATGATTACTC CTTCAGCGTC TCACATCCCC TTCACACTGG TGCTGTCATT   
 
1921 TACTCCAATC TCATGACCTC CATGAGTGGA CCCAATCAAT CTGAGGTGTC CAGTGGAAGC AAACCCGATA TGCGAATTCG   
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2001 CTCACATCAG CGCCAGCTAT ACGAGCAGTG TACTTTTGAA TCGGTGATCG TCCTCGGGAG TGCAATAGCT CGGCTTCTGC   
 
2081 GTGAAAATCC CTCCGCGCTG TCGATTTTGA GCAATCCCAA AATGGCTGAG CGCTTACGGA CGTTGGTGTC GAAAACGCAC   
 
2161 ATGGAGTACT CGAGCAGAGG CTACCTGGAC AAGAATGCAG TCTCCTTTTT CAGTAACAAT GTGGACCAGT TGGGTGAGAC   
 
2241 CCTCGTCTAT CAATTCGGCG TCACTCCACC CTCACCACCT GTGCCGCCAC AGACTCCACC TCCTGCCTAT GACGAAGACC   
 
2321 CCCTTGCTAG CACCGTTCAT CAGCTTAGCT TTGATTCACA CAATGATCGT CTTCTGGAGG CGTGGCTGCT GAAACAAATC   
 
2401 CAAGATAAAA CGACTGTTCC CATCACCCTC TGGTCTTTCA GTGGACCTCT CCATGGAGAT GAGGATGGCG AGTCGACCCT   
 
2481 GTTGTCGAAA GATAGATTTC GGCTGCATTC CAGCAGCGGT TACTCATCAT CCTCCTCTCG AGGGGCGTGG GGTGGGGGCA   
 
2561 AGGAGAACGG AGAGGAGGGC GAGGAAAATG GGGCGGAGGA CAACCGGAAC GATGCGATCG CCTTCAAGAC TTTCGTTGAC   
 
2641 AACCTCTTCG AGAAGCCCTA CGACAAACCG CGCTGGGGTG GCAGTGGCTC TCTGCGTCCC ACCGATGGCT CCATAACTGA   
 
2721 GGCCGATTGT GCCTTCAGCT TCCTCTCACG CTGGTTTGGT GTCAGTTGTG TCGTTGGCAA CTGGATATTC GCCATGGGCG   
 
2801 TTCTTATCAT CATCGCTATA CCTGTGGTCG CTGTCGTGCT TGCTTACTTC CGGCGACGTC TGCGAGAGGC AGAAAAACTC   
 
2881 ACCCGGAAGC CCTATGAAGA ACTTTGCGCT CTTTTGGCTG ACGTCAATAT CCCACTAACT GACATCGTTA TCAATCGCCG   
 
2961 AATCGGTGAC GGTGCCTTTG GTTTGGTGTA CGGTGGAGAA GCCAAGTTTG CGGGTCGTTG GGAAGCGGTG GCAGTGAAGA   
 
3041 TGAATACCAA CCGCACCACC TACGAGGCGA AGGTGGAGTT CCTCTCTGAG GCCAAGTTGA TGCGTGACCT GCGACACAAG   
 
3121 AATGTGGTAC GTCTCGTCGG TGTCTGCATG GATCGGCCGC AGGATGAAAT CTATCTCATT ATGGAACTCA TGCTACTTGG   
 
3201 TGACCTCAAA AAGTACCTCC TTGAACGCCG TCTCACCGCC CAGCGATGTC CGGACCACGA GGATATTTGT CCGACGACGC   
 
3281 TGACTCGGAT GGCGTTAGAC ATAGCCGAGG GGCTGGCGTA TCTGCACAGT AAACAGCTCA TTCATCGCGA TATCGCTTGT   
 
3361 CGTAACTGCC TGGTGGGCCC GGACCACGTG GTGAAAATAG GCGACTTCGG ACTGACGCGC GAGGCTACTG CGGGCTCGCC   
 
3441 GTATGGCTAC TACCGCTTTA CGCGCAACGT CGAGCTGCCT ATCCGGTGGA TGCCGCCCGA GGCGGTGCAG TTCGGCATCT   
 
3521 TCTCGGTTAA GTCGGACCTC TGGTCCTATG GCATCGTTCT TTATGAGATT ATTACCTTCG GCATGTTTCC CTACGCTGAA   
 
3601 CTCGGCGACG TGGAAGTTGT TGAACGGGTC AAACGATCCG AGTTCTCGAT CACGCAGATT CTTCCGCCTG CTGCCAACGG   
 
3681 AACTACTGTG TGGCGTCTGA TCGTGAGCTG CTGTCAGTAC TACTGGCAAC ACCGTCCTGA GTCAATGCTC CAGGTTATAG   
 
3761 AGGAGATACG GGCCAACGAG AACTGCATTC GACCCTACCT CACCGACGAA CCACCTACTC TAGAGACCAC GGCGATTCCT   
 
3841 TTCCTTCCTG GTCCGGGTGC GTGCATAATG CCGGAGCCGC CGCCGGTTCC ACAGCCTGCC TTCTCGGCGC CGATGGGGGC   
 
3921 ACGTGCCTGG GTTGGCGGTG CACCCTTTAT GAACCCCTCG ATGCCCTTCA CGGAGCCCCC CTCAGCGGGC GAGGGGCCCC   
 
4001 AACTCCATAC AGCCGCCAAC AGCAGCAGTG GTGGCTGCGG TGGTGGTGGA GGATGTAGTC AGAAGGTCTA TTTCTCCTCT   
 
4081 GCCAACTCTT CTTCCTCCCT TACATCCAAC TCCGCCTCCT CCAGACGTCC CCACAATGCT GCTTTAAACA TCAGACAAAC   
 
4161 TCCGGTCAAA CAAGCTCCAC CTCCCACTTC GGTCTATGCG CCGCCTGGAC ATCCTGGTTA CCAACCATCG GATGAATTGA   
 
4241 ATCCCCTTCT CAACCCCTCC AACCGATCGA TGTCCTTGGA GTTCCTGCAA AAGTCAGACT TCCATCTCCA AACACTGCCG   
 
4321 TCGAGGAGAG CGAACGAAAT TGATGTCGAG GAAGAGTTAG AGAGAATCAG CGAGAGCGGG GACGTTGATC TTCGGCGTGA   
 
4401 GGTGGAGGAC GAGGAAGGTG AGGTGGATTT TCAAGGTCGC AGAACCAAGC ACCAGCGTAC CTCACGTCCC CAAAAGCCCT   
 
4481 CTCTTTTGAG TCGCAGCCCC TTCAGCGTCT CCGTGGATCC TAGTGGTGGG ACACGACGGC AACAGCAGCA CAGTGGTAAC   
 
4561 TTCTTTGCAC GCACATTTGC GGTCGCATTG GATCCGCGTG GCGGCGCCGG GAAGTCGCAC CCCCGACGCC CGGTGGGACT   
 
4641 GGCCTCCTTT CTGCACAGCG ATCAGTCCTC CTCTATACGA ATGCGACTGC TGCCCTCTTT ACGCCATCAT AATCAACAAC   
 
4721 ACCACTTTCA TCAAACAGCC GCCGCTGTCG CTTTTTCCCC CCCATCCTCC TCGCACAATG AACTTACTGC CAAGTCTCTT   
 
4801 CCTCAGGTGA GCGGTACCAA CTGTCACACC TCTACAGTAG TGTCGATGAC GAAAACGTCA CGGCGAGGCG CGTGCAGCTC   
 
4881 GGCAGGGGAC GCGCACTACC TTGCGCGACC ACGTCCACCC ACGACTGCGG CCTTCTCCAC CTCTGCCTCT CGCTCATCCT   
 
4961 CAGCAGCGGT GGCTGTGGGG TCGCCTCGGG GTCAGCGACC GCCCATAGTG ACGCAGAACG GCGCCGCGGG CCTGATTACC   
 
5041 TCCAGCGGGA GTAGTCCCAC CTTTTCTTAT CCATCCCCAC CTCCTCCTCC TCCGCACAAC TCCTTCGTCT AG  
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EmVKR Protein sequence 
 
1    MNAMVAFVHL TFLLCTVSLC VLAKQGLDLS ESCLAAKEKA KWIRSLHFNN KSFSLNVEVN DRPSHWIINY IFEILIRERF   
 
81   GYRNINFIYT PWDSSSNAIN RLNCEKSNDC SCPPPIHVNL ELWLRTGEQA SDYAPPHRVN MNGPLGPITR WGLYTNEELV   
 
161  GRQAPQLSTD PRISQDVHPS QSFGEGVLFY DRPSMLKAYK TLLSEDGMSM EMHVEQRPTQ FLWNLTTQAP RFPILLNWYP   
 
241  NTLTLKSRLV RLGVPDCVAL RARTPVDSSV DSTCAFEVNQ LVKVSWAGLA EAAPLVTQLI NRFHIKQTDY IQLLRRVSPN   
 
321  LLNYTDAIER GEEKQFRARF RETACWWLRM HRSRWEQWTE GWNVKKEIII GGMFTFAGTE EFKDLAPNAF HAVDVLNGDE   
 
401  KYFGNSEFAI RLQIRNLTCS QNVVLNDFFN FLTVNPNNES ILGVILALCP DAIEATVRLA NLRRVLVISP TVESASFLWQ   
 
481  KHYKFFFRTI PSAYTASFIF IRLFQQWQWK RVTMFRKDDH YFYRDAFTAN NITLVDDFEV KESMLTYAVA QKNVMSVKQR   
 
561  NGRIIIVDHS AAATAIILCA AFHLNMRAEK GYVWFLSPWL SKNFWESPEV IPPECSANDL KVMHDYSFSV SHPLHTGAVI   
 
641  YSNLMTSMSG PNQSEVSSGS KPDMRIRSHQ RQLYEQCTFE SVIVLGSAIA RLLRENPSAL SILSNPKMAE RLRTLVSKTH   
 
721  MEYSSRGYLD KNAVSFFSNN VDQLGETLVY QFGVTPPSPP VPPQTPPPAY DEDPLASTVH QLSFDSHNDR LLEAWLLKQI   
 
801  QDKTTVPITL WSFSGPLHGD EDGESTLLSK DRFRLHSSSG YSSSSSRGAW GGGKENGEEG EENGAEDNRN DAIAFKTFVD   
 
881  NLFEKPYDKP RWGGSGSLRP TDGSITEADC AFSFLSRWFG VSCVVGNWIF AMGVLIIIAI PVVAVVLAYF RRRLREAEKL   
 
961  TRKPYEELCA LLADVNIPLT DIVINRRIGD GAFGLVYGGE AKFAGRWEAV AVKMNTNRTT YEAKVEFLSE AKLMRDLRHK   
 
1041 NVVRLVGVCM DRPQDEIYLI MELMLLGDLK KYLLERRLTA QRCPDHEDIC PTTLTRMALD IAEGLAYLHS KQLIHRDIAC   
 
1121 RNCLVGPDHV VKIGDFGLTR EATAGSPYGY YRFTRNVELP IRWMPPEAVQ FGIFSVKSDL WSYGIVLYEI ITFGMFPYAE   
 
1201 LGDVEVVERV KRSEFSITQI LPPAANGTTV WRLIVSCCQY YWQHRPESML QVIEEIRANE NCIRPYLTDE PPTLETTAIP   
 
1281 FLPGPGACIM PEPPPVPQPA FSAPMGARAW VGGAPFMNPS MPFTEPPSAG EGPQLHTAAN SSSGGCGGGG GCSQKVYFSS   
 
1361 ANSSSSLTSN SASSRRPHNA ALNIRQTPVK QAPPPTSVYA PPGHPGYQPS DELNPLLNPS NRSMSLEFLQ KSDFHLQTLP   
 
1441 SRRANEIDVE EELERISESG DVDLRREVED EEGEVDFQGR RTKHQRTSRP QKPSLLSRSP FSVSVDPSGG TRRQQQHSGN   
 
1521 FFARTFAVAL DPRGGAGKSH PRRPVGLASF LHSDQSSSIR MRLLPSLRHH NQQHHFHQTA AAVAFSPPSS SHNELTAKSL   
 
1601 PQVSGTNCHT STVVSMTKTS RRGACSSAGD AHYLARPRPP TTAAFSTSAS RSSSAAVAVG SPRGQRPPIV TQNGAAGLIT   
 
1681 SSGSSPTFSY PSPPPPPPHN SFV*  
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B  Table S1 Primer List 
Name Gene, Order and Date Primer Sequence 5' - 3' 
AKO-cDNA sigma_08_10_2012 ATCTCTTGAAAGGATCCTGCAGGTTTTTT
TTTTTTTTTTTTTTTTTTTTA 
AKO-011 pBAD Forward ATGCCATAGCATTTTTATCC 
AKO-012 pBAD Reverse GATTTAATCTGTATCAGG 
T7-Primer sequencing primer for several plasmids TAATACGACTCACTATAGGG 
AKO-024 Exon-2b_VFTK_Primer_fwd_21.03.2012_Sigma GCTAGGCGAAGAAGGAAACGAAATC 
AKO-025 Exon-2b_VFTK_Primer_rev_RC_21.03.2012_Sigma GTGATAACTTTACCGCGCTTGGGG 
AKO-026 5-UTR_VFTK_Primer_fwd_21.03.2012_Sigma GAGTTATCTCCCGTAACTCATGTGCG 
AKO-027 3-UTR_VFTK_Primer_rev_RC_21.03.2012_Sigma GACGGACATTCGCATACAGGGG 
AKO-028 Exon-1_VFTK_Primer_fwd_21.03.2012_Sigma ATGGTGGCGTTTGTTCACTTTGTTCAC 
AKO-029 Exon-2_VFTK_Primer_fwd_21.03.2012_Sigma GGCCTTCCCACTGGATCATAAAC 
AKO-030 Exon-3_VFTK_Primer_fwd_21.03.2012_Sigma CTCTTTTACGACCGCCCATCTATGC 
AKO-031 Exon-3_VFTK_Primer_rev_RC_21.03.2012_Sigma GTCGTGACTTGAGCGTCAGAG 
AKO-032 Exon-9_VFTK_Primer_fwd_21.03.2012_Sigma CACATCAGCGCCAGCTATACG 
AKO-033 Exon-10_VFTK_Primer_fwd_21.03.2012_Sigma GTGGACCAGTTGGGTGAGACCCTCG 
AKO-034 Exon-10_VFTK_Primer_rev_RC_21.03.2012_Sigma CCAGAGGGTGATGGGAACAGTCG 
AKO-035 Exon-17_VFTK_Primer_rev_RC_21.03.2012_Sigma GGACTACTCCCGCTGGAGGTAATCAGG 
AKO-036 EM10/15 (elp fwd) AATAAGGTCAGGGTGACTAC 
AKO-037 EM10/16 (elp rev) TTGCTGGTAATCAGTCGATC 
AKO-042 Exon-1_VFTK_Primer_fwd_03.05.2012_Sigma_second_primer ATGGTGGCGTTTGTTCACTTGAC 
AKO-043 5-UTR_VFTK_Primer_fwd_04.05.2012_Sigma_second_primer CTGAATCAAACCTTAGACAATGAATGC 
AKO-044 3-UTR_VFTK_Primer_rev_04.05.2012_Sigma_second_primer GGGGATTTGGGCTGCGTCCTAGACG 
AKO-045 3-UTR_VFTK_Primer_rev_04.05.2012_Sigma_third_primer CGTCCTAGACGAAGGAGTTGTGC 
AKO-046 VFTK_Exon_1_PstI__fwd_Sigma_09.05.2012 TATCTGCAGATGAATGCAATGGTGGCGTT
TG 
AKO-047 VFTK_Exon_10_NheI_fwd_Sigma_09.05.2012 GTGGACCAGTTGGGTGAGAC 
AKO-048 VFTK_Exon_10_NheI_fwd_Sigma_09.05.2012 ACTGTTCCCATCACCCTCTG 
AKO-049 VFTK_Exon_17_NotI_rev_Sigma_09.05.2012 TATGCGGCCGCCTAGACGAAGGAGTTGT
GC 
AKO-050 VFTK_Exon_10_NheI_rev_Sigma_09.05.2012 CAGAGGGTGATGGGAACAGT 
AKO-053 EmPLK-5'UTR_fwd_(dw) GACTTCTGCCCGGGTATGGATA 
AKO-054 EmPLK-3UTR_rev_(up) GGAAGACGGCAAACATGTGAT 
AKO-055 EmPLK-350_fwd_(dw) CTCTCATGGAACTGCATAAGAG 
AKO-056 EmPLK-650_rev_(up) CGGACCACGAATCTACCTC 
AKO-057 EmPLK-830_fwd_(dw) GAGCATGTTCAGTGTGATGG 
AKO-058 EmPLK-1150_rev_(up) GCCATACTTGTCCGAATAATC 
AKO-059 EmPLK-1350_fwd_(dw) ACTTGCTTCACTAGTTACATGC 
AKO-060 EmPLK-1650_rev_(up) CGATCTATCATATCGTAGGCG 
AKO-061 Em_eEF1A_fwd CACAACTGCGAGTGTCGG 
AKO-065 EmPlk1_NcoI_fwd_pGBKT7-BD_sigma_09_07_2012 ATACCATGGATGGATAAGTCAAAAGCGAA
GG 
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AKO-066 EmPlk1_PstI_rev_pGBKT7-BD_sigma_09_07_2012 ATCTGCAGTTTGTGTTTCAGAACATCAAC
C 
AKO-067 EmPlk1_ATG_fwd_sigma_09_07_2012 ATGGATAAGTCAAAAGCGAAGG 
AKO-068 EmPLK_NO-STOP_rev_sigma_09_07_2012 TTTGTGTTTCAGAACATCAACCTTTGG 
AKO-069 EmPlk1_EcoRI_fwd_pGBKT7-AD_sigma_09_07_2012 ATATGAATTCATGGATAAGTCAAAAGCGA
AGG 
AKO-070 EmPlk1_SacI_rev_pGBKT7-AD_sigma_09_07_2012 TATGAATTCTTTGTGTTTCAGAACATCAAC
C 
AKO-080 EmPlk1_Mutations_T182D_sigma_18_07_2012_fwd GGTGAAATGAAGAAGGACTTATGTGGGA
CGCC 
AKO-081 EmPlk1_Mutations_T182D_sigma_18_07_2012_rev CCCACATAAGTCCTTCTTCATTTCACCTT
C 
AKO-082 EmPlk1_Mutations_T182V_sigma_18_07_2012_fwd GGTGAAATGAAGAAGGTGTTATGTGGGA
CGCC 
AKO-083 EmPlk1_Mutations_T182V_sigma_18_07_2012_rev CCCACATAACACCTTCTTCATTTCACCTT
C 
AKO-084 Em_VFTK_Primer_EcoRI_fwd_1995bp_sigma_23_07_2012 CCATGAGTGGACCCAATCAATCTGAGGT 
AKO-085 Em_VFTK_Primer_EcoRI_rev_1995bp_sigma_23_07_2012 GCTCGTATAGCTGGCGCTGATGTGAG 
AKO-086 Em_VFTK_Primer_XbaI_fwd_3820bp_sigma_23_07_2012 CCAACGAGAACTGCATTCGACCCTACC 
AKO-087 Em_VFTK_Primer_XbaI_rev_3820bp_sigma_23_07_2012 CACCCGGACCAGGAAGGAAAGGAATC 
AKO-095 pJET 1.2 fwd_plasmid primer for sequencing CGACTCACTATAGGGAGAGCGGC 
AKO-096 pJET 1.2 rev_ plasmid primer for sequencing AAGAACATCGATTTTCCATGGCAG 
AKO-106 EmPlk1 EcoRI ATAGAATTCATAATGGATAAGTCAAAAGC
GAAGGAG 
AKO-107 EmPlk1 NotI TATGCGGCCGCTTGTGTTTCAGAACATCA
ACC 
AKO-109 EmVFTK_Exon_8_fwd GATTCCTCCCGAGTGCAGTGCCAATG 
AKO-110 EmVFTK_NotI_fwd_for_pSecTag2/Hygro A (Xenopus oocytes) ATATATGCGGCCGCAATGAATGCAATGG
TGGCGTTTG 
AKO-111 EmVFTK_NotI_rev_for_pSecTag2/Hygro A (Xenopus oocytes) ATATATGCGGCCGCGACGAAGGAGTTGT
GCGGAGG 
AKO-120 Primer_GPCR_VKR_5'UTR_fwd GCTGTCCCTGATATGCTCTTCTTCC 
AKO-121 Primer_GPCR-VKR_3'UTR_rev_short_NO-1_RC ACTTCCTCCAAATCATCGGCCG 
AKO-122 Primer_GPCR-VKR_middle_1st_fwd CGGTTTTGAATAACTCCCGTGTCGC 
AKO-123 Primer_GPCR-VKR_middle_1st_rev_RC GCGACACGGGAGTTATTCAAAACCG 
AKO-124 Primer_GPCR_middle_2nd_fwd CGGCTTTGACCCGCCGTCAACTCGCG 
AKO-125 Primer_GPCR_middle_2nd_rev_RC CGCGAGTTGACGGCGGGTCAAAGCCG 
AKO-126 Primer_GPCR-VKR_3'UTR_No-2_rev_NO-2_RC CATATTCTAAAGATTCCTATACGGAGC 
AKO-132 EmVKR_Primer_5'-end_fwd_31012013 CGCACAAAGACACAGTACATAGTAGAAAT
GTCAAGTGAACAAACGCCACCATTGCATT
CAT 
AKO-133 EmVKR_Primer_5'-end_rev_31012013 CACTTGACATTTCTACTATGTACTGTGTC
TTTGTGCGTTCTTGCCAAACAAGGCCTTG
ATTTAAGCG 
AKO-134 EmVKR_Primer_3'-end_fwd_31012013 GGCCTGATTACCTCCAGCGGGAGTAGTC
CCACCTTTTCTTATCCATCCCCACCTCCT
CCTCCTCCGCACAACTCCTTCGTCTAG 
AKO-135 EmVKR_Primer_3'-end_rev_31012013 GGACTACTCCCGCTGGAGGTAATCAGGC
CCGCGGCGCCGTTCTGCGTCACTATGGG 
AKO-136 EmVKR_Primer_3'-end_NotI_fwd_31012013 GGCCTGATTACCTCCAGCGGGAGTAGTC
CCACCTTTTCTTATCCATCCCCACCTCCT
CCTCCTCCGCACAACTCCTTCGTCGCGG
CCGCATATAT 
AKO-137 EmVKR_Primer_5'-end_NotI_fwd_31012013 CGCACAAAGACACAGTACATAGTAGAAAT
GTCAAGTGAACAAACGCCACCATTGCATT
CATTGCGGCCGCATATAT 
AKO-138 EmPlk1 T179D_rev (mutations for Xenopus oocytes) GGTGAAATGAAGAAGGACTTATGTGGGA
CGCCAAACTATATTGCTCC 
AKO-139 EmPlk1 T179D_fwd (mutations for Xenopus oocytes) CCACATAAGTCCTTCTTCATTTCACCTTCT
TTAGTAATTCTAG 
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AKO-140 EmPlk1 T179V_fwd (mutations for Xenopus oocytes) GGTGAAATGAAGAAGGTATTATGTGGGA
CGCCAAACTATATTGCTCC 
AKO-141 EmPlk1 T179V_rev (mutations for Xenopus oocytes) CCACATAATACCTTCTTCATTTCACCTTCT
TTAGTAATTCTAG 
AKO-142 EmPlk1_D163NA165_fwd  (mutations for Xenopus oocytes) GATCGGGGATAATGCTTTGGCCTCTAGA
ATTACTAAAGAAGG 
AKO-143 EmPlk1_D163NA165_rev (mutations for Xenopus oocytes) CTAGAGGCCAAAGCATTATCCCCGATCTT
TACAATC 
AKO-144 EmVKR_Start_fwd ATGAATGCAATGGTGGCGTTTGTTCACTT
GACATTTCTAC 
AKO-145 EmVKR_Ende-rev CTAGACGAAGGAGTTGTGCGGAGGAGGA
GGAGGTGGGGATG 
AKO-146 EmPlk1_D163SV165_fwd (mutations for Xenopus oocytes) GACATGATTGTAAAGATCGGGGATTCGG
TGTTGGCCTCTAGAATTACTAAAGAAGG 
AKO-147 EmPlk1_D163SV165_rev (mutations for Xenopus oocytes) GTAATTCTAGAGGCCAACACCGAATCCC
CGATCTTTACAATCATGTCATCATTTAAAA
ACAGATTGGC 
AKO-148 EmVKR_3'ende_TAG_rev CTAGACGAAGGAGTTGTGCGGAGGAGGA
GGAGGTGGGGATGGATAAGAAAAGGTG
GGACTACTCCCGCTGGAG 
AKO-149 EmVKR_5'_NotI_+70bp_fwd_sigma_22042013 TATATGCGGCCGCCAAACAAGGCCTTGA
TTTAAGCGAAAGTTGTCTTGC 
AKO-150 EmVKR_3'_NotI_+5065bp_rev_sigma_22042013 TATATGCGGCCGCAAAGGTGGGACTACT
CCCGCTGGAGGTAATCAGG 
ASO-151 EmPLK4_forward_ATG_sigma_18092013 (full transcript) ATGTACGTTCAACCAAACCTAAAGGGGTT
AGG 
ASO-152 EmPLK4_reverse_TAG_sigma_18092013 (full transcript) TCAGGGTGGAGTTTTAGACCTCGAACGG
AGAC 
ASO-159 EmPlk1_reverse_ kinases domain AGTGCACTGACAGGGAGACCGGTG 
ASO-160 EmPlk1_reverse_ kinases domain_II TGCACTGACAGGGAGACCGGT 
ASO-161 EmVKR_fwd ATGAATGCAATGGTGGCGTTTGTTCACTT
GACATTTCTACTATGTACTGTGTCTTTGT
GCG 
ASO-162 EmVKR_rev CTAGACGAAGGAGTTGTGCGGAGGAGGA
GGAGGTGGGGATGGATAAGAAAAGGTG
GGACTACTCCCGCTGGAGGTAATCAGGC
C 
ASO-163 EmPlk1_fwd_NcoI ATATATCCATGGTATGTGAGAGGGAGGTT
TCTTGGAAAAGGAGGCTTCGC 
ASO-164 EmPlk1_rev_BamHI ATATATGGATCCGTCCATCACACTGAACA
TGCTCGGCCGCTTTTGTG 
ASO-165 EmPlk1_fwd_NcoI ATATATCCATGGTGTATGTGAGAGGGAG
GTTTCTTGGAAAAGGAGGCTTCGC 
ASO-166 EmPlk1_rev_BamHI ATATATATGGATCCCTAACTGTGGTCCAT
CACACTGAACATGCTCGGCCGCTTTTGT
G 
ASO-167 EmVKR_fwd_+NotI 69bp cut GTACTGTGTCTTTGTGCGTTCTTGCGGCC
GCCAAACAAGGCCTTGATTTAAGCG 
ASO-168 EmVKR_rev_+NotI 5073 cut GGGAGTAGTCCCACCTTTGCGGCCGCTC
TTATCCATCCCCACCTCCTCCTCCTCCGC 
ASO-169 TB1-5 (beta tubulin 1 fwd; full transcript; Brehm 2000) CAGGCTACCGCAGGCTACCG 
ASO-170 TB1-3 (beta tubulin 1 rev; full transcript; Brehm 2000) AGAATGCAAGGAAGAAATAGCTA 
ASO-171 TB2-5 (beta tubulin 2 fwd; full transcript; Brehm 2000) TTTGGATTTGGATTCGCTTG 
ASO-172 TB2-3 (beta tubulin 2 rev; full transcript; Brehm 2000) GAAATTTTATTGATAAAGCACATG 
ASO-173 TB3-5 (beta tubulin 3 fwd; full transcript; Brehm 2000) ATTCTCCAACATGCGTGAGC 
ASO-174 TB3-3 (beta tubulin 3 rev; full transcript; Brehm 2000) ATCTAATCCCAAGATAATTTGTTG 
ASO-175 EmVKR  CCTCCCACTTCGGTCTATGC 
ASO-176 EmVKR  TACCGCTCACCTGAGGAAGA 
ASO-177 EmVKR  CTCCCACTTCGGTCTATGCG 
ASO-178 EmVKR ATCGCTGTGCAGAAAGGAGG 
ASO-179 beta tubulin-1 5' (RT-PCR) TGCAACCATGTCAGGTGTGA 
ASO-180 beta tubulin-1 3' (RT-PCR) ACCGACATCTTGAGTCCACG 
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ASO-181 beta tubulin-2 5' (RT-PCR) AACCAGTCGTGGTAGTCAGC 
ASO-182 beta tubulin-2 3' (RT-PCR) AACAGCTCTTGTATGGCGGT 
ASO-183 beta tubulin-3 5' (RT-PCR) TGGTTCCCTTTCCACGTCTG 
ASO-184 beta tubulin-3 3' (RT-PCR) ACTCCGCTTCCGAAAACTCC 
ASO-185 EmVKR fwd VFT-Modul (in situ probe version A) TCCCAATGCCTTCCATGCAG 
ASO-186 EmVKR rev VFT-Modul (in situ probe version A) GTTTTCGACACCAACGTCCG 
ASO-187 EmVKR fwd VFT-Modul (in situ probe version B) GGCACCGAGGAGTTCAAAGAT 
ASO-188 EmVKR rev VFT-Modul (in situ probe version B) GCTCAGCCATTTTGGGATTGC 
ASO-189 EmVKR fwd TK-Domain (in situ probe version A) CTTTGCGCTCTTTTGGCTGA 
ASO-190 EmVKR rev TK-Domain(in situ probe version A) AGTTCTCGTTGGCCCGTATC 
ASO-191 EmVKR fwd TK-Domain (in situ probe version B) TGGCTGACGTCAATATCCCAC 
ASO-192 EmVKR rev TK-Domain(in situ probe version B) AGTACTGACAGCAGCTCACG 
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C   List of Abbreviations 
 aa           Amino acids 
 ABZ          Albendazole 
 ABZSO          Albendazole Sulfoxide 
 ABZSN          Albendazole Sulfone 
 AE          Alveolar Echinococcosis 
 AKO          Andreas Kalbfleisch Oligo (Primer) 
 AKS          Andreas Schubert Oligo (Primer) 
 AKP          Andreas Kalbfleisch Plasmid 
 ASP          Andreas Schubert Plasmid 
 AKS          Andreas Kalbfleisch Strain (Bacterial stain, DMSO-Stock) 
 ASS          Andreas Schubert Strain (Bacterial stain, DMSO-Stock) 
 bp           Base pairs 
 BI 2536/6727       Boehringer Ingelheim 2536/6727 
 C. elegans        Caenorhabditis elegans 
 CML          chronic myelogenous leukemia 
 Ctrl          Control 
 D. melanogaster      Drosophila melanogster 
 E. multilocularis       Echinococcus multilocularis 
 EmPlk1         Echinococcus multilocularis Polo-like kinase 1 
 EmPlk4         Echinococcus multilocularis Polo-like kinase  
 EmVKR         Echinococcus multilocularis Venus kinase receptor 
 EmVRTK         Echinococcus multilocularis Venus kinase receptor 
 H. microstoma       Hymenolepis microstoma 
 IGF          Insulin like growth factor 
 LBD          Ligand binding domain 
 Mc          Metacestode vesicles 
 MAP          Mitogen-activated protein 
 MAPK         Mitogen activated protein kinase 
 Na3VO4         Sodium orthovanadate 
 nt           Nucleotides 
 ORF          Open reading frame 
 Pc           Primary cells 
 PS+          Activated protoscoleces 
 Ps-          Nonactivated protoscoleces 
 S. japonicum       Schistosoma japonicum 
 S. mansoni        Schistosoma mansoni 
 T. crassiceps       Taenia crassiceps 
 T. solium         Taenia solium 
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